fluorides profile

ID Source	ID
PubMed CID	28179
CHEMBL ID	1362
CHEBI ID	17051
MeSH ID	M0008615

Synonym
CHEBI:17051 ,
fluoride(1-)
fluorine anion
f(-)
16984-48-8
fluorine ion(1-)
fluoride ion(1-)
fluorine ion
drinking water, fluoride treated
fluoride as dust
fluoride dust
perfluoride
fluoride ion(f-)
fluorides ,
fluoride
F- ,
C00742
fluoride ion
bdbm26978
chembl1362
unii-q80vpu408o
q80vpu408o ,
fluoride [vandf]
fluroride-ion
fluorine ion(f1-)
AKOS015903717
KRHYYFGTRYWZRS-UHFFFAOYSA-M
mfcd00144315
DB11257
DTXSID9049617 ,
Q407350
fluoride standard
fluoride standard: f- @ 1000 microg/ml in h2o
fluoride ion chromatography standard: f- @ 100microg/ml in h2o
fluoride standard: f- @ 10000 microg/ml in h2o
f?
fluoride standard: f- @ 100 microg/ml in h2o
fluorine-
dtxcid3029576
topex neutral ph fluoride gelstrawberry
topex neutral ph fluoride gel
topex neutral ph fluoride gelmint

Research Excerpts

Actions

Excerpt	Reference	Relevance
"Fluorides can cause corrosion and degradation in mechanical properties of commonly used archwires by forming hydrofluoric acid HF and causing disruption of protective titanium oxide layer. "	( Effect of fluoride mouth rinses on various orthodontic archwire alloys tested by modified bending test: an in vitro study. Chandra, PK; Kamat, N; Srivastava, K, )	1.57

Treatment

All treatments (fluorides and CHX) significantly reduced the biofilm viability compared to placebo varnish and negative control. Treatment with fluorides (F(-)) is known to be the main method for preventing plaque formation and dental caries.

Excerpt	Reference	Relevance
"All treatments (fluorides and CHX) significantly reduced the biofilm viability compared to placebo varnish and negative control."	( Protective Effect of 4% Titanium Tetrafluoride Varnish on Dentin Demineralization Using a Microcosm Biofilm Model. Buzalaf, MAR; Dos Santos, DMS; Magalhães, AC; Pires, JG; Salomão, PMA; Silva, AB, 2019)	0.85
"Treatment with fluorides (F(-)) is known to be the main method for preventing plaque formation and dental caries."	( Influence of noble metals alloying additions on the corrosion behaviour of titanium in a fluoride-containing environment. Borzone, G; Delsante, S; Rosalbino, F; Scavino, G, 2012)	0.72

Toxicity

Inorganic fluorides were declared toxic under the Canadian Environmental Protection Act in 1993 based on their potential to cause long-term harmful effects. The other fluorides tested showed no toxic effects in dosages relevant for caries prophylaxis and with oral application.

Excerpt	Reference	Relevance
" Phenobarbital treatment enhanced production of fluroxene metabolites, including the highly toxic trifluoroethanol."	( Fluroxene toxicity induced by phenobarbital. Embro, WJ; Fiserova-Bergerova, V; Holaday, DA; Malagodi, MH; Munson, ES; Perry, JC; Shields, RP; Tham, MK, 1975)	0.25
" The Norwegian Adverse Drug Reaction Committe received 34 case reports of adverse effects ascribed to fluoride prophylaxis, from 1970 to 1977."	( Acceptance, caries reduction and reported adverse effects of fluoride prophylaxis in Norway. Birkeland, JM; Lökken, P, 1978)	0.26
" The other fluorides tested showed no toxic effects in dosages relevant for caries prophylaxis and with oral application."	( [Comparison of embryotoxic effects of inorganic fluorides]. Stratmann, KR, 1979)	0.91
"Male and female Drosophila melanogaster with special sex chromosome or special autosome constitutions were fed with the mutagenic chemicals Trenimon (2,3,5-trisethyleneimino-1,4-benzoquinone) and PDMT (1-phenyl-3, 3-dimethyltriazene) and with the toxic substance Na2PO3F (sodium monofluorophosphate)."	( Induced dominant lethal mutations and cytotoxic effects in germ cells of Drosophila melanogaster with Trenimon, PDMT and sodium monofluorophosphate. Büchi, R, 1977)	0.26
" The main purpose of the investigation reported here was to determine maximum possible fluoride intake in adults who were heavy tea drinkers in a fluoridated city and relate it to toxic thresholds."	( Fluoride intake and its safety among heavy tea drinkers in a British fluoridated city. Jenkins, GN, 1991)	0.28
"The LD50 for fluoride was elevated from less than 60 mg F/kg body weight to 172 mg F/kg when magnesium (as MgCl2), equivalent to 3 times that of F, was administered by gavage 30 min after the F dose."	( The LD50, excretion and serum and bone levels of F after a high single F and F + Mg dose in rats with findings on cardiac Ca and Mg. Koskinen-Kainulainen, M; Luoma, H; Tuomisto, J, 1990)	0.28
"Fasted Sprague-Dawley male rats were used in three experiments to determine the acute LD50 values of fluoride when it was administered intragastrically as NaF, disodium monofluorophosphate (Na2PO3F, MFP) or NaF and MFP."	( Acute oral toxicity of sodium fluoride and monofluorophosphate separately or in combination in rats. Birdsong-Whitford, NL; Finidori, C; Whitford, GM, 1990)	0.28
" The concept of a "probably toxic dose" (PTD) is advanced."	( Fluoride in dental products: safety considerations. Whitford, GM, 1987)	0.27
"Although ingestion of an acute toxic dose of fluoride is extremely rare in dental treatments, practitioners should be familiar with the signs and symptoms and with emergency measures of treating accidental overdosage."	( Topical fluoride therapy: discussion of some aspects of toxicology, safety, and efficacy. Newbrun, E, 1987)	0.27
" Furthermore, (+)-catechin seems capable of protecting against the direct toxic effect of halothane metabolites resulting from the reductive pathways."	( Halothane hepatotoxicity in glutathione depleted rats. Sellin, D; Siegers, CP; Wilhelm, KP; Younes, M, 1987)	0.27
" Comparisons of certainly lethal and safely tolerated doses for commonly used fluoride agents and procedures show that they can be applied with little or no risk of adverse acute effects, as long as they are used judiciously."	( Amounts of fluoride in self-administered dental products: safety considerations for children. Heifetz, SB; Horowitz, HS, 1986)	0.27
" A clear dose-response pattern for the above toxic effects was evident with 10 ppm in the males being an effect level."	( Inhalation toxicity of hexafluoroisobutylene. Cramp, AL; Darr, RW; Gad, SC; Hoffman, GM; Peckham, JC; Rusch, GM, 1986)	0.27
" The compound was found to be moderately toxic following single 4-hr exposures, with an LC50 of 980 mg/m3."	( Inhalation toxicity of ammonium perfluorooctanoate. Barnes, JR; Brittelli, MR; Chen, HC; Hall, GT; Kennedy, GL, 1986)	0.27
" However, there is an increasing potential for ingestion of toxic doses of fluoride because of the increasing use of pleasant-tasting fluoride products."	( Diagnosis and treatment of acute fluoride toxicity. Bayless, JM; Tinanoff, N, 1985)	0.27
" Based on this study, exposure to BF3 at 17 mg/m3 resulted in renal toxicity, while exposure at 6 mg/m3, although showing elevations of fluoride amounts, did not result in a toxic response."	( Inhalation toxicity studies with boron trifluoride. Hoffman, GM; McConnell, RF; Rinehart, WE; Rusch, GM, 1986)	0.27
" It is concluded that the nature of the group substituted at the enzyme active site determines the toxic response."	( Organophosphorus and other inhibitors of brain 'neurotoxic esterase' and the development of delayed neurotoxicity in hens. Johnson, MK, 1970)	0.25
" CLDs and STDs for most commonly used fluoride agents and procedures show that they can be applied with little or no risk of adverse effects, as long as they are handled judiciously."	( The amounts of fluoride in current fluoride therapies: safety considerations for children. Heifetz, SB; Horowitz, HS, )	0.13
" The phosphate industry, along with university researchers and the Association of American Feed Control Officials, set up standards for safe levels of fluoride in feed phosphates."	( Industrial considerations related to fluoride toxicity. Thompson, DJ, 1980)	0.26
" However, there is a need for further studies to evaluate the tissue accumulation of fluoride and its potential to cause toxic effects."	( Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Arora, NK; Bhan, MK; Jena, A; Pradhan, KM; Susheela, AK, 1995)	0.29
"Methoxyflurane nephrotoxicity is mediated by cytochrome P450-catalyzed metabolism to toxic metabolites."	( Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Hankins, DC; Kharasch, ED; Thummel, KE, 1995)	0.29
"In a prospective case controlled study, we evaluated the adverse effects of long-term fluoride ingestion on the gastrointestinal tract."	( Toxic effects of chronic fluoride ingestion on the upper gastrointestinal tract. Das, TK; Dasarathy, S; Gupta, IP; Susheela, AK; Tandon, RK, 1994)	0.29
" Abundant scientific data accumulated over the years have demonstrated that other than dental fluorosis, there are no known adverse effects of long-term fluoride ingestion for caries prevention."	( Fluoride: safety issues. Li, Y, )	0.13
" In repeat dose irritancy or oral toxicity tests in rabbits or rats, no adverse effects of Fomblin HC products were noted; in particular, daily oral administration (1000 mg/kg/day) to rats over 28 days produced no significant reaction."	( Safety evaluation of perfluoropolyethers, liquid polymers used in barrier creams and other skin-care products. Bootman, J; Malinverno, G; Pantini, G, 1996)	0.29
" Moderate duration low-flow sevoflurane anesthesia, during which compound A formation occurs, appears to be as safe as low-flow isoflurane anesthesia."	( Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. Artru, A; Bowdle, TA; Frink, EJ; Kharasch, ED; Nogami, WM; Zager, R, 1997)	0.3
" Our results suggest that the toxic effect of F- on the kidney may be more pronounced in the proximal tubule than the glomeruli region, and that the disorder of the proximal tubule is more serious in the S3 segment than S1 or S2 segment."	( Urinary biomarkers monitoring for experimental fluoride nephrotoxicity. Dote, T; Kono, K; Miyata, K; Nishiura, H; Nishiura, K; Shimahara, M; Sugimoto, K; Usuda, K, 1998)	0.3
"Although an excess intake of fluoride has been reported to cause skeletal fluorosis, very little is known about the mechanism of adverse effects of fluoride on bone."	( Fluoride mediates apoptosis in osteosarcoma UMR 106 and its cytotoxicity depends on the pH. Ando, M; Hirano, S, 1997)	0.3
" There were no compound-related, adverse effects on body weight, food consumption, survival, clinical signs of toxicity, ophthalmoscopically observable ocular lesions, serum hormone concentrations, or clinical pathology parameters at any exposure concentration in either male or female rats."	( Chronic toxicity, oncogenicity, and mutagenicity studies with chlorotetrafluoroethane (HCFC-124). Bentley, KS; Brock, WJ; Elliott, GS; Frame, SR; Malley, LA; Rusch, GM; Trochimowicz, HJ, 1998)	0.3
" its toxicity resulted in a parabolic curve with nerve agents and other similarly toxic compounds in the center."	( Effects of chemical reactivity of the toxicity of phosphorus fluoridates. White, WE, 1999)	0.3
" These findings demonstrate differences in aluminum species and highlights the importance of these factors in modulating the toxic effect of aluminum."	( Ligand specific effects on aluminum incorporation and toxicity in neurons and astrocytes. Fraser, PE; Lévesque, L; McLachlan, DR; Mizzen, CA, 2000)	0.31
"This article reviews the different treatments currently available for osteoporosis and examines the benefits and adverse events that are associated with each."	( Comparative safety of bone remodeling agents with a focus on osteoporosis therapies. Kleerekoper, M; Schein, JR, 2001)	0.31
" Many clients take multiple medications; therefore, dental hygienists must be aware of the issues related to drug use, including indications, interactions, and adverse drug effects."	( Managing the side effects of medications. Spolarich, AE, 2000)	0.31
" Over the 6-month observation period, the sodium hexametaphosphate and the marketed control dentifrices were comparable in terms of adverse event type and severity, and no subject discontinued treatment due to an oral soft tissue adverse event."	( Anticalculus efficacy and safety of a novel whitening dentifrice containing sodium hexametaphosphate: a controlled six-month clinical trial. Baker, R; Gerlach, R; Liu, H; Ramsey, L; Segreto, V; Vastola, K, 2002)	0.31
" All the toothbrushes tested in this investigation were found to be safe with no evidence of hard or soft tissue trauma."	( A 3-month comparative investigation of the safety and efficacy of a new toothbrush: results from two independent clinical studies. Galustians, HJ; Jacobs, DM; King, DW; Low, MA; Qaqish, JG; Sharma, NC; Weber, DA, 2000)	0.31
" The treatment was well tolerated, with only few mild or moderate adverse events."	( Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study. Ringe, JD; Setnikar, I, 2002)	0.31
" The toxic effects of CFA, which is an excellent substrate but a poor inactivator of GSTZ1-1, have not been investigated."	( Nephrotoxicity of chlorofluoroacetic acid in rats. Anders, MW; Baggs, RB; Krenitsky, DM; Lantum, HB, 2002)	0.31
"Inorganic fluorides were declared toxic under the Canadian Environmental Protection Act in 1993 based on their potential to cause long-term harmful effects in aquatic and terrestrial ecosystems, but information on the toxicity of sediment-associated fluoride to freshwater benthic organisms was considered incomplete."	( Toxicity of aqueous and sediment-associated fluoride to freshwater organisms. de Solla, SR; Holtze, KE; Metcalfe-Smith, JL; Reid, JJ; Sirota, GR, 2003)	0.72
" The toxic action of fluoride resides in the fact that fluoride ions act as enzymatic poisons, inhibiting enzyme activity and, ultimately, interrupting metabolic processes such as glycolysis and synthesis of proteins."	( Fluoride toxicity to aquatic organisms: a review. Camargo, JA, 2003)	0.32
" As hydrogen peroxide is a necessary factor for triggering a number of important toxic effects of nitrite, the latter increases its toxicity by inhibiting catalase."	( Nitrite-catalase interaction as an important element of nitrite toxicity. Petrenko, YM; Titov, VY, 2003)	0.32
"During the 2-week treatment period, twelve adverse reactions were recorded as potentially attributable to the study products, evenly split between the two test groups."	( Safety evaluation of a novel whitening gel, containing 6% hydrogen peroxide and a commercially available whitening gel containing 18% carbamide peroxide in an exaggerated use clinical study. Collins, LZ; Gallagher, A; Maggio, B; Schäfer, F; York, M, 2004)	0.32
" It is concluded that both products are safe for their intended use."	( Safety evaluation of a novel whitening gel, containing 6% hydrogen peroxide and a commercially available whitening gel containing 18% carbamide peroxide in an exaggerated use clinical study. Collins, LZ; Gallagher, A; Maggio, B; Schäfer, F; York, M, 2004)	0.32
" In 1998, storm water from the cylinder storage yards was found to be toxic to Ceriodaphnia, at concentrations exceeding limits in the site's discharge permit."	( Source of toxicity in storm water: zinc from commonly used paint. Konetsky, BK; Kszos, LA; Morris, GW, 2004)	0.32
"Many years have passed since domestic water fluoridation was adopted to reduce the incidence of caries in developed countries; however, since there is an additional dose of fluorides ingested with foods and drinks prepared with such waters, the problem has emerged of possible adverse effects on health associated to them, so that in some countries fluorine integrator selling is allowed only with preventive medical prescription."	( [Fluoride toxicity]. Giachini, M; Pierleoni, F, 2004)	0.52
" A 1- and 3-month recovery period was included to evaluate the reversibility of toxic effects."	( Subchronic toxicity of a fluoroalkylethanol mixture in rats. Buck, RC; Everds, NE; Ladics, GS; Makovec, GT; Stadler, JC, 2005)	0.33
" The toxic effect of antibacterial agents was in the order: AgF>JJZ>NaF."	( Cytotoxicity of direct current with antibacterial agents against host cells in vitro. Nakamura, Y; Nishikawa, H; Sakagami, H; Shimetani, A; Takahashi, K, 2005)	0.33
" In addition, it is urgent that governmental and international agencies adopt safe standards of fluoride content in tea commodities."	( Fluoride levels in various black tea commodities: measurement and safety evaluation. Cao, J; Deng, HJ; Li, Y; Liu, JW; Yi, J; Zhao, Y, 2006)	0.33
" In conclusion, alpha-TCP- or CaF2-modified 4-META/MMA-TBB resin seemed to allow easy and safe debonding of orthodontic brackets without loss of proper bracket bond strength."	( Modification of 4-META/MMA-TBB resin for safe debonding of orthodontic brackets--influence of the addition of degradable additives or fluoride compound. Hayakawa, T; Kasai, K; Kawabata, R, 2006)	0.33
" In conclusion, increased low-energy guanylate and inosylate as well as decreased xanthine concentrations in snail muscle can be indicators of the toxic influence of fluoride on the organism."	( Guanine and inosine nucleotides, nucleosides and oxypurines in snail muscles as potential biomarkers of fluoride toxicity. Dołegowska, B; Machoy, Z; Rać, ME; Safranow, K, 2007)	0.34
" This study revealed that there were minimal aroma/flavor differences among the ham treatments between 0 and 36 mg/ml, and that dry cured ham that was fumigated with SF was safe and met legal requirements for consumption."	( Sulfuryl fluoride fumigation effects on the safety, volatile composition, and sensory quality of dry cured ham. Aikins, MJ; Hasan, MM; Mikel, WB; Phillips, TW; Schilling, MW; Sekhon, RK, 2010)	0.36
" Therefore it can be concluded that black berry administration could minimize the toxic effects of fluoride indicating its free radical-scavenging and potent anti-oxidant activities."	( Evaluation of free radical-scavenging and anti-oxidant properties of black berry against fluoride toxicity in rats. Abdel-Aziz, AF; Hassan, HA, )	0.13
" Here, we asked if F(-) was more toxic at low pH, as measured by increased cell stress and decreased cell function."	( The acid test of fluoride: how pH modulates toxicity. Bartlett, JD; Sharma, R; Skobe, Z; Tannous, BA; Tsuchiya, M, 2010)	0.36
"The World Health Organization (WHO)/United Nations Children's Fund (UNICEF) Joint Monitoring Programme (JMP) for Water Supply and Sanitation was designed to provide reference figures for access in individual countries to safe water."	( How safe are the global water coverage figures? Case study from Madhya Pradesh, India. Godfrey, S; Labhasetwar, P; Pimpalkar, S; Wate, S, 2011)	0.37
"Methods include examination of national health agency reviews, primarily the National Research Council (NRC), Agency for Toxic Substances & Disease Registry (ATSDR), standard medical toxicology references, text books, as well as reports and documents from both private and public research as well as consumer-based NGOs."	( Fluorine--a current literature review. An NRC and ATSDR based review of safety standards for exposure to fluorine and fluorides. Prystupa, J, 2011)	0.58
" Based on an analysis of the affects of fluoride demonstrated consistently in the literature, safe levels have not been determined nor standardized."	( Fluorine--a current literature review. An NRC and ATSDR based review of safety standards for exposure to fluorine and fluorides. Prystupa, J, 2011)	0.58
" Cases of serious systemic toxicity and fatalities due to acute exposures are now rare, but overexposures causing toxic signs and symptoms are not."	( Acute toxicity of ingested fluoride. Whitford, GM, 2011)	0.37
"To determine the prevalence of signs and symptoms of suspected dental, skeletal, and non-skeletal fluorosis, along with food habits, addictions, and use of fluoride containing toothpaste among participants taking water with fluoride concentration above the permissible limit, and to assess the changes in clinical manifestations of the above participants after they started consuming safe drinking water."	( Health impact of supplying safe drinking water containing fluoride below permissible level on flourosis patients in a fluoride-endemic rural area of West Bengal. Majumdar, KK, )	0.13
"A longitudinal intervention study was conducted in three villages in Rampurhat Block I of Birbhum district of West Bengal to assess the occurrence of various dental, skeletal, and non-skeletal manifestations of fluorosis, along with food habits, addictions, and use of fluoride containing toothpaste among the study population and the impact of taking safe water from the supplied domestic and community filters on these clinical manifestations."	( Health impact of supplying safe drinking water containing fluoride below permissible level on flourosis patients in a fluoride-endemic rural area of West Bengal. Majumdar, KK, )	0.13
"Fuji Plus, Vitrebond and Fuji VIII, which released fluoride in higher quantities than other GICs, were highly toxic to human DPSCs."	( Cytotoxic effects of glass ionomer cements on human dental pulp stem cells correlate with fluoride release. Arsenijevic, N; Kanjevac, T; Lukic, A; Lukic, ML; Markovic, D; Milovanovic, M; Tesic, Z; Volarevic, V; Zdravkovic, N, 2012)	0.38
" Intervention in the form of alternate safe water supply in five villages showed significant reduction in the urinary fluoride concentration when compared to the control village."	( Urinary fluoride as a monitoring tool for assessing successful intervention in the provision of safe drinking water supply in five fluoride-affected villages in Dhar district, Madhya Pradesh, India. Gautam, A; Jaiswal, SC; Singh, P; Srikanth, R, 2013)	0.39
"In developing countries, the lack of safe water options leads to many health risks."	( Determining behavioral factors for interventions to increase safe water consumption: a cross-sectional field study in rural Ethiopia. Huber, AC; Mosler, HJ, 2013)	0.39
"The results support the possibility of an adverse effect of high fluoride exposure on children's neurodevelopment."	( Developmental fluoride neurotoxicity: a systematic review and meta-analysis. Choi, AL; Grandjean, P; Sun, G; Zhang, Y, 2012)	0.38
"Laboratory experiments were performed to examine the toxic effects of fluoride (F(-)) on the survival and behavior of white-clawed crayfish (Austropotamobius pallipes)."	( Fluoride bioaccumulation and toxic effects on the survival and behavior of the endangered white-clawed crayfish Austropotamobius pallipes (Lereboullet). Aguirre-Sierra, A; Alonso, A; Camargo, JA, 2013)	0.39
"Long-term excessive fluoride intake is known to be toxic and can damage a variety of organs and tissues in the human body."	( Fluoride-elicited developmental testicular toxicity in rats: roles of endoplasmic reticulum stress and inflammatory response. Chen, Y; Cui, Y; Gao, H; Guan, Z; Jiang, C; Lei, R; Liu, H; Wang, A; Wang, Z; Wu, X; Xia, T; Yang, L; Yu, L; Zeng, Q; Zhang, C; Zhang, S; Zhang, X, 2013)	0.39
" It was concluded that, regardless of the increase in enamel hardness due to the application of fluoride solutions, the treated enamel surface did not prevent the toxic effects caused by the 16% CP gel to odontoblast-like cells."	( Effect of fluoride-treated enamel on indirect cytotoxicity of a 16% carbamide peroxide bleaching gel to pulp cells. de Souza Costa, CA; Hebling, J; Lima, AF; Ribeiro, AP; Sacono, NT; Soares, DG, 2013)	0.39
" Natural calcium fluoride with low solubility and toxicity from ingestion is distinct from fully soluble toxic industrial fluorides."	( Physiologic conditions affect toxicity of ingested industrial fluoride. Sauerheber, R, 2013)	0.6
"Fluorine is an abundant element and is toxic to organisms from bacteria to humans, but the mechanisms by which eukaryotes resist fluoride toxicity are unknown."	( Eukaryotic resistance to fluoride toxicity mediated by a widespread family of fluoride export proteins. Breaker, RR; Davis, JH; Gordon, PB; Li, S; Smith, KD; Strobel, SA, 2013)	0.39
" In the present study, we have synthesized europium doped NaYF4 (NaYF4:Eu(3+)) nanoparticles with three diameters and used endothelial cells (ECs) as a cell model to explore the potential toxic effect."	( Size-dependent cytotoxicity of europium doped NaYF ₄ nanoparticles in endothelial cells. Chen, S; Duan, J; Jia, G; Wang, S; Zhang, C; Zhang, J, 2014)	0.4
" Soluble fluoride salts are toxic at high concentrations; their reproductive toxicity was assessed in this study by administering different fluoride salt concentrations to mice."	( Adverse Effects of High Concentrations of Fluoride on Characteristics of the Ovary and Mature Oocyte of Mouse. Chen, X; Song, C; Wu, H; Yin, S; Zhang, Y, 2015)	0.42
"9 percent) were more likely to agree that it was safe (69."	( Perceived safety and benefit of community water fluoridation: 2009 HealthStyles survey. Griffin, S; Mork, N, 2015)	0.42
" All ILs tested were not biodegradable; while some of them were toxic toward activated sludge."	( Synthesis and toxicity evaluation of hydrophobic ionic liquids for volatile organic compounds biodegradation in a two-phase partitioning bioreactor. Amrane, A; Biard, PF; Couvert, A; Guihéneuf, S; Le Guével, R; Paquin, L; Rodriguez Castillo, AS, 2016)	0.43
"5 % of LD50 values for NaF."	( Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers. Dote, T; Ito, Y; Kono, K; Tamaki, J; Ueno, T; Usuda, K; Yokoyama, H, 2016)	0.43
" Previous studies indicate the highly toxic nature of SPL."	( Cytotoxicity of Spent Pot Liner on Allium cepa root tip cells: A comparative analysis in meristematic cell type on toxicity bioassays. Andrade-Vieira, LF; Campos, JM; Davide, LC; Dos Santos Gedraite, L; Palmieri, MJ, 2016)	0.43
" Aluminum fluoride was comparatively more toxic than aluminum."	( Role of Spirulina in mitigating hemato-toxicity in Swiss albino mice exposed to aluminum and aluminum fluoride. Sharma, KP; Sharma, S, 2016)	0.43
" Certainly, the new information will be added to those already established for regulatory purposes as a safe way to promote oral healthcare and prevent oral carcinogenesis."	( Putative mechanisms of genotoxicity induced by fluoride: a comprehensive review. Claudio, SR; da Silva, VHP; de Barros Viana, M; Estadella, D; Oshima, CTF; Ribeiro, DA; Yujra, VQ, 2017)	0.46
" The present study has been undertaken with the aim to assess the F dose-dependent clinical and subclinical symptoms of fluorosis and reversal of the disease by providing safe drinking water."	( Dose-dependent effect of fluoride on clinical and subclinical indices of fluorosis in school going children and its mitigation by supply of safe drinking water for 5 years: an Indian study. Gopalan, V; Gourineni, SR; Khandare, AL; Nagalla, B; Validandi, V, 2018)	0.48
" This paper reviews the present research on the potential adverse effects of overdose fluoride on various organisms and aims to improve our understanding of fluoride toxicity."	( Toxic effects of fluoride on organisms. Chen, K; Chen, L; Kong, M; Lü, P; Qiu, L; Wu, P; Yang, Y; Zuo, H, 2018)	0.48
"The present study aimed to determine the serum trace elements (copper (Cu), zinc (Zn), calcium (Ca), magnesium (Mg)) along with erythrocyte carbonic anhydrase (CA) activity and effect of intervention with safe drinking water for 5 years in the school children of fluorosis endemic area."	( Fluoride Alters Serum Elemental (Calcium, Magnesium, Copper, and Zinc) Homeostasis Along with Erythrocyte Carbonic Anhydrase Activity in Fluorosis Endemic Villages and Restores on Supply of Safe Drinking Water in School-Going Children of Nalgonda District Boiroju, N; Khandare, AL; Validandi, V, 2018)	0.48
" Many studies have shown that the chronic exposure of fluoride in high concentrations causes adverse effects in multiple organs; the use of bioactive compounds present in foods as a tool to mitigate the effects of fluoride could potentially be useful for populations in different parts of the world are exposed to fluoride in a chronic and systemic way."	( Role of polyphenols and nonpolyphenols against toxicity induced by fluoride: a comprehensive review. Aguiar, O; Claudio, SR; Gomes de Moura, CF; Handan, BA; Oshima, CTF; Ribeiro, DA; Viana, MB; Yamauchi, LY, 2019)	0.51
" To determine whether this is also a relevant factor in retinal toxicity, we analyzed eight PFO batches associated with adverse ocular events."	( How to Ward Off Retinal Toxicity of Perfluorooctane and Other Perfluorocarbon Liquids? Dresp, J; Feltgen, N; Hoerauf, H; Lechner, T; Menz, DH; Menz, H; Müller, BK, 2018)	0.48
" (C) A toxic PFO batch (061014) was purified to remove reactive and underfluorinated impurities."	( How to Ward Off Retinal Toxicity of Perfluorooctane and Other Perfluorocarbon Liquids? Dresp, J; Feltgen, N; Hoerauf, H; Lechner, T; Menz, DH; Menz, H; Müller, BK, 2018)	0.48
" The H-value is a measure for reactive and underfluorinated impurities that cause toxicity of PFCLs and should be incorporated in each endotamponade specification with a limit of 10 ppm to prove the effectiveness of the ultra-purification required and ensure a safe product."	( How to Ward Off Retinal Toxicity of Perfluorooctane and Other Perfluorocarbon Liquids? Dresp, J; Feltgen, N; Hoerauf, H; Lechner, T; Menz, DH; Menz, H; Müller, BK, 2018)	0.48
" To address these limitations, efforts to identify sublethal endpoints that increase FET test sensitivity and allow for the prediction of sublethal adverse effects have begun."	( Identifying sublethal endpoints for evaluating neurotoxic compounds utilizing the fish embryo toxicity test. Jeffries, MKS; Krzykwa, JC; Saeid, A, 2019)	0.51
" We believe that dietary salt products are safe at retail, and the long-term dietary exposure of cooking salts will not pose any significant health risk."	( Is the Cooking Salt Safe in China? Assessment of Chemical Contaminants in Cooking Salt. Jia, X; Wang, Z; Zhou, J, 2019)	0.51
" Two major genetic factors that are discussed include genetic polymorphisms in plasma membrane transporters that catalyze uptake and accumulation or efflux and elimination of environmental chemicals, and genetic polymorphisms in bioactivation enzymes that generate toxic and reactive metabolites."	( Environmental and Genetic Factors Influencing Kidney Toxicity. Lash, LH, 2019)	0.51
" SDF treated discs were toxic to HGF and bacteria after 9 weeks of rinsing."	( Cytotoxic effects of silver diamine fluoride. Fancher, ME; Fournier, S; Lallier, TE; Townsend, J, 2019)	0.51
" Excessive accumulation of the toxic methylglyoxal was reversed due to the activation of the glyoxalase system (comprising of glyoxalase I and II) and the ascorbate-glutathione cycle."	( Spermine ameliorates prolonged fluoride toxicity in soil-grown rice seedlings by activating the antioxidant machinery and glyoxalase system. Banerjee, A; Roychoudhury, A; Samanta, S, 2020)	0.56
"The present study was undertaken to investigate the toxic effect of sodium fluoride (NaF)- and fluoride (F)-contaminated groundwater on male reproduction and it's reversibility in male rats."	( A Comparative Analysis of Fluoride-Contaminated Groundwater and Sodium Fluoride-Induced Reproductive Toxicity and Its Reversibility in Male Rats. Chaithra, B; Sarjan, HN, 2020)	0.56
" Second, systemic fluoride uptake is suspected of causing adverse effects, in particular neurotoxicity during early development."	( Developmental fluoride neurotoxicity: an updated review. Grandjean, P, 2019)	0.51
" Neurotoxicity appeared to be dose-dependent, and tentative benchmark dose calculations suggest that safe exposures are likely to be below currently accepted or recommended fluoride concentrations in drinking water."	( Developmental fluoride neurotoxicity: an updated review. Grandjean, P, 2019)	0.51
" Recently, there has been renewed concern in the public sector as to whether fluoride is safe at the current exposure levels."	( Principles of fluoride toxicity and the cellular response: a review. Johnston, NR; Strobel, SA, 2020)	0.56
" These findings suggest that Cd and F can potentiate their individual toxic effects on the liver tissue through disruption of the cellular redox status, inflammation, and apoptosis pathway."	( Co-exposure to non-toxic levels of cadmium and fluoride induces hepatotoxicity in rats via triggering mitochondrial oxidative damage, apoptosis, and NF-kB pathways. Ahangar, N; Amiri, FT; Arab-Nozari, M; Mohammadi, E; Shaki, F; Shokrzadeh, M, 2020)	0.56
" This article reviews current scientific findings on health-related issues on drinking water and discusses the challenges for safe and healthy drinking water in China."	( Challenges for Safe and Healthy Drinking Water in China. Wu, J, 2020)	0.56
" According to literature, water scarcity is still a severe ongoing issue, and regional disparity affects the access to safe and healthy drinking water."	( Challenges for Safe and Healthy Drinking Water in China. Wu, J, 2020)	0.56
"Recently, epidemiological studies have suggested that fluoride is a human developmental neurotoxicant that reduces measures of intelligence in children, placing it into the same category as toxic metals (lead, methylmercury, arsenic) and polychlorinated biphenyls."	( Toxicity of fluoride: critical evaluation of evidence for human developmental neurotoxicity in epidemiological studies, animal experiments and in vitro analyses. Degen, G; Diel, P; Edlund, K; Eisenbrand, G; Engel, KH; Epe, B; Grune, T; Guth, S; Heinz, V; Hengstler, JG; Henle, T; Humpf, HU; Hüser, S; Jäger, H; Joost, HG; Kulling, SE; Lampen, A; Mally, A; Marchan, R; Marko, D; Mühle, E; Nitsche, MA; Nöthlings, U; Röhrdanz, E; Roth, A; Stadler, R; van Thriel, C; Vieths, S; Vogel, RF; Wascher, E; Watzl, C, 2020)	0.56
" A priori, a product was considered safe if the change in measured SMH values over the course of six treatment cycles was both significantly greater than the negative control and was not significantly different from the positive control."	( Laboratory screening evaluation of the safety of low pH oral care rinse products to dental enamel. Chen, H; Grender, JM; Moore, J; Schneiderman, E; Strand, R; White, DJ, 2020)	0.56
" One of the 10 marketed oral care rinses failed to meet the a priori criteria needed to be considered safe as the product was significantly better than the negative control but also significantly lower than the positive control treatment."	( Laboratory screening evaluation of the safety of low pH oral care rinse products to dental enamel. Chen, H; Grender, JM; Moore, J; Schneiderman, E; Strand, R; White, DJ, 2020)	0.56
"The aims of this study were to: (i) examine the toxic effects of sodium fluoride (NaF) in blood, liver, spleen, and brain cells of Wistar rats after the subacute exposure; (ii) explore the potential protective properties of selenium (Se) against fluoride toxicity after the simultaneous administration."	( Genotoxicity of fluoride subacute exposure in rats and selenium intervention. Antonijević, B; Antonijević-Miljaković, E; Baralić, K; Bulat, Z; Ćurčić, M; Djordjevic, AB; Javorac, D; Kolarević, S; Kostić-Vuković, J; Kračun-Kolarević, M; Mandić, J; Mandinić, Z; Marić, JJ; Milutinović-Smiljanić, S; Radovanović, J; Sunjog, K; Vuković-Gačić, B; Đukić-Ćosić, D, 2021)	0.62
" Primary outcome measures were antimicrobial effect and adverse events."	( Effectiveness and Safety of Ozone Therapy in Dental Caries Treatment: Systematic Review and Meta-analysis. Benavent Caldas Bellotto, EF; Bussadori, SK; de Oliveira Cruz Latorraca, C; Martimbianco, ALC; Mota, P; Pacheco, RL; Riera, R; Santos, EM; Santos, GM, 2020)	0.56
" Regarding safety of ozone therapy, results from individual studies presented no adverse events during or after treatment."	( Effectiveness and Safety of Ozone Therapy in Dental Caries Treatment: Systematic Review and Meta-analysis. Benavent Caldas Bellotto, EF; Bussadori, SK; de Oliveira Cruz Latorraca, C; Martimbianco, ALC; Mota, P; Pacheco, RL; Riera, R; Santos, EM; Santos, GM, 2020)	0.56
"Under the same parameters, the combined group and PDT have good germicidal efficacy, but PDT has fewer adverse reactions and less damage."	( [Comparison of the effect and safety of Er:YAG laser combined with fluoride and methylene blue-photodynamic therapy on caries prevention]. Yao, LP; Yu, XH; Zhang, L, 2020)	0.56
"To evaluate and describe the adverse events (AEs) related to fluoride varnish, the US Food and Drug Administration's Manufacturer and User Facility Device Experience database was used."	( Is fluoride varnish safe?: Validating the safety of fluoride varnish. Mascarenhas, AK, 2021)	0.62
" Thus fluoride varnish can be considered a safe dental product."	( Is fluoride varnish safe?: Validating the safety of fluoride varnish. Mascarenhas, AK, 2021)	0.62
" Although F is safe at optimal concentrations in water supply, human exposure to high levels could trigger neurofunctional deficits."	( Human cultured IMR-32 neuronal-like and U87 glial-like cells have different patterns of toxicity under fluoride exposure. Bittencourt, LO; Buzalaf, MAR; Lima, RR; Nogueira, IC; Oliveira, EH; Puty, B, 2021)	0.62
" The fluoride in drinking water is evident to induce toxic effects including neurodegeneration, skeletal and dental fluorosis as well as organ damage."	( Toxic effects of fluoride in intestinal epithelial cells and the mitigating effect of methanol extract of coconut haustorium by enhancing de novo glutathione biosynthesis. Alfarhan, A; Job, JT; Narayanankutty, A; Rajagopal, R; Ramesh, V, 2021)	0.62
" Alternatively, terminal fluorination could have induced a dose-dependent toxic effect on a wide range of cellular processes, leading to cell dysfunction and death."	( Suicide by vaping the synthetic cannabinoid 4F-MDMB-BINACA: cannabinoid receptors and fluoride at the crossroads of toxicity? Anseeuw, K; Covaci, A; Jacobs, W; Mahieu, B; Neels, H; van Nuijs, ALN; Van Rafelghem, B, 2021)	0.62
" Fluoride generates reactive oxygen species and free radicals which induce oxidative stress in target cells and mediate its toxic effects."	( 3,4-Dihydroxybenzaldehyde mitigates fluoride-induced cytotoxicity and oxidative damage in human RBC. Anjum, R; Maheshwari, N; Mahmood, R, 2022)	0.72
" Selenomethionine (Se-Met) at low levels has been reported to alleviate oxidative damage and inflammation caused by toxic substances, but whether it can alleviate fluoride-induced toxicity in zebrafish embryos has not been elucidated."	( Selenomethionine alleviated fluoride-induced toxicity in zebrafish (Danio rerio) embryos by restoring oxidative balance and rebuilding inflammation homeostasis. Cao, J; Chen, J; Cheng, F; Cheng, Y; Feng, C; Wang, G; Wang, T; Yun, S; Zhang, X, 2022)	0.72
" Therefore, the aim of this study was to evaluate and compare the potential toxic effects of a wide range of commercially available SLS and NLS of varying physicochemical properties (lithium (Li) or fluoride (F) content and size)."	( An in vitro assessment of the toxicity of two-dimensional synthetic and natural layered silicates. Brown, DM; Maciaszek, K; Stone, V, 2022)	0.72
"Groundwater co-contamination with toxic pollutants like arsenic-fluoride or lead-fluoride is a serious threat for safe rice cultivation, since major stretches of land, involved in cultivation of this staple food crop are presently experiencing severe endemic pollution from these xenobiotic combinations."	( Rhizofiltration of combined arsenic-fluoride or lead-fluoride polluted water using common aquatic plants and use of the 'clean' water for alleviating combined xenobiotic toxicity in a sensitive rice variety. Banerjee, A; Roychoudhury, A, 2022)	0.72
" A large amount of fluoride accumulated in animals will not only produce the toxic effects, but it also causes cell damage and affect the normal physiological activities of the body."	( Challenges of fluoride pollution in environment: Mechanisms and pathological significance of toxicity - A review. Iqbal, M; Li, Y; Mehmood, K; Tang, Z; Wang, Y; Wu, S; Zhang, H, 2022)	0.72
" Products that pass the non-inferiority test in ACD (surface softening) are proposed as safe for enamel as there is no suggestion from this data that teeth are at risk of tissue loss due to these products."	( Application of non-inferiority testing in microhardness and its relationship to erosion: Relevance for hard tissue safety evaluations. Chen, H; Grender, J; Hornsby, A; Moore, J; Schneiderman, E; St John, S; White, DJ, 2022)	0.72
"To perform a 10-year scientometric analysis of the characteristics of the worldwide publication on the toxic effects of fluoride."	( A 10-year Scientometric Analysis of the Characteristics of the Worldwide Publication on the Toxic Effects of Fluoride. Calderón, KLM; Camayo, JS; Granda, VGC; Gutiérrez-Ilave, M; Mayta-Tovalino, F; Rodríguez, AC, 2022)	0.72
"A bibliometric study of the worldwide scientific production on the toxic effects of fluoride during the years 2011-2020 was performed."	( A 10-year Scientometric Analysis of the Characteristics of the Worldwide Publication on the Toxic Effects of Fluoride. Calderón, KLM; Camayo, JS; Granda, VGC; Gutiérrez-Ilave, M; Mayta-Tovalino, F; Rodríguez, AC, 2022)	0.72
"We found that the "Biological Trace Element Research" was the most productive journal with 22 published manuscripts and that the most productive universities on the systemic toxic effects of fluoride on the body were Shanxi Agricultural University, Guizhou Medical University, and Huazhong University of Science and Technology with 31, 11, and 10 manuscripts, respectively."	( A 10-year Scientometric Analysis of the Characteristics of the Worldwide Publication on the Toxic Effects of Fluoride. Calderón, KLM; Camayo, JS; Granda, VGC; Gutiérrez-Ilave, M; Mayta-Tovalino, F; Rodríguez, AC, 2022)	0.72
" In all 3 days of cytotoxicity testing, the group that used Riva Silver was found to be the least toxic material, while the group that used ChemFil Rock did not have viable cells after the 1st day."	( Comparison of Antibacterial Activity, Cytotoxicity, and Fluoride Release of Glass Ionomer Restorative Dental Cements in Dentistry. Adiguzel, O; Cangul, S; Celenk, S; Eroglu Cakmakoglu, E; Gunay, A; Ozcan, N, 2023)	0.91
"Sustainable remediation of arsenic-fluoride from rice fields through efficient bio-extraction is the need of the hour, since these toxicants severely challenge safe cultivation of rice and food biosafety."	( Bio-priming with a Novel Plant Growth-Promoting Acinetobacter indicus Strain Alleviates Arsenic-Fluoride Co-toxicity in Rice by Modulating the Physiome and Micronutrient Homeostasis. Banerjee, A; Roychoudhury, A, 2023)	0.91
" Healthcare providers and dental professionals should emphasize the importance of promoting safe toothpaste use, especially in vulnerable populations such as young children who are more prone to accidental ingestion."	( Toothpaste ingestion-evaluating the problem and ensuring safety: systematic review and meta-analysis. Kojić, S; Luzio, A; Marković, E; Milić, L; Perić, T; Petrović, B; Stojanović, GM, 2023)	0.91

Pharmacokinetics

Excerpt	Reference	Relevance
" Blood, tissue, and urinary PCTFE concentrations measured postexposure were used to develop a physiologically based pharmacokinetic (PB-PK) model."	( Polychlorotrifluoroethylene (PCTFE) oligomer pharmacokinetics in Fischer 344 rats: development of a physiologically based model. Andersen, ME; Conolly, RB; Kinkead, ER; Pollard, DL; Seckel, CS; Vinegar, A, 1992)	0.28
" Pharmacokinetic studies in growing dogs show that 90% of a single injected fluoride dose is retained shortly after birth, but at maturity it decreases to about 50%."	( Pharmacokinetics of fluoride in man and its clinical relevance. Ekstrand, J; Spak, CJ; Vogel, G, 1990)	0.28
" The pharmacokinetic parameters were calculated according to a linear one-compartment open model."	( Fluoride pharmacokinetics in good and poor responders to fluoride therapy. Baylink, DJ; Farley, SM; Fitzsimmons, RJ; Kraenzlin, C; Kraenzlin, ME, 1990)	0.28
" Pharmacokinetic data should, therefore, form part of the basis for the optimal and safe use of fluoride products."	( Pharmacokinetic aspects of topical fluorides. Ekstrand, J, 1987)	0.55
"The present study was undertaken to estimate bio-availability and biological half-life of fluoride and accumulation of fluoride in bone in the domestic pig."	( Pharmacokinetics of chronic fluoride ingestion in growing pigs. Kragstrup, J; Nielsen-Kudsk, F; Richards, A, 1985)	0.27
" The total estimation of the pharmacokinetic data was performed by a simultaneous curve fitting to all single values, using a direct search procedure based on an open two-compartment model and three-compartment model, respectively."	( [Pharmacokinetics of a fluoride-calcium preparation for the treatment of osteoporosis]. Fuchs, C; Haase, W; Maurer, H, 1984)	0.27
"The pharmacokinetic parameters of fluoride have been studied, after a single oral administration to human volunteers of two fluoridated compounds: sodium fluoride, and a new organic fluoride salt, nicomethanol hydrofluoride."	( [Blood pharmacokinetics of fluorine in man after the oral administration of nicomethanol hydrofluoride]. Cheymol, G; Mahuzier, G; Poitou, P; Souleau, M, 1984)	0.27
" Pharmacokinetic analysis of the net plasma F concentrations showed that the apparent plasma half-life of F was longer when urine was acid (4."	( Fluoride pharmacokinetics during acid-base balance changes in man. Ehrnebo, M; Ekstrand, J; Järnberg, PO; Whitford, GM, 1980)	0.26
"A sex-specific, physiologically based pharmacokinetic (pbpk) model has been developed to describe the absorption, distribution, and elimination of fluorides in rats and humans."	( A physiologically based pharmacokinetic model for fluoride uptake by bone. Beliles, RP; Rao, HV; Turner, CH; Whitford, GM, 1995)	0.49
"The pharmacokinetic profiles of a sustained-release monofluorophosphate (MFP-SR) preparation (76 mg) and of plain MFP (76 mg) were compared in six osteoporotic females."	( Pharmacokinetic profile of a new fluoride preparation: sustained-release monofluorophosphate. Baylink, D; Bettica, P; Farley, S; Libanati, C; Resch, H; Tabuenca, M; Talbot, J; Tritthart, W, 1994)	0.29
"Fluoride pharmacokinetic data are presented for infants given a fluoride supplement."	( Fluoride pharmacokinetics in infancy. Ekstrand, J; Fomon, SJ; Nelson, SE; Ziegler, EE, 1994)	0.29
" There were some significant differences in the maximum F concentration, the area under the salivary fluoride concentration curve (AUC) when plotted against time, and the salivary stimulating effect among the four products, but as a whole they were small and probably of minor clinical importance."	( Salivary fluoride clearance after a single intake of fluoride tablets and chewing gums in children, adults, and dry mouth patients. Birkhed, D; Norén, JG; Persson, LG; Sjögren, K, 1993)	0.29
" The two products were found bioequivalent with regard to the release of fluoride, both on the basis of the AUC and Cmax of fluoride in plasma and of the urinary excretion of fluoride during the 48 h following the administration."	( Bioavailability and pharmacokinetics of fluoride from two glutamine monofluorophosphate preparations. Setnikar, I; Warneke, G, 1993)	0.29
" The various pharmacokinetic parameters measured were not related to changes in LS BMD; however, there was an inverse relationship between trough fluoride concentration during long-term dosing and change in FN BMD."	( Fluoride pharmacokinetics and changes in lumbar spine and hip bone mineral density. Chan, JK; Hosking, DJ; Patel, S, 1996)	0.29
" The method has been successfully used in a pharmacokinetic study."	( Determination of the unstable drug otilonium bromide in human plasma by LC-ESI-MS and its application to a pharmacokinetic study. Ding, L; Fan, HW; Leng, Y; Qi, XM; Rao, YK; Yu, Y; Zhao, YR, 2010)	0.36
" Limited pharmacokinetic data is available in humans; however, human data exists for two communities with drinking water contaminated by PFAAs."	( Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. Andersen, ME; Campbell, JL; Clewell, HJ; Loccisano, AE, 2011)	0.37
" While DSF has been available in various formulations for many years, most of its pharmacokinetic aspects within the therapeutic concentration range have never been fully characterized."	( Short term serum pharmacokinetics of diammine silver fluoride after oral application. Castillo, JL; Chirinos, E; Dills, R; Mancl, LL; Milgrom, P; Taves, DR; Vasquez, E; Watson, GE; Zegarra, G, 2012)	0.38
" A classical three compartments pharmacokinetic model developed for the study of environmental contaminants was fitted to the breath data."	( Post-operative elimination of sevoflurane anesthetic and hexafluoroisopropanol metabolite in exhaled breath: pharmacokinetic models for assessing liver function. Catania, N; Comite, C; Di Francesco, F; Fuoco, R; Ghimenti, S; Onor, M; Pleil, JD; Stiegel, MA; Trivella, MG, 2013)	0.39
" Therefore, a physiologically-based pharmacokinetic model for fluoride published in the literature was used and adapted in Excel for a typical 4-year-old and 8-year-old child."	( A Physiologically-Based Pharmacokinetic Modeling Approach Using Biomonitoring Data in Order to Assess the Contribution of Drinking Water for the Achievement of an Optimal Fluoride Dose for Dental Health in Children. Gagnon, F; Jean, KJ; Valcke, M; Wassef, N, 2018)	0.48
" Serum fluoride and silver were measured, and population pharmacokinetic modeling was used to estimate pharmacokinetic parameters and simulate silver concentration versus time profiles in cohorts of children (15 to 50 kg)."	( Pharmacokinetics of 38 Percent Silver Diamine Fluoride in Children. Chen, KF; Ellenikiotis, H; Lin, YS; Milgrom, P; Rothen, ML; Soleimani-Meigooni, DN; Thompson, B, 2022)	0.72
"3]), and a longer predicted silver half-life (15."	( Pharmacokinetics of 38 Percent Silver Diamine Fluoride in Children. Chen, KF; Ellenikiotis, H; Lin, YS; Milgrom, P; Rothen, ML; Soleimani-Meigooni, DN; Thompson, B, 2022)	0.72

Compound-Compound Interactions

Excerpt	Reference	Relevance
"A study has been made to determine the inhibitory action upon the progress of dental caries of two trace elements (fluorine and molybdenum) combined with chlorohexidine with the goal of increasing the efficiency of fluoride treatment."	( [Effects of inorganic and organic fluorides combined with molybdenum and chlorohexidine upon processes of metabolism, fluoride content, and cariosity of the teeth of Wistar rats (author's transl)]. Kolesnik, AG; Novikov, LL; Schaper, R; Stösser, L; Treide, A, 1980)	0.54
" The third group received topical treatment with the sodium fluoride varnish combined with a NaF + Mg addition to the diet."	( Caries prevention in rats by fluoride varnish treatment combined with addition of fluoride to dietary sugar. Koskinen, M; Luoma, H; Seppä, L; Syrjänen, S, 1984)	0.27
" The results confirm that the change in fluorescence in the dentinal caries lesion is correlated with the very initial changes in mineral content, and that EPMA used in combination with COMPO images is a useful tool for determining small changes in mineral elements in the carious and adjacent areas of dentin."	( Mineral element analysis of carious and sound rat dentin by electron probe microanalyzer combined with back-scattered electron image. Hietala, EL; Larmas, M; Tjäderhane, L, 1995)	0.29
" We thus performed a randomized, double-blind, placebo-controlled intervention study to prospectively investigate the effect of a low dose of fluoride, in combination with HRT, on BMD and biochemical markers of bone turnover."	( Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. Alexandersen, P; Christiansen, C; Riis, BJ, 1999)	0.3
"To compare the effects of one year treatment of estrogen and tamoxifen, either alone or combined with fluoride on bone metabolism in ovariectomized rats."	( [One year observation on effects of estrogen, tamoxifen combined with or without fluoride on preventing bone loss in ovariectomized rats]. Liu, H; Liu, J; Peng, H, 2002)	0.31
"A 3-year, open-label, monocenter study was performed on 60 patients with postmenopausal established osteoporosis treated with monofluorophosphate and calcium supplement (MFP/Ca) combined with hormone replacement therapy (HRT)."	( Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study. Ringe, JD; Setnikar, I, 2002)	0.31
" The results indicate that mucin in combination with various fluorides seems to affect enamel remineralization significantly."	( Effect of mucin alone and in combination with various dentifrices on in vitro Remineralization. Hopfenmuller, W; Kielbassa, AM; Meyer-Lueckel, H; Umland, N, )	0.37
"6 microm CO2 laser irradiation alone or combined with fluoridated products reduced demineralization progression in enamel."	( Effect of the CO2 laser combined with fluoridated products on the inhibition of enamel demineralization. Lima, EB; Nobre-dos-Santos, M; Rodrigues, LK; Steiner-Oliveira, C, 2008)	0.35
" The aim of this in vitro study was to evaluate the effects of fluoride mouthrinses or gels in combination with de-/remineralizing saliva substitutes on dentinal subsurface lesions."	( Mineral distribution of artificial dentinal caries lesions after treatment with fluoride agents in combination with saliva substitutes. Meyer-Lueckel, H; Tschoppe, P, 2011)	0.37
"Under the in vitro conditions chosen, use of fluoride agents in combination with a demineralizing saliva substitute resulted in reduced mineral loss."	( Mineral distribution of artificial dentinal caries lesions after treatment with fluoride agents in combination with saliva substitutes. Meyer-Lueckel, H; Tschoppe, P, 2011)	0.37
" Therefore, this in vitro study evaluated the effects of fluoride toothpastes differing in fluoride concentration in combination with de- and remineralizing saliva substitutes using two lesion types."	( Effects of regular and highly fluoridated toothpastes in combination with saliva substitutes on artificial enamel caries lesions differing in mineral content. Meyer-Lueckel, H; Tschoppe, P, 2012)	0.38
"The aim of this study was to evaluate the anticaries effect of low-fluoride toothpastes combined with hexametaphosphate (HMP) on enamel demineralization."	( Effect of low-fluoride toothpastes combined with hexametaphosphate on in vitro enamel demineralization. da Camara, DM; Danelon, M; Delbem, AC; Miyasaki, ML; Sassaki, KT, 2014)	0.4
" In addition, ProSchmelz did not demonstrate beneficial effects in combination with SN on subsurface dentin lesion remineralization."	( Saliva substitutes in combination with high-fluoride gel on dentin remineralization. Kielbassa, AM; Sampaio, JE; Tschoppe, P; Zandim-Barcelos, DL, 2015)	0.42
"Within the limitations of an in vitro study, it was concluded that the application of a high-fluoride gel did not promote additional effects on remineralization of subsurface dentin lesions in combination with saliva substitutes when compared to products with lower fluoride concentration."	( Saliva substitutes in combination with high-fluoride gel on dentin remineralization. Kielbassa, AM; Sampaio, JE; Tschoppe, P; Zandim-Barcelos, DL, 2015)	0.42
"To test if a novel dual-phase gel system (calcium silicate and phosphate with 1450 ppmF, as NaF/MFP; TG) combined with a toothpaste (calcium silicate and sodium phosphate with 1450 ppmF, as MFP; TG) was able to re-harden previously acid-challenged enamel to a greater extent than other toothpastes."	( Remineralisation effect of a dual-phase calcium silicate/phosphate gel combined with calcium silicate/phosphate toothpaste on acid-challenged enamel in situ. Gupta, AK; Joiner, A; Naeeni, MM; Schäfer, F; Zero, DT, 2014)	0.4
"It is concluded that the test regimen based on the novel dual-phase gel system combined with toothpaste was able to re-harden acid-challenged tooth enamel to a greater extent than a normal fluoride toothpaste."	( Remineralisation effect of a dual-phase calcium silicate/phosphate gel combined with calcium silicate/phosphate toothpaste on acid-challenged enamel in situ. Gupta, AK; Joiner, A; Naeeni, MM; Schäfer, F; Zero, DT, 2014)	0.4
"This in situ study evaluated the effect of fluoride varnish combined with CO2 laser in controlling enamel demineralization caused by cariogenic challenges."	( In situ study of the anticariogenic potential of fluoride varnish combined with CO2 laser on enamel. Colucci, V; Corona, SA; Serra, MC; Souza-Gabriel, AE; Tenuta, LM; Turssi, CP, 2015)	0.42
" It may be concluded that Er:YAG laser was able to control the permeability of eroded root dentin and the combination with fluoride varnish increased laser action."	( Effect of Fluoride Varnish Combined with Er:YAG Laser on the Permeability of Eroded Dentin: An In Situ Study. Carvalho, SC; Colucci, V; Corona, SA; Galo, R; Nemezio, MA; Scatolin, RS, )	0.13
"Four adhesive systems also appropriate for use as enamel sealants were combined with four bracket types, resulting in 16 adhesive-bracket combinations, each of which was tested on 15 permanent bovine incisors."	( Effects of enamel sealing on shear bond strength and the adhesive remnant index : Study of three fluoride-releasing adhesives in combination with metal and ceramic brackets. Ebert, T; Elsner, L; Hanke, S; Hirschfelder, U; Hofmann, E, 2017)	0.46
"To explore the clinical effect of fluoride coating combined with pit and fissure sealing or preventive resin filling on prevention of young first permanent molars caries."	( [Evaluation of the clinical effect of fluoride coating combined with pit and fissure sealing or preventive resin filling on prevention of first permanent molars caries]. Jin, SQ; Luo, LP; Wu, QJ; Xu, Y, 2018)	0.48
"For suspected young permanent molars caries, fluoride coating combined with pit and fissure sealing or separate pit and fissure sealing has a certain effect on prevent dental caries, but the fluoride coating combined with preventive resin filling is better."	( [Evaluation of the clinical effect of fluoride coating combined with pit and fissure sealing or preventive resin filling on prevention of first permanent molars caries]. Jin, SQ; Luo, LP; Wu, QJ; Xu, Y, 2018)	0.48
"To investigate the effect of pit and fissure sealant combined with fluorine protective paint on prevention of children caries aged 5-8 years old."	( [Effects of pit and fissure sealant combined with fluorine protective paint on prevention of children caries aged 5-8 years old]. Lin, J; Yao, H, 2019)	0.51
" They were grouped by random number table method: the control group (60 cases, 109 teeth) underwent pit and fissure sealant, and the experimental group (60 cases, 112 teeth) underwent pit and fissure sealant combined with fluorine protective paint."	( [Effects of pit and fissure sealant combined with fluorine protective paint on prevention of children caries aged 5-8 years old]. Lin, J; Yao, H, 2019)	0.51
"To compare the anti-caries effect and safety of Er:YAG laser combined with fluoride and methylene blue-photodynamic therapy (MB-PDT)."	( [Comparison of the effect and safety of Er:YAG laser combined with fluoride and methylene blue-photodynamic therapy on caries prevention]. Yao, LP; Yu, XH; Zhang, L, 2020)	0.56
"6 μm) combined with a stannous/fluoride-containing solution for preventing erosion in human/bovine enamel."	( Effect of CO2 laser combined with AmF/NaF/SnCl2 solution on the prevention of human and bovine enamel erosion. Engel, Y; Freitas, PM; Mantilla, TF; Ramos-Oliveira, TM; Silva, CVD; Tavares, JP, 2022)	0.72
"To determine the effect of fluoride varnish application combined with a simulated oral environment prior to bracket bonding on the shear bond strength (SBS) between brackets and tooth enamel."	( Effect of fluoride varnish in combination with simulated oral environment on enamel-bracket shear bond strength. Kawamoto, B; Lohfeld, S; Walker, MP; Wang, Y, 2023)	0.91
" However, the impact of Er:YAG laser irradiation combined with fluoride on the dynamic microbial changes that occur in dental plaques is still uncertain."	( The impact of Er:YAG laser combined with fluoride treatment on the supragingival plaque microbiome in children with multiple caries: a dynamic study. Pathak, JL; Pujue, Z; Sujuan, Z; Wenbin, W; Wenyan, H; Yuejun, W; Yuhang, H; Zhenni, L; Ziling, L, 2022)	0.72
" IOS use, in combination with motivational texts and an anti-gingivitis toothpaste, could be further deployed to promote oral hygiene behaviour change in patients and improve gingival health, in a cost-effective manner."	( A randomised controlled trial evaluating the impact of oral health advice on gingival health using intra oral images combined with a gingivitis specific toothpaste. Claydon, N; Daly, S; Newcombe, R; Parkinson, C; Seong, J; West, N, 2023)	0.91

Bioavailability

Excerpt	Reference	Relevance
" The 100% bioavailability of sodium fluoride tablets during fasting was greatly decreased by coadministration of milk products: with Diet 1 the absolute bioavailability calculated from combined plasma and urine data was in the range 50--79% and with Diet 2 it ranged from 50--71%."	( Influence of milk products on fluoride bioavailability in man. Ehrnebo, M; Ekstrand, J, 1979)	0.26
" When apparrent bioavailability was calculated from plasma and from urinary data, there was a great intra- and intersubject variation, as well as poor agreement between the two methods of calculations."	( Fluoride bioavailability after intravenous and oral administration: importance of renal clearance and urine flow. Boréus, LO; Ehrnebo, M; Ekstrand, J, 1978)	0.26
"The bioavailability of Ossin, a drug for the treatment of osteoporosis, containing 40 mg of NaF, was investigated."	( [Biological availability of Ossin, a sodium-fluoride dragee for osteoporosis therapy]. Becker, R, 1979)	0.26
" The presence of iron and vitamins affect the bioavailability of fluoride as measured by the area under the time-plasma fluoride concentration curve."	( Influence of vitamins and iron on plasma fluoride levels in rats. Chan, JT; Jeske, AH; Stark, CM; Wild, TW, )	0.13
"The aims of this work were (a) to assess the oral bioavailability of fluoride delivered from dentifrices and (b) to test for a possible link between the results and clinical data obtained with the same dentifrices."	( Oral fluoride measurements for estimation of the anti-caries efficacy of fluoride treatments. Duckworth, RM; Gilbert, RJ; Morgan, SN, 1992)	0.28
" As the bioavailability of sodium fluoride (NaF) can be impaired by concomitant absorption of calcium, both drugs have to be ingested separately."	( Bioavailability of fluoride in postmenopausal women: comparative study between sodium fluoride and disodium monofluorophosphate-calcium carbonate. Bardin, C; Brouard, A; Kuntz, D; Lioté, F; Liou, A; Terrier, JL, 1992)	0.28
" The release rate was related to the water absorption rate of the tablets."	( Development and testing of bioadhesive, fluoride-containing slow-release tablets for oral use. Bottenberg, P; Cleymaet, R; Coomans, D; de Muynck, C; Michotte, Y; Remon, JP; Slop, D, 1991)	0.28
" Fluoride was measured in plasma and urine with a specific electrode and fluoride bioavailability from the three drugs was compared."	( [Fluoride bioavailability from sodium fluoride alone or in association with different calcium salts]. Bellony, R; Brazier, M; Desmet, G; Fardelonne, P; Sebert, JL, 1991)	0.28
" Compared with fluoride from NaF, the relative bioavailability of fluoride from sepiolite was found to be very weak."	( Bioavailability of fluoride from dietary sepiolite in the lamb. Chaso, A; Madrid, JA; Pascual, R; Salido, GM, 1991)	0.28
" The bioavailability of fluorine was evaluated on the basis of the plasma levels and of the urinary excretion of fluoride."	( Bioequivalence of sodium monofluorophosphate with sodium fluoride and compatibility with calcium. Maurer, H; Setnikar, I, 1990)	0.28
" The bioavailability of F in those dietary elements which have the highest F concentration was determined."	( [Caries prevention through a nutritional vehicle]. Cisternas, P; Guerrero, S; Mönckeberg, F; Villa, A, 1990)	0.28
" It is also very important to determine fluoride contents of foodstuffs and biological samples with regard to bioavailability of fluoride in vivo."	( [Modified microdiffusion method for fluoride analysis of foodstuffs]. Hinoide, M; Koga, H; Takaesu, Y; Tanabe, Y, 1990)	0.28
" In older patients, who may have achlorhydria, calcium carbonate should be taken with food or another form of calcium that is well absorbed should be used."	( Treatment of osteoporosis. What is the role of calcium? Trachtenbarg, DE, 1990)	0.28
"003), suggesting that this difference in efficacy and tolerance is related to a better bioavailability of fluoride provided by MFP than by NaF."	( Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride. Chapuy, MC; Delmas, PD; Duboeuf, F; Dupuis, J; Meunier, PJ, 1990)	0.28
" The bioavailability was evaluated on the basis of the plasma levels and of the urinary excretion of fluoride."	( Relative bioavailability of fluoride from monofluorophosphate tablets after single oral administration. Maurer, H; Setnikar, I, 1990)	0.28
" The fluoride bioavailability from two preparations is identical with an areas under the curve corresponding to 61."	( [Comparison of the fluoride bioavailability from two oral preparations of monofluorophosphate disodium in combination with various calcium salts]. Bellony, R; Brazier, M; Desmet, G; Fardelonne, P; Hary, L; Richard, MO; Sebert, JL, )	0.13
"The relative bioavailability of enteric-coated sodium fluoride (NaF) tablets (10 mg F-) has been assessed following administration with a standard calcium-rich breakfast or calcium-poor lunch, and 2 h before or simultaneously with antacid administration (2."	( Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets. Arnold, P; Biollaz, J; Chapuy, MC; Grandjean, EM; Meunier, PJ; Schelling, JL; Wermeille, M, 1989)	0.28
"The bioavailability of fluoride (F) is not known to be reduced by any food except for milk and milk products."	( [Effect of food on fluoride bioavailability]. Trautner, K, 1989)	0.28
"The aim of the present work was to study the usefulness of disodium monofluorophosphate (MFP) as a milk-fluoridating agent by measuring the bioavailability of F from MFP in milk relative to that of F from NaF in water."	( Fluoride bioavailability from disodium monofluorophosphate fluoridated milk in children and rats. Cisternas, P; Guerrero, S; Monckeberg, F; Villa, A, 1989)	0.28
" The relative bioavailability of F from seafoods was 40."	( Pharmacokinetics of fluoride absorbed from dried seafoods by healthy adults. Hattab, FN, 1988)	0.27
" Bioavailability of F from four dentifrices with either aminefluoride (AMF) or monofluorophosphate (MFP) was compared with that of NaF."	( Human plasma fluoride levels following intake of dentifrices containing aminefluoride or monofluorophosphate. Einwag, J; Trautner, K, 1988)	0.27
" Bioavailability of F from bone-meal, calcium and CaF2 tablets was evaluated in relation to that of NaF."	( Factors influencing the bioavailability of fluoride from calcium-rich, health-food products and CaF2 in man. Einwag, J; Trautner, K, 1987)	0.27
"A factorial experiment was conducted with weanling rats fed a purified diet to determine the influence of dietary magnesium (200, 500 or 2500 ppm) as the carbonate on fluoride bioavailability (2 or 10 ppm as sodium fluoride)."	( Influence of dietary magnesium on fluoride bioavailability in the rat. Cerklewski, FL, 1987)	0.27
"A factorial experiment was conducted with weanling rats fed a purified diet to determine the influence of dietary protein type (casein or lactalbumin) and level (120 or 360 g/kg) on fluoride bioavailability (2 or 10 mg/kg as NaF)."	( Influence of type and level of dietary protein on fluoride bioavailability in the rat. Boyde, CD; Cerklewski, FL, 1987)	0.27
" This was presumably because of the lower, though still significant, bioavailability of 'insoluble' components of the fume particles."	( Toxic and genotoxic action of electric-arc welding fumes on cultured mammalian cells. Arlauskas, A; Baker, RS; Crisp, PT; Ellis, J; Tandon, RK, 1986)	0.27
"50%) as sodium chloride on fluoride bioavailability (2 or 10 ppm as sodium fluoride)."	( Influence of dietary chloride on fluoride bioavailability in the rat. Bills, ND; Cerklewski, FL; Ridlington, JW, 1986)	0.27
" During a 6-wk trial, neither divalent zinc nor divalent iron affected fluoride bioavailability based on skeletal uptake of fluoride."	( Influence of zinc and iron on dietary fluoride utilization in the rat. Cerklewski, FL; Ridlington, JW, 1985)	0.27
" This should help develop the bioavailability profiles for individual foods and beverages essential for accurate assessment of dietary F intake."	( Dietary intake and bioavailability of fluoride. Rao, GS, 1984)	0.27
" The bioavailability of F from the alginate was about 55% of the total F in the administered dose."	( Absorption of fluoride following inhalation and ingestion of alginate impression materials. Hattab, F, 1981)	0.26
" The results showed a less-than-20% bioavailability of fluoride when administered with calcium-rich food."	( Fluoride pharmacokinetics in the domestic pig. Ekstrand, J; Fejerskov, O; Richards, A, 1982)	0.26
" When the pH was less than 5, fluoride absorption rate was inversely related to pH."	( Fluoride absorption through the hamster cheek pouch: a pH-dependent event. Callan, RS; Wang, HS; Whitford, GM, 1982)	0.26
" In contrast, there was no difference in the areas under the curves, indicating that the relative bioavailability of fluoride is the same in all preparations."	( [Bioavailability of monofluoride preparations for dental caries prophylaxis (author's transl)]. Férault-Larue, DH; Fuchs, C; Heimann, G, 1980)	0.26
" In conclusion, the sustained-release preparations of MFP led to a decrease of fluoride bioavailability and avoided high peak serum concentrations."	( A comparative bioavailability study on two new sustained-release formulations of disodiummonofluorophosphate versus a nonsustained-release formulation in healthy volunteers. Erlacher, L; Magometschnigg, D; Templ, H, 1995)	0.29
"This investigation was done to determine the bioavailability of fluoride (F) after toothbrushing associated with different water rinsing procedures."	( Effect of water rinsing after toothbrushing on fluoride ingestion and absorption. Birkhed, D; Ekstrand, J; Sjögren, K, 1994)	0.29
" The bioavailability in dogs was only 60%."	( A biopharmaceutic approach in designing a controlled release tablet of sodium monofluorophosphate: 1. In vitro and in vivo studies in beagle dogs. Ritschel, WA; Vattikonda, CS, 1994)	0.29
" The results indicated that decaffeinated coffee and caffeine had no effect on F metabolism, whereas caffeinated coffee appeared to increase the initial absorption rate but not the 4-hour bio-availability."	( Lack of significant effect of coffee and caffeine on fluoride metabolism in rats. Chen, X; Whitford, GM, 1994)	0.29
" These included fluoride bioavailability tests, enamel lesion de- and remineralisation studies ('pH-cycling') and in situ caries studies."	( The caries preventive effect of a fluoride dentifrice containing Triclosan and zinc citrate, a compilation of in vitro and in situ studies. ten Cate, JM, 1993)	0.29
"A two-way cross-over study was conducted on 12 Caucasian male healthy volunteers aged between 25 and 38 years in order to determine the bioavailability and pharmacokinetics of fluoride after single oral administration in fasting conditions of two products (tablets and powder for oral use) of L-glutamine monofluorophosphate (G-MFP, CAS 116420-36-1)."	( Bioavailability and pharmacokinetics of fluoride from two glutamine monofluorophosphate preparations. Setnikar, I; Warneke, G, 1993)	0.29
"A two-treatment cross-over study was conducted on 8 Caucasian male healthy volunteers aged between 26 and 32 years in order to determine the influence of a standard meal on the bioavailability and pharmacokinetics of fluoride after a single oral administration of tablets containing the equivalent of 10 mg fluoride as sodium monofluorophosphate (Na-MFP, CAS 10163-15-2) in a fixed combination with 300 mg Ca as calcium gluconate and calcium citrate."	( Effects of meal on the pharmacokinetics of fluoride from oral monofluorophosphate. Setnikar, I; Warneke, G, 1993)	0.29
" Since the rate of absorption is also strongly influenced by the rapidity of gastric emptying, we have compared the relative importance of gastric acidity and gastric emptying in overall F absorption."	( Influence of gastric acidity on fluoride absorption in rats. Messer, HH; Ophaug, RH, 1993)	0.29
" The main criticisms of milk fluoridation are decreased bioavailability of the fluoride, the cost and administrative burden involved, and (in some cases) lack of sound clinical conclusions regarding its preventive efficacy."	( Should we use milk fluoridation? A review. Mariño, R, 1995)	0.29
" These figures are likely to be overestimates due to the intake of nutrients from other sources reducing formulae consumption and also due to the lower bioavailability of fluoride from milk-based formulae."	( Fluoride content of infant formulae in Australia. Reynolds, EC; Silva, M, 1996)	0.29
"This paper reports a reassessment of the bioavailability of fluoride from monofluorophosphate (MFP, CAS 10163-15-2)."	( Bioavailability of fluoride administered as sodium fluoride or sodium monofluorophosphate to human volunteers. Morosano, M; Puche, RC; Rigalli, A, 1996)	0.29
"The absolute bioavailability and other pharmacokinetic parameters of two fluoride formulations were investigated in 13 healthy volunteers, aged 61-70 years."	( Absolute bioavailability of fluoride from disodium monofluorophosphate and enteric-coated sodium fluoride tablets. Duursma, SA; Glerum, JH; van Asten, P; van Dijk, A; van Rijn, HJ; Ververs, FF, 1996)	0.29
" MFP had significantly higher bioavailability [102."	( Absolute bioavailability of fluoride from disodium monofluorophosphate and enteric-coated sodium fluoride tablets. Duursma, SA; Glerum, JH; van Asten, P; van Dijk, A; van Rijn, HJ; Ververs, FF, 1996)	0.29
"The MFP formulation showed higher bioavailability with smaller variation than the NaFor formulation."	( Absolute bioavailability of fluoride from disodium monofluorophosphate and enteric-coated sodium fluoride tablets. Duursma, SA; Glerum, JH; van Asten, P; van Dijk, A; van Rijn, HJ; Ververs, FF, 1996)	0.29
" Since the therapeutic effect depends on the concentration of fluoride ions achieved in the plasma, differences in fluoride content and bioavailability must be taken into account when using sodium fluoride or sodium monofluorophosphate."	( [Value of fluoride therapy in osteoporosis]. Ringe, JD, 1997)	0.3
" In conclusion, the results of this study demonstrate that fluoride ingested with milk is excreted through the salivary glands, indicating that the bioavailability of fluoride from milk equals that of other vehicles."	( Fluoride concentration in whole saliva and separate gland secretions in schoolchildren after intake of fluoridated milk. Nederfors, T; Petersson, LG; Twetman, S, 1998)	0.3
"Two studies on the rate and extent of bioavailability of fluoride from a single dose of oral preparations of sodium monofluorophosphate (Na2FPO3) combined with calcium supplement were conducted according to a cross-over design on 18 (Study 1) and 20 (Study 2) male healthy volunteers, respectively."	( Bioavailability and pharmacokinetic characteristics of two monofluorophosphate preparations with calcium supplement. Barkworth, MF; Rovati, LC; Schmid, K; Setnikar, I; Vens-Cappell, B, 1998)	0.3
" The results showed that F absorption increased and F excretion/F absorption rate decreased in 2 groups of rats with fluorosis compared with control group and there were positive correlations between concentration of urine F and water F, as well as concentration of F urine and time of drinking F water."	( [Accumulation and excretion of fluorine and effect of selenium on them in rats with chronic fluorosis]. Bian, J; Ji, Q; Xian, S; Ye, P, 1997)	0.3
"According to previous pharmacokinetic studies the bioavailability of fluorine (F) from sodium monofluorophosphate (MFP) doubles that of sodium fluoride (NaF)."	( In postmenopausal osteoporosis the bone increasing effect of monofluorophosphate is not dependent on serum fluoride. Bocanera, R; Masoni, A; Morosano, M; Pera, L; Puche, RC; Rigalli, A; Tozzini, R, 1999)	0.3
" MFP and P-NaF showed greater bioavailability than Neosten and much higher Cmax that exceeded the toxic threshold of Fser (190 ng/ml)."	( A comparison of fluoride bioavailability from a sustained-release NaF preparation (Neosten) and other fluoride preparations. Gitomer, WL; Pak, CY; Sakhaee, K, 2000)	0.31
" The laboratory results indicate that the calcium and phosphate salts delivered by the remineralizing Enamelon dentifrice increase the bioavailability of fluoride to substantially exceed that of the clinically proven standard dentifrice."	( Laboratory enamel solubility reduction and fluoride uptake from enamelon dentifrice. Schemehorn, BR; Winston, AE; Wood, GD, 1999)	0.3
"The bioavailability of fluoride from krill exoskeleton and the effect of additional calcium on the bioavailability of fluoride from krill paste were evaluated using young rats."	( Reduction of the bioavailability of fluoride from Antarctic krill by calcium. Alvarenga, RC; Tenuta-Filho, A, 1999)	0.3
" Pharmacokinetic experiments done in human volunteers revealed that the bioavailability of fluoride from sodium fluoride (NaF, CAS 7681-49-4) enteric coated tablets was 33% of that of plain (immediate release) tablets."	( Intestinal absorption of fluoride at high luminal concentration of fluoride. Beinlich, A; Puche, RC; Rigalli, A, 2001)	0.31
" The apparently missing detrimental effects of the alkaline deposits on soil microbial activities are probably due to the low bioavailability of contaminants in the calcareous soil."	( Effects of alkaline dust deposits from phosphate fertilizer production on microbial biomass and enzyme activities in grassland soils. Günther, T; Langer, U, 2001)	0.31
" For a new fluoride product the bioavailability of the ion should be demonstrated."	( How to measure the effects of fluoride treatments in clinical trials? The role of caries prevalence and caries assessment. Reich, E, 2001)	0.31
" The purpose of this study is to evaluate the effect of calcium and magnesium to decrease the bioavailability of fluoride in a lethal model of fluoride poisoning."	( Calcium neutralizes fluoride bioavailability in a lethal model of fluoride poisoning. Cairns, CB; Dart, RC; Heard, K; Hill, RE, 2001)	0.31
"6 mM/kg intraperitoneally) to decrease the bioavailability of the fluoride ion."	( Calcium neutralizes fluoride bioavailability in a lethal model of fluoride poisoning. Cairns, CB; Dart, RC; Heard, K; Hill, RE, 2001)	0.31
"Calcium chloride administered simultaneously with sodium fluoride reduces the bioavailability of fluoride poisoning in a mouse model."	( Calcium neutralizes fluoride bioavailability in a lethal model of fluoride poisoning. Cairns, CB; Dart, RC; Heard, K; Hill, RE, 2001)	0.31
"To assess the bioavailability of fluoride added into milk."	( [A study on the bioavailability of fluoride added into milk]. Bian, J; Cao, C; Wang, W, 2001)	0.31
"The bioavailability of fluoride in fluoridated milk reached 80."	( [A study on the bioavailability of fluoride added into milk]. Bian, J; Cao, C; Wang, W, 2001)	0.31
"Fluoride bioavailability in fluoridated milk is still high and sufficient."	( [A study on the bioavailability of fluoride added into milk]. Bian, J; Cao, C; Wang, W, 2001)	0.31
" The bioavailability of fluoride from these diets was evaluated in relation to that of sodium fluoride in solution form."	( Bioavailability of fluoride in humans from commonly consumed diets in India. Gauba, K; Goyal, A; Tewari, A, 1998)	0.3
" Furthermore, the bioavailability of dentifrices, in terms of formation of total fluorine (TF), CaF2, and fluorapatite (FA) on human dental enamel, was evaluated."	( [Dose-response effect of a dentifrice formulation with low fluoride concentration - an in vitro study]. Cury, JA; Negri, HM, )	0.13
" Aquatic organisms living in soft waters may be more adversely affected by fluoride pollution than those living in hard or seawaters because the bioavailability of fluoride ions is reduced with increasing water hardness."	( Fluoride toxicity to aquatic organisms: a review. Camargo, JA, 2003)	0.32
"This paper reports that in the rat coadministration of calcium (calcium chloride, CAS 10043-52-4, Ca2+) enhances intestinal absorption and bioavailability of monofluorophosphate (sodium monofluorophosphate, CAS 10163-15-2, MFP)."	( Intestinal absorption of disodium monofluorophosphate in the rat as affected by concurrent administration of calcium. Beinlich, AD; Brun, LR; Puche, RC; Rigalli, A, 2003)	0.32
" Therefore, a higher fluoride bioavailability is possible."	( Total and acid-soluble fluoride content of infant cereals, beverages and biscuits from Brazil. Buzalaf, MA; Cardoso, VE; de Almeida, BS; Furlani, Tde A; Olympio, KP, 2004)	0.32
" Any differences in fluoride bioavailability between drinking waters in which fluoride is present naturally or added artificially, or the waters are hard or soft, were small compared with large within- and between-subject variations in F absorption."	( Bioavailability of fluoride in drinking water: a human experimental study. Hindmarch, PN; Maguire, A; Mathers, JC; Moynihan, PJ; Steen, IN; Zohouri, FV, 2005)	0.33
" Concerns have been raised about the bioavailability of fluoride from artificially-fluoridated water compared with naturally-fluoridated water."	( The interrelationship between diet and oral health. Moynihan, P, 2005)	0.33
"This double-blind study assessed the fluoride (F) concentration in whole saliva and F bioavailability after the use of low-F dentifrices with reduced pH."	( Low-fluoride dentifrices with reduced pH: fluoride concentration in whole saliva and bioavailability. Bardal, PA; Bastos, JR; Buzalaf, MA; Cardoso, VE; Oliveira, RC; Olympio, KP, 2007)	0.34
" The results suggest a non-significant enhancement of oral Al bioavailability by citrate and maltolate, some Al complex dissociation in the GI tract, and less absorption of Al than citrate or maltolate."	( The influence of citrate, maltolate and fluoride on the gastrointestinal absorption of aluminum at a drinking water-relevant concentration: A 26Al and 14C study. Harris, WR; Yokel, RA; Zhou, Y, 2008)	0.35
"Post-brushing water rinsing may reduce the risk of fluoride (F) ingestion from dentifrice, however the decreased salivary F bioavailability may compromise any consequent anticaries benefits."	( Low-fluoride dentifrice and the effect of postbrushing rinsing on fluoride availability in saliva. Cury, JA; Tenuta, LM; Zamataro, CB, 2008)	0.35
"Changing food patterns in combination with ineffective oral hygiene measures and insufficient bioavailability of fluoride from drinking water and other sources seem to impair the dental health status in developing countries, especially in the younger population."	( Fluoride availability from natural resources in The Gambia--implications for oral health care. Gaengler, P; Jordan, RA; Markovic, L, 2008)	0.35
"Age-related recommendations for oral health care and for additional fluoride bioavailability are given, taking into account local socio-economic conditions in the Republic of The Gambia and similar developing countries."	( Fluoride availability from natural resources in The Gambia--implications for oral health care. Gaengler, P; Jordan, RA; Markovic, L, 2008)	0.35
"This study evaluated the bioavailability of fluoride after topical application of a dual-fluoride varnish commercially available in Brazil, when compared to Duraphat."	( Urinary fluoride output in children following the use of a dual-fluoride varnish formulation. Bijella, MF; Buzalaf, MA; Cardoso, VE; Delbem, AC; Olympio, KP; Pessan, JP, )	0.13
" Consequently, the bioavailability of F tended to be higher on LP than NP or HP diets."	( Effect of long-term fluoride exposure on growth, nutrient utilization and fluoride kinetics of calves fed graded levels of dietary protein. Khan, SA; Lohakare, J; Pattanaik, A, 2010)	0.36
" Because the bioavailability of fluoride is generally reduced in humans when consumed with milk or a calcium-rich diet, it is highly recommended that the inhabitants of fluoride-contaminated areas should incorporate calcium-rich foods in their routine diet."	( Fluoride in the environment and its metabolism in humans. Damodaran, T; Jha, SK; Mishra, VK; Sharma, DK, 2011)	0.37
" Although POs-Ca+F gum was not superior in TMR recovery rate when compared with POs-Ca gum, WAXRD results highlighted the importance of fluoride ion bioavailability in the formation of HAp crystallites in enamel subsurface lesions in situ (NCT01377493)."	( Effects of a chewing gum containing phosphoryl oligosaccharides of calcium (POs-Ca) and fluoride on remineralization and crystallization of enamel subsurface lesions in situ. Hamba, H; Ikeda, M; Kitasako, Y; Sadr, A; Tagami, J; Tanaka, M, 2011)	0.37
" It has been reported that the fluoride bioavailability was reduced with increasing water hardness, however, the dietary fluoride derived from KM exoskeleton accumulates in vertebral bones of marine fish with growth inhibition, as has already been shown for freshwater fish."	( Effect of dietary fluoride derived from Antarctic krill (Euphausia superba) meal on growth of yellowtail (Seriola quinqueradiata). Nagano, I; Yoshitomi, B, 2012)	0.38
" According to the highly individual profile of fluoride in saliva and plaque, both levels of bioavailability correlated for the first 30 minutes, and the fluoride content of saliva and plaque was back to baseline after 6 hours."	( Fluoride bioavailability in saliva and plaque. Arnold, WH; Gaengler, P; Hertenstein, P; Jordan, RA; Kuehnl, P; Markovic, L; Naumova, EA, 2012)	0.38
" However, no significant difference in bioavailability between NaF and amine fluoride, in saliva, or in plaque was found."	( Fluoride bioavailability in saliva and plaque. Arnold, WH; Gaengler, P; Hertenstein, P; Jordan, RA; Kuehnl, P; Markovic, L; Naumova, EA, 2012)	0.38
" Nanoindentation and TOF-SIMS results highlighted the benefits of bioavailability of fluoride ion on reinforcement of the superficial zone of subsurface lesions in situ (NCT01377493)."	( Gum containing calcium fluoride reinforces enamel subsurface lesions in situ. Hamba, H; Ikeda, M; Kitasako, Y; Sadr, A; Tagami, J, 2012)	0.38
" These studies have focused on the availability of fluoride in the toothpaste formulations, its bioavailability in saliva and remnants of disturbed biofilm, its reaction with the dental substrate to form loosely bound reservoirs as well as the ultimate reduction of mineral loss and increase in mineral and fluoride content of caries lesions."	( Laboratory and human studies to estimate anticaries efficacy of fluoride toothpastes. Cury, JA; Tenuta, LM, 2013)	0.39
" Fluoride bioavailability was higher in salivary sediment than in supernatant saliva."	( Dynamic changes in saliva after acute mental stress. Al Khatib, P; Arnold, WH; Bochnig, C; Lee, WK; Naumova, EA; Sandulescu, T; Zimmer, S, 2014)	0.4
"According to translocation regulation of fluoride in the typical oasis soil-plant system under field, an ecological risk assessment model of fluoride was established, and this model was used to assess ecological risk to fluoride pollution from suburban oasis soils in Baiyin City, which was specifically expressed with the potential ecological risk of bioavailability (ER(bc)) model to assess ecological risk of fluoride pollution in oasis regions."	( [Study on ecological risk assessment technology of fluoride pollution from arid oasis soil]. Li, P; Nan, ZR; Wang, SL; Xue, SY, 2014)	0.4
" High-F dentifrice enhanced the bioavailability of salivary F, being an option for caries management in patients with high caries risk."	( Salivary fluoride levels after use of high-fluoride dentifrice. Bohn, AC; Cruz, PF; de Moura, MS; Vale, GC, 2015)	0.42
" This is hypothetically attributed to the action of a partial barrier to fluoride transfer from blood to milk in lactating females and a low bioavailability of fluoride ingested together with milk."	( Reconstructing temporal variation of fluoride uptake in eastern grey kangaroos (Macropus giganteus) from a high-fluoride area by analysis of fluoride distribution in dentine. Death, C; Hufschmid, J; Kierdorf, H; Kierdorf, U; Rhede, D, 2016)	0.43
" This finding is consistent with the expected high bioavailability of free Ni ions in halide solutions."	( Differential Toxicities of Nickel Salts to the Nematode Caenorhabditis elegans. Birdsey, JM; Dobbin, KK; Meyer, D; Wendolowski, MA; Williams, PL, 2016)	0.43
" The soil F bioavailability is an important factor influencing its uptake and contents in teas."	( Soil fluoride fractions and their bioavailability to tea plants (Camellia sinensis L.). Ma, L; Qiao, S; Ruan, J; Wang, J; Yi, X, 2017)	0.46
"This study highlighted the importance of calcium and fluoride ion bioavailability in the reinforcement of demineralized enamel lesions by chewing gums."	( White spot lesion remineralization by sugar-free chewing gum containing bio-available calcium and fluoride: A double-blind randomized controlled trial. Kitasako, Y; Sadr, A; Shimada, Y; Sugiura, M; Sumi, Y; Tagami, J, 2016)	0.43
" Therefore, we suggest that the permitted level of F should be confined within soil quality standards for farmland of China in order to upset the effect of high F concentration on bioavailability of soil Cd."	( Accumulation, interaction and fractionation of fluoride and cadmium in sierozem and oilseed rape (Brassica napus L.) in northwest China. Bao, L; Huang, W; Li, Y; Nan, Z; Sun, H; Wang, S; Zang, F; Zhang, Q, 2018)	0.48
" Evidence is presented to show that fluoride (F) inhibits Na + , K + -ATPase activity by altering biological pathways through modifying the expression of genes and the activity of glycolytic enzymes, metalloenzymes, hormones, proteins, neuropeptides and cytokines, as well as biological interface interactions that rely on the bioavailability of chemical elements magnesium and manganese to modulate ATP and Na + , K + -ATPase enzyme activity."	( Fluoride Exposure Induces Inhibition of Sodium-and Potassium-Activated Adenosine Triphosphatase (Na Waugh, DT, 2019)	0.51
" In salivary sediment bioavailability of fluoride lasted longer after application of fluoridated bioactive glass."	( Randomized investigation of the bioavailability of fluoride in saliva after administration of sodium fluoride, amine fluoride and fluoride containing bioactive glass dentifrices. Arnold, WH; Hill, RG; Kouji, O; Modric, J; Naumova, EA; Pierchalla, T; Rybka, M; Staiger, M, 2019)	0.51
"Toothbrushing with the fluoride containing bioactive glass dentifrices had positive effects on the fluoride bioavailability within two hours."	( Randomized investigation of the bioavailability of fluoride in saliva after administration of sodium fluoride, amine fluoride and fluoride containing bioactive glass dentifrices. Arnold, WH; Hill, RG; Kouji, O; Modric, J; Naumova, EA; Pierchalla, T; Rybka, M; Staiger, M, 2019)	0.51
"Although soy beverages are promoted as healthy alternatives to bovine milk the added sugar and low calcium bioavailability of the soy drink makes frequent consumption a caries risk."	( Effects of soy and bovine milk beverages on enamel mineral content in a randomized, double-blind in situ clinical study. Fernando, JR; Reynolds, C; Reynolds, EC; Shen, P; Stanton, DP; Walker, GD; Yuan, Y, 2019)	0.51
"Both CPP-ACP and bioactive glass enhanced ion release without compromising the bioavailability of fluoride."	( A comparative evaluation of ion release characteristics of three different dental varnishes containing fluoride either with CPP-ACP or bioactive glass. Baysan, A; Hill, RG; Karpukhina, NG; Sleibi, A; Tappuni, AR, 2019)	0.51
" The toxicity and bioavailability of aluminum depends mainly on the form in which it occurs."	( Chemical Speciation of Aluminum in Wine by LC-ICP-MS. Frankowski, M; Karaś, K; Zioła-Frankowska, A, 2020)	0.56
" TSF concentration (µg F/mL) in TR was determined as an indicator of fluoride bioavailability during toothbrushing and the areas under curves of saliva fluoride concentration versus time (area under the curve, AUC = µg F/mL × min) were calculated as an indicator of fluoride bioavailability after toothbrushing."	( Chemically Soluble Fluoride in Na2FPO3/CaCO3-Based Toothpaste as an Indicator of Fluoride Bioavailability in Saliva during and after Toothbrushing. Coelho, CSS; Cury, JA; Tabchoury, CPM, 2020)	0.56
"The aim of this in vitro study was to determine the fluoride concentration in silver diamine fluoride (SDF) products and their bioavailability with demineralized dentine."	( Fluoride Concentration in SDF Commercial Products and Their Bioavailability with Demineralized Dentine. Cury, JA; Soares-Yoshikawa, AL; Tabchoury, CPM, 2020)	0.56
"HCl significantly improved the fluoride bioavailability in CFDs (p<0."	( Enhanced Fluoride Bioavailability with Incorporation of Arginine in Child Dentifrices. Bijle, MN; Carey, CM; Ekambaram, M; Lo, ECM; Tsoi, J; Yiu, CKY, 2020)	0.56
" Incorporating arginine (L-arginine or L-arginine monohydrochloride) at 2% w/w improves fluoride bioavailability of the child formula dentifrices."	( Enhanced Fluoride Bioavailability with Incorporation of Arginine in Child Dentifrices. Bijle, MN; Carey, CM; Ekambaram, M; Lo, ECM; Tsoi, J; Yiu, CKY, 2020)	0.56
"Nano-hydroxyapatite (NHAP), possessing high defluoridation capacity, has been widely used to remove fluoride (F) from polluted water, but little is known about how it affects the bioavailability and toxicity of soil F towards plants."	( Remediation of fluoride contaminated soil with nano-hydroxyapatite amendment: Response of soil fluoride bioavailability and microbial communities. Gan, CD; Jia, YB; Yang, JY, 2021)	0.62
"The use of fluoridated dentifrices is recognized as the main reason for the decline of dental caries and its effect is associated with the bioavailability of fluoride (F) in the oral cavity."	( Nocturnal Salivary Fluoride Bioavailability After Brushing with a High-fluoride Dentifrice. Carvalho, GAO; de Sousa Lopes, MS; Macena, NS; Mota, BIS; Prado, VLG; Santana, GB; Vale, GC, 2022)	0.72
" Mouthrinses with 226 ppm F as NaF and low pH presented significantly greater bioavailability of fluoride on enamel than those with higher pH or lower NaF concentration."	( Fluoride bioavailability on demineralized enamel by commercial mouthrinses. Botelho, JN; Cury, JA; Giacaman, RA; Pedro Ricomini-Filho, A; Tabchoury, CPM; Valdivia-Tapia, AC, )	0.13
" Mouth rinses with 226 ppm F as NaF and low pH presented significantly greater bioavailability of fluoride on enamel than those with higher pH or lower NaF concentration."	( Fluoride bioavailability on demineralized enamel by commercial mouth rinses. Botelho, JN; Cury, JA; Giacaman, RA; Pedro Ricomini-Filho, A; Tabchoury, CPM; Valdivia-Tapia, AC, )	0.13
"Fluoride chemically soluble in toothpaste is an indicator of fluoride bioavailability when the teeth are brushed, and the same should be expected systemically when toothpaste is ingested."	( Soluble Fluoride in Na2FPO3/CaCO3-Based Toothpaste as an Indicator of Systemically Bioavailable Fluoride. Caldas da Rocha, DR; Cury, JA; Ricomini Filho, AP, 2022)	0.72
"Fluoride (F) is an emerging pollutant that originates from multiple sources and adversely affects plant growth and nutrient bioavailability in soil."	( Effects of soil fluoride pollution on wheat growth and biomass production, leaf injury index, powdery mildew infestation and trace metal uptake. Ahmad, MN; Ahmad, Y; Alam, SS; Ashmore, M; Dawar, KM; Mahmood, R; Riaz, M; van den Berg, L; Zia, A, 2022)	0.72
" Moreover, trace metal bioavailability was high in front of industrial discharge areas."	( Assessment of trace elements and fluoride originating from phosphogypsum in the sediment of Gulf of Gabes (southeastern Tunisia): what are the potential sources of accumulation and bioavailability? Aleya, L; Amri, S; Brik, B; Dahim, MA; Martins, MVA; Oueslati, W; Trabelsi, L; Zaaboub, N, 2023)	0.91
" For this endeavor, 21-days-old mice received 10 or 50 mg/L of fluoride in drinking water for 60 days and the results indicated that the increased plasma fluoride bioavailability was associated with the triggering of short- and long-term memory impairments after high F concentration levels."	( Prolonged exposure to high fluoride levels during adolescence to adulthood elicits molecular, morphological, and functional impairments in the hippocampus. Aragão, WAB; Bittencourt, LO; Buzalaf, MAR; de Carvalho Cartágenes, S; Dionizio, A; do Socorro Ferraz Maia, C; Ferreira, MKM; Lima, RR; Puty, B; Zohoori, FV, 2023)	0.91
"25%β-CaGPn into 1100F formulation increased the bioavailability of calcium and phosphate, promoting a higher remineralizing effect."	( Effect of the association of microparticles and nano-sized β-calcium glycerophosphate in conventional toothpaste on enamel remineralization: In situ study. Danelon, M; de Camargo, ER; Delbem, ACB; Emerenciano, NG; Gonçalves, FMC; Quinteiro, JP; Silva-Sousa, YTC, 2023)	0.91

Dosage Studied

Clinicians prescribing home-applied high-concentration fluorides need to be cognizant of the symptoms of fluoride toxicity, carefully monitor the patient's compliance with the treatment regimen. A dose-response relationship has been recently described for fluoride exposure and bronchial hyper-responsiveness.

Excerpt	Relevance	Reference
" This view is supported by the following facts: (a) mersalyl acted with a similar dose-response curve upon an intact as well as a detergent-dispersed cyclase preparation while no effect was observed upon a solubilized Mg2+-ATPase preparation; (b) a covalent p-chloromercuribenzoate-Sephadex preparation (but not its supernatant) inhibited the cyclase from intact membranes."	( Adenylate cyclase from rat-liver plasma membrane: inhibition by mersalyl and other mercurial derivatives. Hanoune, J; Mavier, P, 1975)	0.25
" In the described series of investigations this compound, with which treatment by gradual dosage is possible, has proved its effectiveness."	( [Sodium fluoride in the therapy of osteoporosis]. Krokowski, E, 1979)	0.26
" Dose-response curves to hormones, fluoride, and GMP-P (NH)P were not affected by age."	( Hormone-sensitive fat cell adenylate cyclase in the rat. Influences of growth, cell size, and aging. Cooper, B; Gregerman, RI, 1976)	0.26
" Intravenous injection of parathyroid hormone over the dosage range from 1-50 mug/kg resulted in a dose-dependent increase in phosphate and cyclic AMP excretion with both D-fed and D-deficient thyroparathyroidectomized rats."	( Renal adenylate cyclase and the interrelationship between parathyroid hormone and vitamin D in the regulation of urinary phosphate and adenosine cyclic 3',5'-monophosphate excretion. Anast, CS; Forte, LR; Nickols, GA, 1976)	0.26
" Noradrenaline affinity to the binding sites was decreased and the dose-response curve for the stimulation of adenylate cyclase activity by adrenaline was shifted to the right in hypothyroidism."	( Influence of thyroid state on the specific binding of noradrenaline to a cardiac particulate fraction and on catecholamine-sensitive cardiac adenylate cyclase activity. Will-Shahab, L; Wollenberger, A, 1976)	0.26
" The possible role of cyclic AMP in the action of LH was reexamined by studying the dose-response effect of LH on the stimulation of progesterone synthesis, cyclic AMP-dependent protein kinase activation, and cyclic AMP accumulation."	( Reevaluation of the role of cyclic adenosine 3',5'-monophosphate and protein kinase in the stimulation of steroidogenesis by luteinizing hormone in bovine corpus luteum slices. Ling, WY; Marsh, JM, 1977)	0.26
" Less fluoride was deposited in teeth and bone from AIF6, than from NaF at all dosage levels."	( Dental fluorosis as related to the concentration of fluoride in teeth and bone. Aasenden, R; Bakhos, Y; Brudevold, F, 1978)	0.26
" It is suggested that the decreased bioavailability produced by dairy products should be taken into account when establishing flouride dosage regimens for prophylaxis of caries."	( Influence of milk products on fluoride bioavailability in man. Ehrnebo, M; Ekstrand, J, 1979)	0.26
" Plasma and tissue SMFA concentrations were generally lower than the corresponding stomach fluid SMFA concentrations for all dosage groups."	( Inorganic and organic fluoride concentrations in tissues after the oral administration of sodium monofluoroacetate (Compound 1080) to rats. Egekeze, JO; Oehme, FW, 1979)	0.26
" growth inhibition of cultured cells, and additional a two-peaked dose-response curve was found with cadmium."	( 51Cr release cytotoxicity assay evaluated with fluoride and cadmium. Holland, RI, 1978)	0.26
" A dosage schedule is recommended that decreases the dose of fluoride in infancy and that is inversely related to the concentration of fluoride in the drinking water."	( Dietary fluoride supplementation for the prevention of caries. Newbrun, E, 1978)	0.26
"This study provides the first morphological evidence of significant structural damage following high doses of enflurane alone and confirms previous findings of transient renal functional abnormalities following high dosage enflurane."	( Enflurane nephrotoxicity and pre-existing renal dysfunction. Cousins, MJ; David, W; Fulton, A; Haynes, G; Whitehead, R, 1978)	0.26
" Daily dosage was 50-100 mg."	( [Treatment of osteoporosis with a delayed-action sodium fluoride preparation]. Chlud, K, )	0.13
" Older tooth germs were less affected overal when incubated at the same fluoride dosage and time of treatment."	( Regeneration of tooth development in vitro following sodium fluoride treatment. Kerley, MA; Kollar, EJ, 1977)	0.26
" The drug acted with a similar dose-response curve upon intact as well as detergent-dispersed cyclase preparations."	( RMI 12330 A, an inhibitor of adenylate cyclase in rat liver. Berthelot, P; Guellaen, G; Hanoune, J; Mahu, JL; Mavier, P, 1977)	0.26
" At this dosage of 1 MAC hour, which is equivalent to use as a supplement, UFV did not sub-anaesthetic doses of enflurane are administered at this time interval there appears to be no increased risk of nephrotoxicity."	( Metabolism of enflurane in man following a second exposure. Cousins, MJ; Norgate, CE; Sharp, JH, 1976)	0.26
" The predominant factors in the production of methoxyflurane nephrotoxicity appear to be high methoxyflurane dosage and serum inorganic fluoride concentration."	( Methoxyflurane nephropathy. Mazze, RI, 1976)	0.26
" In comparison to estimates of fluoride intake from communal water supplies, the recommended dosage from fluoride supplements results in daily doses that may be two to six times greater, on the average, for the infant less than age 6 months and three times greater for the average 3-year-old."	( Dietary fluoride intake from supplements and communal water supplies. Infante, PF, 1975)	0.25
" Methoxyflurane dosage was sufficiently low that renal abnormalities did not occur except in rats treated also with phenobarbital; these animals developed polyuria and the morphologic lesion typically associated with F--induced nephrotoxicity."	( A comparison of renal effects and metabolism of sevoflurane and methoxyflurane in enzyme-induced rats. Beppu, WJ; Cook, TL; Hitt, BA; Kosek, JC; Mazze, RI, )	0.13
" The techniques studied should be of particular importance to the pharmaceutical industry where efforts are being made to reduce the levels of particulate matter in parenteral dosage forms."	( Glass for parenteral products: a surface view using the scanning electron microscope. Brown, JA; Roseman, TJ; Scothorn, WW, 1976)	0.26
" via toothpaste the narrow range between beneficial and detrimental dosage the avoidance of fluoride-enriched waste water the prerogative of minimal manipulation of drinking water content."	( Drinking water fluoridation and caries prophylaxis: with special consideration of the experience in the former East Germany. Hahn, T; Netuschil, L; Schweinsberg, F, 1992)	0.28
" Throughout Europe, product dosage and age related dose recommendations for fluoride supplements vary widely."	( A European view of fluoride supplementation. Clarkson, J, 1992)	0.28
"These results suggest that the fluoride dosage regimen commonly proposed is effective against dental caries and does not need any change to reduce the risk of fluorosis."	( [Dental caries, fluoride tablets and enamel opacities]. D'Hoore, W; Van Nieuwenhuysen, JP, )	0.13
" The direct dose-response relation between effectiveness and fluoride concentration of toothpastes is far from clear-cut and, at best, is weak."	( The need for toothpastes with lower than conventional fluoride concentrations for preschool-aged children. Horowitz, HS, 1992)	0.28
" The results of this study suggest that the new rinse may provide a greater cariostatic effect at the same fluoride dosage than does a NaF rinse."	( In vivo fluoride concentrations measured for two hours after a NaF or a novel two-solution rinse. Carey, CM; Chow, LC; Mao, Y; Takagi, S; Vogel, GL, 1992)	0.28
", dose-response effects."	( Sample size considerations in designing studies with intra-oral models. Beiswanger, BB; Dunipace, AJ; Katz, BP; Stookey, GK, 1992)	0.28
" Plaque fluoride measured after four weeks' daily use of the dentifrices exhibited similar dose-response behavior."	( Oral fluoride measurements for estimation of the anti-caries efficacy of fluoride treatments. Duckworth, RM; Gilbert, RJ; Morgan, SN, 1992)	0.28
" A reduction in the dosage of fluoride supplements is recommended for children aged from three to six years (14."	( Current regulations and recommendations concerning water fluoridation, fluoride supplements, and topical fluoride agents. Newbrun, E, 1992)	0.28
"This study evaluated the dose-response relationship between four increasing levels of fluoride from 1000 to 2500 ppm F as sodium monofluorophosphate (MFP) and three-year dental caries increments, as measured by DMFS, DMFT, and DFS-A on 4424 schoolchildren."	( A fluoride dose-response evaluation in an anticaries clinical trial. Cancro, L; Conti, AJ; D'Agostino, R; Marks, RG; Moorhead, JE, 1992)	0.28
" The lipopeptides N-palmitoyl-(S)-[2,3-bis(palmitoyloxy)-(2RS)- propyl]-(R)-cysteinylalanylglycine, N-palmitoyl-(S)-[2,3-bis(palmitoyloxy)- (2RS)-propyl]-(R)-cysteinylseryl-lysyl-lysyl-lysine and (S)-(1,2- dicarboxyhexadecyl)ethyl-N-palmitoylcysteinylseryl-lysyl-lys yl-lysine stimulated both parameters, but the maximal effects on nitrite formation and the shape of the dose-response curves did not parallel the effects on [Ca2+]i."	( Induction and activity of NO synthase in bone-marrow-derived macrophages are independent of Ca2+. Bessler, W; Busse, R; Hauschildt, S; Kohler, J; Lückhoff, A; Mülsch, A, 1990)	0.28
"Proper dosage of dietary fluoride supplements is important for children without access to optimally fluoridated water to balance dental caries prevention and risks of dental fluorosis."	( Provider compliance with recommended dietary fluoride supplement protocol. Levy, SM; Muchow, G, 1992)	0.28
" Hence the evidence does not suggest that this proven caries-inhibiting F- drop/tablet regime dosage should be reduced."	( Incisor enamel mottling prevalence in child cohorts which had or had not taken fluoride supplements from 0-12 years of age. Gilmour, WH; McCall, DR; Stephen, KW, 1991)	0.28
"In order to achieve the greatest clinical benefit from the use of fluoride, we must understand its mechanism of action, so that fluoride can be given at the right time, by the best route, at the optimum dosage and in the most suitable form."	( Fluoride and caries prevention: 2. Clinical rationale. Blinkhorn, AS, 1991)	0.28
" The dose-response curve for sugar and caries is approximately sigmoid (S-shaped)."	( Why free sugars consumption should be below 15 kg per person per year in industrialised countries: the dental evidence. Sheiham, A, 1991)	0.28
" The AAPD guide is reviewed, with dosage recommendations provided."	( Water purification systems and recommendations for fluoride supplementation. Glass, RG, )	0.13
"In order to achieve the greatest clinical benefit from the use of fluoride, we must understand its mechanism of action, so that fluoride can be given at the right time, by the best route, at the optimum dosage and in the most suitable form."	( Fluoride and caries prevention: 1. Scientific rationale. Levine, RS, 1991)	0.28
" Hence, retrospective analyses of data were undertaken, from a 3-yr double-blind caries clinical trial where a linear fluoride dose-response had been obtained."	( Improved sensitivity in caries clinical trials by selection on the basis of baseline caries experience. Burchell, CK; Huntington, E; Schäfer, F; Stephen, KW, 1991)	0.28
" The reasons for this could be due to the study design (unchanged high dosage over four years in contrast to the commonly used individual adaptation of dosage and time); however, also the earlier positive results could be an error."	( [Fluoride therapy of osteoporosis]. Ziegler, R, 1991)	0.28
" Studies on rats, sheep, and pigs have provided details of dosage regimens which produce lesions which resemble those described in human fluorosis."	( Nature and mechanisms of dental fluorosis in animals. Richards, A, 1990)	0.28
" In a prospective study, 35 patients with osteoporosis were treated for about 44 months with a mean dosage of 31."	( Urinary fluoride excretion in responders and nonresponders after fluoride therapy in osteoporosis. De Raadt, ME; Duursma, SA; Glerum, J; Karsdorp, NJ; Raymakers, JA; Van Dijk, A, 1990)	0.28
", co-incubation with fluoride shifted the biphasic calcitonin dose-response curve to a range of lower calcitonin concentrations)."	( Calcitonin (but not calcitonin gene-related peptide) increases mouse bone cell proliferation in a dose-dependent manner, and increases mouse bone formation, alone and in combination with fluoride. Farley, JR; Hall, SL; Tarbaux, NM, 1989)	0.28
" Fluoride supplements beginning with the newborn infant at two weeks of age should be prescribed in accordance with the dosage schedules of the American Academy of Pediatrics and the American Dental Association."	( A fluoride analysis program to reduce tooth decay in rural children. Nichols, WA, 1989)	0.28
" Therefore, the dosage schedule used by 56% of the physicians is higher than the optimal, 27."	( [Fluoroprophylaxis of dental caries. Current status in the provinces of Genoa and Savona]. Cohen, A; Gandolfo, A; Mallamaci, L; Zecca, L; Zecca, M, 1989)	0.28
" The correct dosage must be determined based on patient age and fluoride content of the patient's main water source(s)."	( Dietary fluoride supplements for children--the role of the physician. Alderman, EJ; Alley, JW; Kuthy, RA; Levy, SM, 1989)	0.28
" The correct dosage must be determined based on patient age and fluoride content of the patient's main water source(s)."	( Dietary fluoride supplements for Nebraska's children--the role of the physician. Kuthy, RA; Levy, SM; Young, KL, 1989)	0.28
" The correct dosage must be determined, based on patient age and fluoride content of the patient's drinking water."	( Dietary fluoride supplements for Tennessee's children: the role of the physician. Collier, DR; Kuthy, RA; Levy, SM; Light, R, 1989)	0.28
" The link between phospholipase C activation and these early events of the mitogenic response is demonstrated by the similarity of all dose-response curves for NaF and AlCl3 and by the common sensitivity of the four events to pertussis toxin."	( Coupling between phosphoinositide breakdown and early mitogenic events in fibroblasts. Studies with fluoroaluminate, vanadate, and pertussis toxin. Chambard, JC; Paris, S; Pouysségur, J, 1987)	0.27
" However, a significant anti-caries dose-response was demonstrated over the SMFP range used."	( A 3-year oral health dose-response study of sodium monofluorophosphate dentifrices with and without zinc citrate: anti-caries results. Burchell, CK; Creanor, SL; Downie, CF; Huntington, E; Russell, JI; Stephen, KW, 1988)	0.27
"There exists such a wide margin of safety for prenatal fluoride in regard to fluorosis that 2 mg/day can be used as a simplified prenatal fluoride dosage in all areas, regardless of whether they are fluoridated."	( Optimum dosage for prenatal fluoride supplementation (PNF): Part IX. Glenn, FB; Glenn, WD, )	0.13
" The impact of the variation in drinking-water fluoride concentrations on supplementary fluoride dosage is discussed and recommendations made."	( Variations in the fluoride levels of drinking water in South Africa. Implications for fluoride supplementation. Dreyer, AG; Grobler, SR, 1988)	0.27
" The methoxydifluoroacetate is largely excreted without further metabolism, although a small percentage of this metabolite is broken down to yield fluoride and oxalate, as determined by urine analysis of rats dosed with synthetic methoxydifluoroacetate."	( In vivo nuclear magnetic resonance studies of hepatic methoxyflurane metabolism. II. A reevaluation of hepatic metabolic pathways. London, RE; Perlman, ME; Selinsky, BS, 1988)	0.27
" In this way, the appropriate dosage supplement can be determined and prescribed, and unnecessary risks of fluorosis can be avoided."	( Expansion of the proper use of systemic fluoride supplements. Levy, SM, 1986)	0.27
" Group I was intubated with the Maximum Tolerable Dosage (MTD) of NaF (70 mg/kg)."	( Effects of fluoride on the mouse sperm morphology test. Dunipace, AJ; Li, Y; Stookey, GK, 1987)	0.27
"Three weeks after dosing male Fischer 344 rats with streptozotocin to induce diabetes, enflurane was administered ip, and 1 h later, fluoride levels were measured in plasma and livers were removed."	( Effect of streptozotocin-induced diabetes in the rat on the metabolism of fluorinated volatile anesthetics. Conney, AH; Pantuck, CB; Pantuck, EJ, 1987)	0.27
" This should begin at about 2 weeks of age; the dosage will depend on the concentration of fluoride in the local water supply."	( American Academy of Pediatrics. Fluoride supplementation. Committee on Nutrition. , 1986)	0.27
" A clear dose-response pattern for the above toxic effects was evident with 10 ppm in the males being an effect level."	( Inhalation toxicity of hexafluoroisobutylene. Cramp, AL; Darr, RW; Gad, SC; Hoffman, GM; Peckham, JC; Rusch, GM, 1986)	0.27
" This means that, for dose-response studies of dental fluorosis in this animal, it is not possible to achieve steady-state plasma concentrations as a basis for correlations to the degrees of pathological change observed in the teeth."	( Pharmacokinetics of chronic fluoride ingestion in growing pigs. Kragstrup, J; Nielsen-Kudsk, F; Richards, A, 1985)	0.27
"The aim of this study was to assess the practical value of peroral xylitol at low to moderate dosage as a caries preventive measure."	( Xylitol and caries: the collaborative WHO oral disease preventive programme in Hungary. Bánóczy, J; Scheinin, A, 1985)	0.27
" Barriers to appropriate use include the following factors: complexity of the dosage schedule; priority of preventive regimens in educational institutions; economic factors; and lack of public knowledge--clearly a barrier to their acceptance, appropriate use, and compliance."	( Ways to improve/increase appropriate use of dietary fluorides. Horowitz, AM, )	0.38
"Cumulative dose-response curves were obtained for contractions induced by fluoride in bovine facial veins and arteries in the presence and absence of external Ca (Cao)."	( Effects of vasoactive drugs on fluoride-induced contractions of vascular smooth muscle in calcium-free solution. Nguyen-Duong, H, 1985)	0.27
" After dosage of hens with protective compounds, protection lasts until about 70% of the enzyme site again becomes available for phosphorylation."	( Organophosphorus and other inhibitors of brain 'neurotoxic esterase' and the development of delayed neurotoxicity in hens. Johnson, MK, 1970)	0.25
" The dose-response curve for cAMP formation stimulated by epinephrine was shifted 1 log unit to the right in uremic muscle and adenylyl cyclase stimulation by epinephrine was shifted 1 log unit."	( Skeletal muscle amino acid metabolism in chronic uremia. Garber, AJ; Maillet, C, 1980)	0.26
" There was an absence of relation of the exit dosage to the diameter of the patient and a proportionality of the heart dose to the exit dose."	( Cardiac catheterization: dosimetry on patients. Aletti, P; Claudon, M; Hoeffel, JC; Lostette, Y; Noel, A; Pernot, C, 1980)	0.26
" This paper explores the relationships between microdosimetric concepts and a description of TL properties, such as TL dose-response curves and TL LET dependence."	( Microdosimetry and thermoluminescence. Kliauga, P; Li, K; Rossi, HH, 1984)	0.27
" Twelve per cent of the samples warranted adjustment from the full dosage fluoride supplement."	( Fluoride analyses of patient water supplies requested by North Carolina health professionals. Bawden, JW; Bowden, BS; Levy, SM; Rozier, RG, 1984)	0.27
"There is a dose-response relationship between the prevalence of the questionable category of dental fluorosis as reported by various authors and the drinking water fluoride level."	( Dose-response relationship between water fluoride levels and the category of questionable dental fluorosis. Myers, HM, 1983)	0.27
"Fifteen patients with multiple myeloma were treated with sodium fluoride (50 mg twice daily) plus calcium carbonate (1 g four times daily) or with the same fluoride-calcium dosage plus vitamin D (50,000 U twice weekly)."	( Effect of sodium fluoride, calcium carbonate, and vitamin D on the skeleton in multiple myeloma. Jowsey, J; Kyle, RA, 1980)	0.26
" Based on the available data an advice was given for the dosage of NaF in patients with osteoporosis."	( Fluoride in serum and bone during treatment of osteoporosis with sodium fluoride, calcium and vitamin D. Backer Dirks, O; Duursma, SA; van der Sluys Veer, J; van Kesteren, RG; Visser, WJ, 1982)	0.26
" In general, the dog studies attest to the usefulness of the intravenous human studies for certain U6+ dose-response data and interface well with new retention data on intravenous uranyl citrate in dogs by Stevens et al."	( Inhalation and intravenous studies of UF6/UO2F2 in dogs. Beiter, H; Gelein, R; Morrow, P; Picano, J; Scott, J; Yuile, C, 1982)	0.26
" This dosage turned out to be too low for an effective inhibition of caries."	( [Dental caries in the cantons of Glarus and Waadt, 4 years and 8 years after the introduction of fluordized salt]. Marthaler, TM; Steiner, M, 1981)	0.26
" Sodium fluoride in moderate therapeutic dosage possibly can retard or completely inhibit the activity of bone-resorbing enzymes in the otospongiotic focus, thus retarding or arresting active expansion of a focus and resulting in stabilizing or arresting the progression of sensorineural hearing loss that is associated with otospongiosis."	( Effect of fluoride on alpha-chymotrypsin. Kacker, SK; Shambaugh, GE, 1980)	0.26
" Although salt effects clearly varied with the different anions, the magnitude and dose-response of stimulation of homogenates by Cl- salts were also dependent on the accompanying alkali cation (Li+, Na+, K+, Rb+, Cs+)."	( Anions and cations as stimulators of liver adenylate cyclase. Gregerman, RI; Katz, MS; Kelly, TM; Piñeyro, MA, 1980)	0.26
" Dose-response curves of neuropeptide-induced inositol phosphate generation were dramatically displaced to the right by either 10 microM AntD or 20 microM AntG."	( Substance P-related antagonists inhibit vasopressin and bombesin but not 5'-3-O-(thio)triphosphate-stimulated inositol phosphate production in Swiss 3T3 cells. Freemont, PS; Newman, RH; Rozengurt, E; Seckl, MJ, 1995)	0.29
" Increasing concentrations of NaF (5, 10, 15 ppm F), Na-Silicofluoride, or NaMFP showed similar caries-inhibiting effects without remarkable influence of the fluoride dosage used."	( The effects of non-fluoridated and fluoridated milk on experimental caries in rats. Grosser, W; Kneist, S; Stösser, L, 1995)	0.29
" The dosage of 26."	( Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study. Bisset, JP; Loeb, G; Mennecier, I; Richard, P; Sebert, JL, 1995)	0.29
" However, because higher minimum alveolar concentration of sevoflurane requires a large dosage of anesthetic than other volatile anesthetics, air pollution with sevoflurane in the operating room might be of great concern."	( [Air pollution by sevoflurane in operating room and serum and urine inorganic fluoride of anesthetists]. Fukushima, K; Ochiai, R; Sato, M; Shibata, K; Shimada, M; Takahashi, J; Takeda, J, 1995)	0.29
" However, the number of teeth affected by these enamel defects and their severity did not follow the dose-response relationship expected from the fluoride levels in the drinking water."	( Dental enamel opacities in three groups with varying levels of fluoride in their drinking water. Ellwood, RP; O'Mullane, DM, 1995)	0.29
" Two studies are underway that attempt to describe the dose-response relationship between waterborne fluoride and osteoporosis."	( Fluoride and bone health. Phipps, K, 1995)	0.29
" The model applied for the analysis may be thought to be the best means for the moment to relate dose-response dependencies with what is known or can be hypothesized about the mechanisms underlying activation of adenylate cyclase."	( Analysis of effects of corticotropin, forskolin and fluoride on activity of adenylate cyclase of bovine adrenal cortex. de Foresta, B; Juska, A, 1995)	0.29
" Pathological change in fetal femur presented dose-response relationship with their bone fluoride content."	( [Relationship between bone fluoride content, pathological change in bone of aborted fetuses and maternal fluoride level]. Dai, G; Shi, J; Zhang, Z, 1995)	0.29
" administration can be improved for controlled release dosage forms if the drug release is confined to segments of gastrointestinal tract responsible for absorption."	( Biopharmaceutic approach in designing a controlled release tablet of sodium monofluoro phosphate. Characterization of absorption sites and evaluation of modified dosage form. Herbert, C; Ritschel, WA; Vattikonda, CS, 1994)	0.29
" It is concluded that in sevoflurane anesthesia of long duration, F, sevoflurane dosage and duration of administration do not affect renal function."	( [Effects of inorganic fluoride, inhalation time and dosage of sevoflurane on renal function during sevoflurane anesthesia of long duration]. Hirasaki, A; Nagase, M; Nishiyama, T; Tamai, H; Watanabe, S, 1994)	0.29
" With respect to fluoride levels, clear dose-response relationships have been demonstrated."	( Fluoride toothpastes, rinses, and tablets. Stephen, KW, 1994)	0.29
" Dosage of ascorbic acid was increased to 750 mg per day, keeping the dosages of other drugs unchanged to Group B children."	( Reversal of clinical and dental fluorosis. Gupta, RC; Gupta, SK; Seth, AK, 1994)	0.29
" The release mechanism from the developed dosage form followed the square root of time relationship."	( A biopharmaceutic approach in designing a controlled release tablet of sodium monofluorophosphate: 1. In vitro and in vivo studies in beagle dogs. Ritschel, WA; Vattikonda, CS, 1994)	0.29
" Other drugs, such as fluoride, are employed for their known effects on bone, but in excess dosage can be harmful by producing mineralisation defects."	( Drug-induced disorders of bone metabolism. Incidence, management and avoidance. Jones, G; Sambrook, PN, 1994)	0.29
" Bronchial responsiveness was expressed as the dose-response slope of the line through the origin and last data point."	( Relation between exposure to fluoride and bronchial responsiveness in aluminium potroom workers with work-related asthma-like symptoms. Boe, J; Ekstrand, J; Kongerud, J; Søyseth, V, 1994)	0.29
" dosing with 200 mg/kg HFE to rat, trifluoroacetic acid and trifluoroacetaldehyde hydrate were identified as urinary metabolites."	( Role of P4502E1 in the metabolism of 1,1,2,2-tetrafluoro-1-(2,2,2-trifluoroethoxy)-ethane. Dekant, W; Herbst, J; Kerssebaum, R; Köster, U, 1994)	0.29
" Four studies examined the effects of different concentrations of fluoride, established dose-response profiles with NaF and Na2PO3F, and tested commercial dentifrices."	( An in vitro model for studying the efficacy of fluoride dentifrices in preventing root caries. Beiswanger, AJ; Dunipace, AJ; Stookey, GK; Zhang, W, 1994)	0.29
" A re-evaluation of the need for and dosage schedules of fluoride supplements is warranted."	( Fluoride supplements: current effectiveness, side effects, and recommendations. Ismail, AI, 1994)	0.29
" Dose-response studies were performed with aluminum fluoride and various inhibitors of cytosolic calcium oscillations."	( Mechanisms underlying phasic contractions of pregnant rat myometrium stimulated with aluminum fluoride. Phillippe, M, 1994)	0.29
" Determining the effective dosage is essential."	( [Indications and limitations of non-hormonal treatments of osteoporosis]. Avouac, B, )	0.13
" As the phosphate concentration was increased, the biphasic fluoride dose-response curve was shifted to a lower range of fluoride concentrations."	( Fluoride increases net 45Ca uptake by SaOS-2 cells: The effect is phosphate dependent. Farley, JR; Hall, SL; Herring, S; Tanner, MA, 1993)	0.29
" For each dose the average residual NTE activity in the three tissues 24 h after dosing and the clinical ataxia severity on peak days 15-17 (score out of 4) was: 5 mg/kg: 13, 14, 27% (2,2,2,1); 10 mg/kg: 10, 14, 12%, (4,3,2); 15 mg/kg: 10,11,17%, (3,3,4); 20 mg/kg: 6, 10, 8% (3,3,3,2)."	( The R-(+)isomer of O-n-hexyl S-methyl phosphorothioamidate causes delayed neuropathy in hens after generation of a form of inhibited neuropathy target esterase (NTE) which can be reactivated ex vivo. Johnson, MK; Safi, JM, 1993)	0.29
" An appropriate new dosage schedule for fluoride supplements should be aimed only at identifiable high caries-risk individuals, not at groups defined by age or residence and should result in much lower fluoride intake in the age span birth-eight years than many current recommendations."	( Fluoride supplements in caries prevention: a literature review and proposal for a new dosage schedule. Riordan, PJ, 1993)	0.29
" Australian randomized study of 50 patients is described where NaF dosage is varied proportional to the osteoblast response, and duration is dependent on densitometric and radiographic response."	( Fluoride treatment of osteoporosis: cyclical non-blinded or continuous blinded studies? Bhagat, CI; Gutteridge, DH; Jones, CE; Kent, GN; Nicholson, GC; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG, 1993)	0.29
" Internal validation of in situ models using fluoride dose-response controls is considered to be necessary for studies evaluating the efficacy of new fluoride dentifrice formulations."	( In situ caries models. Zero, DT, 1995)	0.29
" These compounds are the most widely used sources of fluoride in dentifrices, and dose-response clinical standards are available for both."	( The application of in situ models for evaluation of new fluoride-containing systems. Faller, RV, 1995)	0.29
" A limited number of in situ model studies has been conducted, and some fluoride dose-response information has been obtained."	( Model investigations of caries inhibition by fluoride-releasing dental materials. Erickson, RL; Glasspoole, EA, 1995)	0.29
" We conducted a study using lithium fluoride chips to measure the radiation dosage to the surgeon and the operating theatre personnel."	( Radiation dosage from use of the image intensifier in orthopaedic surgery. Goh, PS; Khong, KS; Lo, NN, 1996)	0.29
" If supplements are recommended for children, a more cautious dosage schedule should be used."	( The place of fluoride supplements in caries prevention today. Riordan, PJ, 1996)	0.29
" Plasma fluoride absorption curves were measured from 0 to 6 h after ingestion of MFP at baseline and during long-term dosing in 21 patients with vertebral osteoporosis (T scores < or = 2)."	( Fluoride pharmacokinetics and changes in lumbar spine and hip bone mineral density. Chan, JK; Hosking, DJ; Patel, S, 1996)	0.29
" Thus, periods of especially elevated plasma-fluoride levels in chronically fluoride-stressed deer can cause a disruption in the function of secretory ameloblasts similar to that following acute fluoride dosing in rodents."	( Disturbances of the secretory stage of amelogenesis in fluorosed deer teeth: a scanning electron-microscopic study. Kierdorf, H; Kierdorf, U, 1997)	0.3
" (2) After 90 days of oral administration, no toxicity reaction was found in the lowest dosage group (25 mg/kg), but gastric mucosa was found to have slight injury in the highest dosage group (100 mg/kg), which was conformable to the result of the cumulative toxicity test."	( [A toxicological study on ammonium oxofluoromolybdate [(NH4)2MoO2F4]]. Li, Y; Liu, X; Lu, L, 1996)	0.29
" Cumulative dose-response studies were performed using oxytocin and aluminum fluoride with and without 2-nitro-4-carboxyphenyl-N, N-diphenylcarbamate (NCDC), an inhibitor of PI-PLC."	( The relationship between oxytocin, phosphoinositide-specific phospholipase C, and phasic myometrial contractions. Phillippe, M, )	0.13
" PCMBS inhibited F uptake by up to 83% in a dose-response manner."	( pH-dependent fluoride transport in intestinal brush border membrane vesicles. Ganapathy, V; He, H; Isales, CM; Whitford, GM, 1998)	0.3
" A dose-response relationship has been recently described for fluoride exposure and bronchial hyper-responsiveness, but whether fluorides are the causative agent, co-agent or simply markers for the causative agent(s) for potroom asthma, remains to be determined."	( Exposures in the alumina and primary aluminium industry: an historical review. Abramson, M; Benke, G; Sim, M, 1998)	0.51
"The dose-response of LiF:Mg,Ti (TLD-100) exposed to 15 and 35 kVp (8."	( Thermoluminescent response and relative efficiency of TLD-100 exposed to low-energy x-rays. Brandan, ME; Buenfil, AE; Flores, A; Gamboa-deBuen, I; Rodríguez-Villafuerte, M; Ruiz, CG, 1998)	0.3
" To optimise anticaries benefits and minimise the risk of fluorosis greater control of the fluoride dosing of the drinking water is required."	( Urinary fluoride levels and prevalence of dental fluorosis in three Brazilian cities with different fluoride concentrations in the drinking water. Bastos, JR; Bastos, R; Heintze, SD, 1998)	0.3
"Despite limitations of available measurements in the early production period, we have concluded that the exposure estimates from this study provide a reasonable tool for the estimation of dose-response relations in subsequent epidemiological analyses."	( Exposure to PAH and fluoride in aluminum reduction plants in Norway: historical estimation of exposure using process parameters and industrial hygiene measurements. Haldorsen, T; Romundstad, P; Rønneberg, A, 1999)	0.3
" The conclusions are limited to the information received but there is a clear trend to lower dosage recommendations and no fluoride supplementation to very young children."	( International fluoride supplement recommendations. Banting, DW, 1999)	0.3
" Recent changes in fluoride dosage schedules and deferment of the age of commencing the use of supplements, implemented in many countries, have followed from these concerns."	( Fluoride supplements for young children: an analysis of the literature focusing on benefits and risks. Riordan, PJ, 1999)	0.3
" It is apparent that the current ADA dosage schedule is too high and requires modification; however, the availability of this known-to-be-effective regimen should not be eliminated or restricted."	( The role of dietary fluoride supplements in caries prevention. Horowitz, HS, 1999)	0.3
" This finding prompted another round of dosage schedule recommendations in the early 1990s."	( Overview of the history and current status of fluoride supplementation schedules. Adair, SM, 1999)	0.3
" By altering the present recommended dosage we may deprive children from receiving a proven effective dose."	( The case for retaining the current supplementation schedule. Moss, SJ, 1999)	0.3
" Fluorosis could be prevented, in part, by stopping the improper prescription of fluoride supplements in optimally fluoridated areas and by lowering the dosage currently recommended by the Council on Dental Therapeutics supplemental fluoride schedule."	( The case for reducing the current Council on Dental Therapeutics fluoride supplementation schedule. Newbrun, E, 1999)	0.3
" In the case of supplements, for example, there are differences in the recommended dosage schedules."	( Government policies on fluoride utilization in the Nordic countries. Wang, NJ, 1999)	0.3
" A dose-response relationship was recognized between these F doses and renal tissue injury."	( Toxicokinetics of intravenous fluoride in rats with renal damage caused by high-dose fluoride exposure. Dote, T; Hashiguchi, N; Kono, K; Miyata, K; Nishiura, H; Senda, J; Shimahara, M; Tagawa, T; Tanaka, Y; Usuda, K, 2000)	0.31
" Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol."	( The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate. Feldwick, MG; Mead, RJ; Menon, KI; Noakes, PS, 2001)	0.31
" Dose-response relations were investigated by internal comparisons using Poisson regression and by stratified analyses for standardized mortality ratio."	( Nonmalignant mortality among workers in six Norwegian aluminum plants. Andersen, A; Haldorsen, T; Romundstad, P, 2000)	0.31
" Chronic, low-level dosage of silicofluoride (SiF) has never been adequately tested for health effects in humans."	( Association of silicofluoride treated water with elevated blood lead. Coplan, MJ; Dykes, JE; Hone, BT; Masters, RD, 2000)	0.31
" There is clear evidence for a dose-response relationship between F(-) concentration and caries-preventive effect (25-30% caries reduction achieved with a 1,000 ppm F(-) dentifrice)."	( Is the fluoride concentration limit of 1,500 ppm in cosmetics (EU guideline) still up-to-date? Bloch-Zupan, A, 2001)	0.31
" Eyes and eyelids were macroscopically scored for signs of irritation beginning 3 hours after dosing and periodically until recovery or 35 days."	( Pathology of ocular irritation with acetone, cyclohexanol, parafluoroaniline, and formaldehyde in the rabbit low-volume eye test. Carr, GJ; Cavanagh, HD; Jester, JV; Li, LI; Maurer, JK; Molai, A; Parker, RD; Petroll, WM, )	0.13
" The current dose-response relationship between caries and extrinsic sugars suggests that the sugars levels above 60 g/person/day for teenagers and adults increases the rate of caries."	( Dietary effects on dental diseases. Sheiham, A, 2001)	0.31
" The results of these experiments indicate that sodium fluoride administered at higher concentrations than the usual caries preventive dosage made the generation time of cariogenic oral bacteria and fungi longer, slowing down their multiplication."	( Effect of fluoride on cariogenic oral microorganisms (an in vitro study). Bánóczy, J; Gintner, Z; Herczegh, A; Kamotsay, K; Nász, I; Rozgonyi, F, 2002)	0.31
" Oral administration of strontium salt at low dosage level stimulate bone formation and decrease bone resorption."	( [New osteoformative agents for osteoporosis]. Chaouat, D, 2002)	0.31
" Using the dose-response curves measured for MTS-N detectors after 137Cs gamma ray irradiation and local doses calculated using Monte Carlo generated electron tracks, it was possible to predict the relative TL effectiveness for different X ray energies."	( Microdosimetric interpretation of the photon energy response of LiF:Mg,Ti detectors. Bilski, P; Kim, JL; Olko, P, 2002)	0.31
"5, with 275, 550 and 1,100 ppm F (NaF/silica) were developed in order to assess dose-response effects."	( [Dose-response effect of a dentifrice formulation with low fluoride concentration - an in vitro study]. Cury, JA; Negri, HM, )	0.13
"0 per cm(2), respectively for the rats with varied doses of fluoride, in a dose-response pattern but without statistical significance."	( [Effects of fluoride on osteoclastic activity of rats in vitro]. Bu, LS; Hua, K; Li, GS, 2003)	0.32
"This research suggests that the risk for proximal caries in the posterior primary dentition is raised if contact points are dosed compared to those that are open."	( Interproximal contact points and proximal caries in posterior primary teeth. Allison, PJ; Schwartz, S, )	0.13
"Fluoride concentration in rat hippocampus was significantly correlated with the dosage of fluoride, and there were significant differences among high dosage group [(13."	( [Studies on fluoride concentration and cholinesterase activity in rat hippocampus]. Guo, ZY; Hu, CL; Wang, QN; Zhai, JX; Zhu, QX, 2003)	0.32
" In order to validate this modified model, a dose-response evaluation with fluoride was made."	( A modified pH-cycling model to evaluate fluoride effect on enamel demineralization. Argenta, RM; Cury, JA; Tabchoury, CP, )	0.13
", the dose-response relationship."	( Relationship between dentifrice fluoride concentration and clinical caries reduction. Fisher, SW; Gambogi, RJ; Joziak, M; Mellberg, JR; Tavss, EA, 2003)	0.32
" Reviews of the dental literature identified fair evidence supporting the effectiveness of both fluoride supplements and varnish, although information describing effectiveness and adverse outcomes of supplementation with the most recent dosage schedule is not available."	( Physicians' roles in preventing dental caries in preschool children: a summary of the evidence for the U.S. Preventive Services Task Force. Bader, JD; Frame, PS; Lohr, KN; Rozier, RG, 2004)	0.32
" In addition, the short-term stability was measured to verify the validity of the fitted dose-response curve immediately after beam startup."	( The stability of liquid-filled matrix ionization chamber electronic portal imaging devices for dosimetry purposes. Louwe, RJ; Mijnheer, BJ; Tielenburg, R; van Herk, MB; van Ingen, KM, 2004)	0.32
" It is imperative that each country calculates its own optimal level of fluoride in drinking water based on the dose-response relationship of fluoride in drinking water with the levels of caries and fluorosis."	( Determining the optimal concentration of fluoride in drinking water in Pakistan. Khan, AA; O'Mullane, D; Whelton, H, 2004)	0.32
"There was significant dose-response relationship between the drinking water fluoride and the prevalence of dental fluorosis or the prevalence of defect dental fluorosis."	( [Study on the application of benchmark dose and biological monitoring indexes of fluorides in drinking water]. Chen, BH; Chen, LS; Li, JF; Liang, YX; Wang, CS; Xiang, QY; Zhen, SQ; Zhou, MS, 2004)	0.55
"To obtain baseline knowledge of levels of dental caries in 12-year-old children residing in areas with varying levels of fluoride in drinking water in Pakistan; and to observe a dose-response relationship between the prevalence of dental caries at different concentrations of fluoride in drinking water."	( Is the fluoride level in drinking water a gold standard for the control of dental caries? Khan, AA; O'Mullane, D; Whelton, H, 2004)	0.32
" The influence of pH, temperature, agitation rate and gas concrete dosage on F(-) removal was investigated by conducting a series of batch adsorption experiments."	( Adsorption of fluoride on gas concrete materials. Oguz, E, 2005)	0.33
" On the other hand, correct dosage is important to prevent the risk of dental fluorosis."	( Recommendations for the use of fluoride in caries prevention. Barthel, CR; Jahn, KR; Zimmer, S, 2003)	0.32
"Clinicians prescribing home-applied high-concentration fluorides need to be cognizant of the symptoms of fluoride toxicity, carefully monitor the patient's compliance with the treatment regimen, and adjust the dosage or mode of application to control the total ingested dose of fluoride."	( Controlling the fluoride dosage in a patient with compromised salivary function. Carey, CM; Eichmiller, FC; Eidelman, N, 2005)	0.58
" The dosage of SDS required for ECF was much less than those for dispersed air flotation (DiAF) or dissolved air flotation (DAF) processes because the CaF(2) particles can be collected by hydro-fluoro-aluminum flocs in ECF."	( Removal of fluoride from semiconductor wastewater by electrocoagulation-flotation. Hu, CY; Kuan, WH; Lee, YD; Lo, SL, 2005)	0.33
" Broken and absent teeth were observed in rats dosed with 250 mg kg(-1) day(-1), and microscopic tooth lesions (ameloblast degeneration/disorganization) occurred at 100 and 250 mg kg(-1) day(-1) and persisted with decreased severity throughout recovery."	( Subchronic toxicity of a fluoroalkylethanol mixture in rats. Buck, RC; Everds, NE; Ladics, GS; Makovec, GT; Stadler, JC, 2005)	0.33
" Since correct dosing is important not only for effective caries prophylaxis but also in order to guarantee food safety, the production of fluoridated salt must be accurately monitored."	( Quality control in the production of fluoridated food grade salt. Trachsel, S, 2005)	0.33
"The aim of this study was to establish methodologies for verification of the fluoride solution dose-response relationship using bovine enamel and pH-cycling models."	( Fluoride dose response in pH-cycling models using bovine enamel. Cunha, RF; Cury, JA; Delbem, AC; Rodrigues, E; Sassaki, KT; Vieira, AE, )	0.13
"Means and standard deviations of absorbance values for each group and percentage inhibitory dosage (%ID) for each test material were calculated."	( Cytotoxicity of a new toothpaste based on an ion exchange resin mixture. Li, Y; Muñoz, CA; Torrado, A; Valiente, M; Zhang, W, 2005)	0.33
" The influence of varying the conditions for removal of fluoride, such as the pH of aqueous solution, the initial fluoride concentration, the dosage of adsorbent, and temperature on removal of fluoride have been investigated."	( Factors influencing the removal of fluoride from aqueous solution by calcined Mg-Al-CO3 layered double hydroxides. Duan, X; Evans, DG; He, J; Lv, L; Wei, M, 2006)	0.33
" This study was designed to assess whether asthma occurs excessively among potroom workers and if so, delineate dose-response relationships for possible causal risk factors."	( Incidence of asthma among aluminum workers. Cantley, LF; Cullen, MR; Fiellin, MG; Rabinowitz, PM; Sircar, KD; Slade, MD; Taiwo, OA; Vegso, SJ, 2006)	0.33
" This paper describes the studies and results of dose-response and linearity at much higher doses."	( The dose-response of Harshaw TLD-700H. Luo, LZ; Ramlo, MJ; Rotunda, JE; Velbeck, KJ, 2006)	0.33
" In this study, regeneration temperature, regeneration duration, contact time, regenerated bone char dosage and particle size were investigated."	( Optimization of regenerated bone char for fluoride removal in drinking water: a case study in Tanzania. Kaseva, ME, 2006)	0.33
"Optical absorption (OA) dose-response of LiF:Mg,Ti (TLD-100) is studied as a function of electron energy (ionisation density) and irradiation dose."	( Search for ionisation density effects in the radiation absorption stage in LiF:Mg,Ti. Avila, O; Brandan, ME; Buenfil, AE; Gamboa-Debuen, I; Horowitz, YS; Ipe, N; Nail, I; Olko, P; Oster, L; Rodríguez-Villafuerte, M; Ruiz-Trejo, C; Tovar, VM, 2006)	0.33
" The acidified toothpastes showed a dose-response relationship with all variables."	( In vitro evaluation of acidified toothpastes with low fluoride content. Brighenti, FL; Buzalaf, MA; Delbem, AC; Oliveira, FA; Ribeiro, DB; Sassaki, KT, 2006)	0.33
"87 mg/L in a dose-response manner."	( Dose-effect relationship between drinking water fluoride levels and damage to liver and kidney functions in children. Chen, X; He, P; He, W; Liu, J; Wang, A; Xia, T; Xiong, X; Yang, K, 2007)	0.34
" Optimal parameters needed to obtain highly accurate dosage from LiF powder was investigated, including the setup of the Harshaw 4000 reader."	( Optimum parameters of TLD100 powder used for radiotherapy beams calibration check. Arib, M; Dari, F; Messadi, A; Yaich, A, 2006)	0.33
" Influence of varying the conditions for removal of fluoride, such as the fluoride concentration, the pH of aqueous solution, the dosage of adsorbent, the temperature on removal of fluoride, and the adsorption-desorption studies were investigated."	( Removal of fluoride from aqueous phase by biosorption onto algal biosorbent Spirogyra sp.-IO2: sorption mechanism elucidation. Rajkumar, B; Ramanaiah, SV; Sarma, PN; Venkata Mohan, S, 2007)	0.34
" In this study, we present the first report of a dose-response relationship after exposure to potassium aluminium tetrafluoride (KAlF(4)) and the influence of smoking and atopy."	( Respiratory and ocular symptoms in workers exposed to potassium aluminium-tetrafluoride soldering flux. Karlsson, JE; Larsson, B; Nielsen, J, 2007)	0.34
" The beginning of an attempt to explain this unusual effect is offered in the framework of the track structure theory and kinetic modelling of the beta ray dose-response of the first and second readouts."	( Ionisation density effects following optical excitation in LiF:Mg, Ti (TLD-100). Horowitz, Y; Oster, L; Weiss, D, 2007)	0.34
"Numerous methods have been described employing various materials for fluoride removal due to the risk of high fluoride dosing for human health."	( Screening of commercial sorbents for removal of fluoride in synthetic and groundwater. Elizalde-González, MP; Hernández-Montoya, V; Trejo-Vázquez, R, 2007)	0.34
" Accordingly, adsorption characteristics of fluoride onto schwertmannite adsorbent were studied in a batch system with respect to changes in initial concentration of fluoride, equilibrium pH of sample solution, adsorbent dosage and co-existing ions."	( Removal of fluoride ions from aqueous solution at low pH using schwertmannite. Asai, S; Eskandarpour, A; Ochieng, A; Onyango, MS, 2008)	0.35
" Dose-response curves for VX exposure were generated after applying the fluoride ion reactivation assay to the RBC fraction of serially collected whole blood samples that were taken after whole-body exposures that varied in both duration and concentration."	( Gas chromatography-tandem mass spectrometry analysis of red blood cells from Göttingen minipig following whole-body vapor exposure to VX. Burnett, DC; Byers, CE; Gaviola, BI; Hulet, SW; Jakubowski, EM; McGuire, JM; Thomson, SA, )	0.13
" This sensitive method was successfully applied to the analysis of soman in rat plasma immediately post-exposure, resulting in the construction of dose-response plots."	( Validation and application of a GC-MS method for determining soman concentration in rat plasma following low-level vapor exposure. Dabisch, PA; Evans, RA; Jakubowski, EM; McGuire, JM; Renner, JA; Thomson, SA; Totura, AL, )	0.13
" Analysis of the supplementation behavior indicated that the majority (58%) of the children that should have received fluoride supplements were receiving the incorrect dosage or not being supplemented."	( Relationship of naturally occurring fluoride in Carroll County, Maryland to aquifers, well depths, and fluoride supplementation prescribing behaviors. Osso, D; Roberts, M; Romberg, E; Syme, S; Tinanoff, N, 2008)	0.35
" Diagnosis was based on the characteristic radiologic aspect, and confirmed by the dosage of serum and urine levels of fluorine."	( [Cervical myelopathy revealing bone fluorosis]. Béjia, I; Ben Hammouda, M; Ben Othman, M; Bergaoui, N; Douki, W; Mahmoud, I; Najjar, MF; Touzi, M; Younes, M; Zrour-Hassen, S, 2008)	0.35
" Bovine enamel blocks were subjected to the models and treated with F solutions containing from 70 to 280 microg F/mL in order to validate them in terms of dose-response effect."	( pH-cycling models to evaluate the effect of low fluoride dentifrice on enamel de- and remineralization. Cury, JA; Hara, AT; Paes Leme, AF; Queiroz, CS, 2008)	0.35
" The debate for advocating xylitol use in caries prevention is advancing; however, chewing gum use by young schoolchildren in the United States is hindered by choking hazard concerns and lack of specific xylitol dosing recommendations."	( The potential of dental-protective chewing gum in oral health interventions. Ly, KA; Milgrom, P; Rothen, M, 2008)	0.35
" There was a dose-response effect with respect to both impregnation time and the concentration of the F solution."	( Uptake and release of fluoride from fluoride-impregnated chewing sticks (miswaks) in vitro and in vivo. Baeshen, HA; Birkhed, D; Kjellberg, H; Lingström, P, 2008)	0.35
" The influence of pH, dosage of polyanilines, initial fluoride concentration and temperature on the amount of fluoride removed by the polyanilines were studied."	( Defluoridation of water via doping of polyanilines. Elango, KP; Karthikeyan, M; Satheeshkumar, KK, 2009)	0.35
" Based on the current state of the widespread presence of fluorides in oral hygienic means and employment of topical fluoride-containing preventives the recommendation of systemic administration of fluoride supplements addresses children at increased caries risk only, over three years old and invariably in individual dosage schedule related to fluoride intake background."	( Is systemic fluoride supplementation for dental caries prevention in children still justifiable? Broukal, Z; Lencová, E; Oganessian, E, 2007)	0.58
"Eleven of the reports evaluated dosage schedules similar to that recommended by the American Dental Association."	( Fluoride supplements, dental caries and fluorosis: a systematic review. Hasson, H; Ismail, AI, 2008)	0.35
"The current study proposes a pH-cycling model to verify the dose-response relationship of fluoride-releasing materials in their ability to reduce in vitro demineralization."	( PH-cycling model to verify the efficacy of fluoride-releasing materials in enamel demineralization. de Oliveira, MS; Delbem, AC; Pedrini, D; Rodrigues, E, )	0.13
" The results showed that with increasing applied potential and electrolysis time, the Al(3+) dosage increases, and thereby favouring the fluoride ions removal."	( Study on the treatment of photovoltaic wastewater using electrocoagulation: fluoride removal with aluminium electrodes--characteristics of products. Aoudj, S; Drouiche, N; Ghaffour, N; Hecini, M; Lounici, H; Mameri, N, 2009)	0.35
" Potential benefits include recovery of phosphate for reuse, lower required dosage of calcium for fluoride removal, and less amount of CaF(2) sludge."	( Selective separation of phosphate and fluoride from semiconductor wastewater. Liu, JC; Warmadewanthi, B, 2009)	0.35
"6 mg/kg body weight) for the dose-response relationship study."	( Time-dependent changes of blood parameters and fluoride kinetics in rats after acute exposure to subtoxic hydrofluoric acid. Dote, T; Imanishi, M; Kono, K; Tanida, E; Tsuji, H; Yamadori, E, 2009)	0.35
"Test products were: new dentifrice formulation in a fluoride dose-response (0; 675; 1426 ppm F as sodium fluoride [NaF-0; NaF-675; NaF]); Elmex Kariesschutz (1400 ppm F as amine fluoride [AmF]); and Oral-B Pro-Expert (1450 ppm F-1100 ppm F as stannous fluoride and 350 ppm F as sodium fluoride [SnNaF])."	( Laboratory assessment of the anticaries potential of a new dentifrice. Chauhan, VK; Lippert, F; Lynch, RJ; Newby, EE; Schemehorn, BR, 2009)	0.35
"05) as compared to a benchmark commercial desensitizing toothpaste containing 2% potassium ion, dosed as potassium nitrate, after two weeks, four weeks, and eight weeks of product use."	( Comparing the efficacy in reducing dentin hypersensitivity of a new toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride to a benchmark commercial desensitizing toothpaste containing 2% potassium ion: an eight-week clinical study Bartolino, M; Costacurta, M; Cummins, D; Delgado, E; DeVizio, W; Dibart, S; Docimo, R; Mateo, LR; Maturo, P; Montesani, L; Zhang, YP, 2009)	0.35
"Compared with yogurt consumption at the lowest tertile (<1 time/week), its intake at the highest level (> or =4 times/week) was significantly associated with a lower prevalence of dental caries, showing a clear dose-response relationship (adjusted prevalence ratio=0."	( Intake of dairy products and the prevalence of dental caries in young children. Miyake, Y; Sasaki, S; Tanaka, K, 2010)	0.36
"36-ppm-F community, our results indicate that the use of a low-fluoride dentifrice promotes a proportionally higher increase in plaque [F] when compared with that achieved with a conventional dentifrice, based on dose-response considerations."	( Effects of regular and low-fluoride dentifrices on plaque fluoride. Alves, KM; Buzalaf, MA; Pessan, JP; Ramires, I; Sampaio, FC; Taga, MF; Whitford, GM, 2010)	0.36
" A dose-response regarding F(-) intake and excretion was detected."	( Proteomic analysis of urine in rats chronically exposed to fluoride. Buzalaf, MA; da Silva, TL; de Oliveira, RC; Domont, GB; dos Santos, LD; Kobayashi, CA; Leite, Ade L; Nogueira, FC; Palma, MS; Santos, KS, )	0.13
" This critical review of literature showed that the currently available pH-cycling models are appropriate to detect dose-response and pH-response of fluoride dentifrices, and to evaluate the impact of new active principles on the effect of fluoridated dentifrices, as well as their association with other anti-caries treatments."	( pH-cycling models for in vitro evaluation of the efficacy of fluoridated dentifrices for caries control: strengths and limitations. Buzalaf, MA; Delbem, AC; Hannas, AR; Honório, HM; Magalhães, AC; Rios, D, )	0.13
" Both the proton and alpha particle relative TL efficiencies of the high-temperature TL (HTTL) peaks 7 and 8 are underestimated by an order of magnitude suggesting that the HTTL efficiencies are affected by other factors in addition to radial electron dose; (3) the dose-response supralinearity of peaks 7 and 8 change rapidly with photon energy: this behaviour is explained in the framework of the unified interaction model as due to a very strong dependence on photon energy of the relative intensity of localised recombination and (4) the increased width and decrease in T(max) of composite peak 5 as a function of ionisation density is due to the greater relative intensity of peak 5a (a low-temperature component of peak 5 arising from two-energy transfer events, which leads to localised recombination)."	( Mysteries of LiF TLD response following high ionisation density irradiation: nanodosimetry and track structure theory, dose response and glow curve shapes. Datz, H; Fuks, E; Horowitz, Y; Livingstone, J; Oster, L; Rosenfeld, A, 2011)	0.37
" Providers should carefully monitor the patient's adherence to the fluoride dosing schedule to maximize the potential therapeutic benefit."	( Evidence-based clinical recommendations on the prescription of dietary fluoride supplements for caries prevention: a report of the American Dental Association Council on Scientific Affairs. Adair, S; Aravamudhan, K; Frantsve-Hawley, J; Graham, F; Iafolla, T; Kingman, A; Kohn, W; Krol, D; Levy, S; Meyer, DM; Pollick, H; Rozier, RG; Strock, S; Whitford, G, 2010)	0.36
"4 g/kg×d) and low dosage (0."	( [The influence of fluoride on expression of OPGL and M-CSF genes and their proteins in rats with experimental fluorosis and the therapeutic effect of Danlan Xianpeng Liaofu caspule]. Sun, XJ; Xiao, YM; Yu, YN, 2010)	0.36
" (4) Compared with that of the fluoride group animals, the expression intensity of OPGL mRNA decreased in animals of the control group, the high, mid- and low- dosage medication groups and the borax group."	( [The influence of fluoride on expression of OPGL and M-CSF genes and their proteins in rats with experimental fluorosis and the therapeutic effect of Danlan Xianpeng Liaofu caspule]. Sun, XJ; Xiao, YM; Yu, YN, 2010)	0.36
"This study proposes a pH-cycling model for verifying the dose-response relationship in fluoride-releasing materials on remineralization in vitro."	( Enamel remineralization by fluoride-releasing materials: proposal of a pH-cycling model. Cavassan, L; Delbem, AC; Pedrini, D; Rodrigues, E, 2010)	0.36
" Meanwhile, there was a dose-response relationship between urine fluoride and dental fluorosis (P<0."	( The relationships between low levels of urine fluoride on children's intelligence, dental fluorosis in endemic fluorosis areas in Hulunbuir, Inner Mongolia, China. Ding, Y; Han, H; Ji, X; Liu, X; Sun, D; Sun, H; Wang, W, 2011)	0.37
" Such input would greatly improve understanding of the human dose-response relationship."	( Fluoride in the environment and its metabolism in humans. Damodaran, T; Jha, SK; Mishra, VK; Sharma, DK, 2011)	0.37
" UFC increased as ingested fluoride tablet dosage increased, and it returned to the baseline level on the following day and persisted throughout the study period."	( Urinary fluoride concentration in children with disabilities following long-term fluoride tablet ingestion. Chen, HS; Chen, JR; Hsiao, SY; Huang, ST; Hung, HC; Liu, HY, )	0.13
" Both TLDs were calibrated using 18-MV X-ray beam to investigate their dose-response sensitivity and linearity."	( The use of enriched 6Li and 7Li Lif:Mg,Cu,P glass-rod thermoluminescent dosemeters for linear accelerator out-of-field radiation dose measurements. Bezak, E; Liu, G; Marcu, L; Takam, R, 2012)	0.38
" Changes in mineral distribution effected by F were most pronounced in MeC lesions, with remineralization/mineral redeposition in the original lesion body at the expense of sound enamel beyond the original lesion in a dose-response manner."	( Effect of fluoride, lesion baseline severity and mineral distribution on lesion progression. Butler, A; Hara, AT; Lippert, F; Lynch, RJ, 2012)	0.38
"The present mechanistic in vitro study aimed to investigate dose-response effects of zinc and fluoride on caries lesion remineralization and subsequent protection from demineralization."	( Dose-response effects of zinc and fluoride on caries lesion remineralization. Lippert, F, 2012)	0.38
"05) and dose-response relationship between treatments."	( Anticaries effect of dentifrices with calcium citrate and sodium trimetaphosphate. Bergamaschi, M; Delbem, AC; Missel, EM; Rodrigues, E; Sassaki, KT; Vieira, AE, 2012)	0.38
" The effects of HDTMA loading, pH (3-10), reaction time (5-60 min) and the adsorbent dosage (0."	( The investigation of kinetic and isotherm of fluoride adsorption onto functionalize pumice stone. Asgari, G; Ghanizadeh, G; Roshani, B, 2012)	0.38
"To investigate the relative fluoride dose-response of human and bovine enamel caries lesions under remineralizing conditions and utilizing an established pH cycling model."	( Fluoride dose-response of human and bovine enamel caries lesions under remineralizing conditions. Hara, AT; Lippert, F, 2012)	0.38
" Human and bovine enamel showed a good fluoride dose-response for REM and correlated well."	( Fluoride dose-response of human and bovine enamel caries lesions under remineralizing conditions. Hara, AT; Lippert, F, 2012)	0.38
" There was no indication of a dose-response effect."	( Results from the Xylitol for Adult Caries Trial (X-ACT). Amaechi, BT; Bader, JD; Brown, JP; Funkhouser, KA; Gilbert, GH; Laws, RL; Leo, MC; Makhija, SK; Ritter, AV; Shugars, DA; Vollmer, WM, 2013)	0.39
" Findings for intermediate fluoridation exposure suggested a dose-response relationship."	( Effects of fluoridated drinking water on dental caries in Australian adults. Do, L; Roberts-Thomson, K; Sanders, AE; Slade, GD; Spencer, AJ, 2013)	0.39
" However, it seems that at the dosage used, fluoride toxicity may be a direct effect on the antioxidant enzymes."	( Comparative study on the influence of fluoride on lipid peroxidation and antioxidants levels in the different brain regions of well-fed and protein undernourished rats. Adebayo, OL; Adenuga, GA; Ajani, EO; Salau, BA; Shallie, PD, 2013)	0.39
" The dose-response equation: I = min + (max - min)/(1 + 10(lgEC50-lgC)) may be used to fit the relationship between percent inhibition (I) and F(-) or Cl(-) concentration (C); however, F(-) was distinct from Cl(-) in terms of effects on parameter 'min'."	( Effects of fluoride and chloride on the growth of Chlorella pyrenoidosa. Li, Q; Wu, YD; Wu, YY, 2013)	0.39
" A dose-response was observed between fluoride concentration in toothpastes and fluoride present in enamel, regardless of dilution."	( In vitro enamel remineralization by low-fluoride toothpaste with calcium citrate and sodium trimetaphosphate. Danelon, M; Delbem, AC; Freire, IR; Hirata, E, 2013)	0.39
" Western blotting was done for confirmation of the proteomic data A dose-response was observed in serum F levels."	( Proteomic analysis of liver in rats chronically exposed to fluoride. Buzalaf, MA; Cestari, TM; Charone, S; Leite, Ade L; Lobo, JG; Pereira, HA; Peres-Buzalaf, C, 2013)	0.39
" Unlike UC nanocrystals previously reported in the literature with multicolor emission obtained by varying the rare-earth dopants, the current work developed a new approach to tune the UC emission color by controlling the NaF concentration without changing the ratio and dosage of rare-earth ions."	( Controllable multicolor upconversion luminescence by tuning the NaF dosage. Li, H; Wang, L, 2014)	0.4
" Adsorption studies were performed in a batch system, and the effects of various parameters, such as the pH value of the solution, adsorbent dosage and initial fluoride concentration, were evaluated."	( Adsorption of fluoride from aqueous solution by enhanced chitosan/bentonite composite. Huang, R; Liu, Q; Liu, Y; Yang, B, 2013)	0.39
"No in situ protocol has assessed the dose-response effects of fluoride dentifrices involving low-fluoride formulations."	( In situ protocol for the determination of dose-response effect of low-fluoride dentifrices on enamel remineralization. Afonso, RL; Cantagallo, CF; Danelon, M; Delbem, AC; Igreja, BB; Pessan, JP, )	0.13
"To assess the ability of an in situ remineralization model in determining dose-response effects of dentifrices containing low fluoride concentrations ([F]) on bovine enamel."	( In situ protocol for the determination of dose-response effect of low-fluoride dentifrices on enamel remineralization. Afonso, RL; Cantagallo, CF; Danelon, M; Delbem, AC; Igreja, BB; Pessan, JP, )	0.13
" A dose-response effect of CPP-ACP usage on MS was observed, where MS was present in eight percent of regular CPP-ACP users, 28 percent of irregular users, and 47 percent of non-users (P<."	( A randomized controlled trial of a 10 percent CPP-ACP cream to reduce mutans streptococci colonization. Barnett, AG; Holcombe, TF; Plonka, KA; Pukallus, ML; Seow, WK; Walsh, LJ, 2013)	0.39
"To study the dose-response relationship between fluoride content in drinking water and prevalence of dental fluorosis on the national scale, then to determine the safety threshold of fluoride in drinking water."	( [Using fractional polynomials to estimate the safety threshold of fluoride in drinking water]. An, W; Li, H; Pan, S; Yang, M, 2014)	0.4
" There was a better dose-response relationship among the varnishes exposed to water than to artificial saliva."	( Evaluation of fluoride release from experimental TiF4 and NaF varnishes in vitro. Buzalaf, MA; Comar, LP; Grizzo, LT; Magalhães, AC; Souza, BM, 2014)	0.4
"We reviewed the literature on health effects, community exposure data, and dose-response relationships of the principal hazardous agents emitted."	( Community health risk assessment of primary aluminum smelter emissions. Larivière, C; Martin, SC, 2014)	0.4
"There seems to be a dose-response relationship between frequency of SSB consumption and caries increment in adults."	( Sugar-sweetened beverages and dental caries in adults: a 4-year prospective study. Aromaa, A; Bernabé, E; Sheiham, A; Suominen, AL; Vehkalahti, MM, 2014)	0.4
" Reanalysis of dose-response relationships between dietary sugars and caries incidence in teeth with different levels of caries susceptibility in children was done using data from Japanese studies conducted by Takeuchi and co-workers."	( A new understanding of the relationship between sugars, dental caries and fluoride use: implications for limits on sugars consumption. James, WP; Sheiham, A, 2014)	0.4
" The objective of this study was to re-examine the dose-response and quantitative relationship between sugar intake and the incidence of dental caries and to see whether the WHO goal for sugar intake of 10% of energy intake (E) is optimum for low levels of caries in children and adults."	( A reappraisal of the quantitative relationship between sugar intake and dental caries: the need for new criteria for developing goals for sugar intake. James, WP; Sheiham, A, 2014)	0.4
" A re-analysis of the dose-response relation between dietary sugar and caries incidence in teeth with different levels of susceptibility to dental caries in nationally representative samples of Japanese children."	( A reappraisal of the quantitative relationship between sugar intake and dental caries: the need for new criteria for developing goals for sugar intake. James, WP; Sheiham, A, 2014)	0.4
"This laboratory study aimed to (a) compare the fluoride dose-response of different caries lesions created in human and bovine enamel (HE/BE) under pH-cycling conditions and (b) investigate the suitability of Knoop and Vickers surface microhardness (K-SMH/V-SMH) in comparison to transverse microradiography (TMR) to investigate lesion de- and remineralization."	( Fluoride dose-response of human and bovine enamel artificial caries lesions under pH-cycling conditions. Juthani, K; Lippert, F, 2015)	0.42
" Thus, the law does not consider that both caries and fluorosis are dependent on the dosage and duration of fluoride exposure because they are both chronic diseases."	( Fluoride concentrations in the water of Maringá, Brazil, considering the benefit/risk balance of caries and fluorosis. Barbana, M; Bergamo, ET; Cury, JA; Fujimaki, M; Terada, RS, 2015)	0.42
"Highly significant linear and, with the exception of SMHR, quadratic dose-response relationships were observed between all efficacy variables and fluoride concentration."	( Dose-response effect of fluoride dentifrice on remineralisation and further demineralisation of erosive lesions: A randomised in situ clinical study. Bosma, ML; Butler, A; Creeth, JE; Hara, AT; Kelly, SA; Lynch, RJ; Martinez-Mier, EA; Zero, DT, 2015)	0.42
" Although not as visually prominent as the maxillary central incisors, some of the late-erupting teeth are esthetically important and this should be taken into consideration when making recommendations about dosing of fluoride intake."	( Timing of fluoride intake and dental fluorosis on late-erupting permanent teeth. Bhagavatula, P; Broffitt, B; Levy, SM; Warren, JJ; Weber-Gasparoni, K, 2016)	0.43
"The aim of this exploratory double-blinded, randomized, cross-over, in situ study was to compare the effects of various model parameters ('intervention', 'brushing', 'position') on enamel caries lesions in a dose-response model."	( The effect of various model parameters on enamel caries lesions in a dose-response model in situ. Dörfer, CE; Gninka, B; Heldmann, P; Meyer-Lueckel, H; Paris, S; Wierichs, RJ, 2015)	0.42
" Values for NaF1450 revealed a similar dose-response as LA1360."	( The effect of various model parameters on enamel caries lesions in a dose-response model in situ. Dörfer, CE; Gninka, B; Heldmann, P; Meyer-Lueckel, H; Paris, S; Wierichs, RJ, 2015)	0.42
"The design of the present in situ study was able to reveal a fluoride dose-response to hamper further demineralization of enamel specimens for 'easily cleanable' and 'plaque-retaining' sites being brushed or not."	( The effect of various model parameters on enamel caries lesions in a dose-response model in situ. Dörfer, CE; Gninka, B; Heldmann, P; Meyer-Lueckel, H; Paris, S; Wierichs, RJ, 2015)	0.42
"The TLD-100 dose-response curves were obtained."	( Evaluation of LiF:Mg,Ti (TLD-100) for Intraoperative Electron Radiation Therapy Quality Assurance. Cella, L; D'Avino, V; Liuzzi, R; Pugliese, M; Savino, F, 2015)	0.42
" Fluoride dose-response effect was analysed by quadratic regression and the effects of toothpastes by Tukey's test."	( Evaluation of low fluoride toothpaste using primary enamel and a validated pH-cycling model. Cury, JA; Romão, DA; Tabchoury, CP; Velo, MM, 2016)	0.43
"The developed pH-cycling model may be used to evaluate and compare the anti-caries potential of toothpaste formulations with low fluoride concentration because it presents dose-response effects on the reduction of primary enamel demineralization."	( Evaluation of low fluoride toothpaste using primary enamel and a validated pH-cycling model. Cury, JA; Romão, DA; Tabchoury, CP; Velo, MM, 2016)	0.43
" This longitudinal study aimed to explore 1) the shape of the dose-response association between sugars intake and caries in adults, 2) the relative contribution of frequency and amount of sugars intake to caries levels, and 3) whether the association between sugars intake and caries varies by exposure to fluoride toothpaste."	( The Shape of the Dose-Response Relationship between Sugars and Caries in Adults. Bernabé, E; Lundqvist, A; Sheiham, A; Suominen, AL; Vehkalahti, MM, 2016)	0.43
" All three fluoride toothpastes were more efficacious than placebo, and there were no safety concerns following single dosing in this short-term in situ model."	( Erosion Remineralization Efficacy of Gel-to-Foam Fluoride Toothpastes in situ: A Randomized Clinical Trial. Hara, AT; Jeffery, P; Lippert, F; Mason, S; Nehme, M; Zero, DT, 2016)	0.43
" Recent evidence from high-quality systematic reviews supports the dose-response relationship between caries prevention and fluoride levels, and there is good evidence from randomised clinical trials to support the use of high fluoride dentifrices."	( High Fluoride Concentration Toothpastes for Children and Adolescents. Pretty, IA, 2016)	0.43
"A dose-response relationship was verified between F concentrations in the dentifrices and in the biofilm fluid."	( Fluoride and calcium concentrations in the biofilm fluid after use of fluoridated dentifrices supplemented with polyphosphate salts. Buzalaf, MA; Delbem, AC; Hall, KB; Nagata, ME; Pessan, JP, 2017)	0.46
"In order to reduce acid and alkali dosing in wastewater treatment process of polycrystalline silicon by using denitrification after fluoride removal."	( [Feasibility and Economic Analysis of Denitrification of Photovoltaic Wastewater Containing High Fluorine]. Cui, JH; Huang, Y; Li, X; Ma, H; Yang, PB; Zhu, L, 2016)	0.43
" The suitable dosage and supplementation periods of choline await further exploration."	( Choline supplementation alleviates fluoride-induced testicular toxicity by restoring the NGF and MEK expression in mice. Liang, C; Wang, J; Wang, N; Zhang, J; Zhang, Y; Zheng, H, 2016)	0.43
" A clear dose-response relationship was seen between F concentration/amount of dentifrice applied and the mean area under the curve (AUC) of salivary F concentrations (P<0."	( Influence of the Amount of Dentifrice and Fluoride Concentrations on Salivary Fluoride Levels in Children. Cunha, RF; Danelon, M; de Moraes, FR; Delbem, AC; Hall, KB; Hosida, TY; Nagata, ME; Pessan, JP, 2016)	0.43
"Model showed fluoride dose-response for both variables (2×F>F>placebo)."	( The effects of fluoride, strontium, theobromine and their combinations on caries lesion rehardening and fluoridation. Lippert, F, 2017)	0.46
" The correlation between water fluoride concentration and intelligence level was assessed by a dose-response meta-analysis."	( Association between water fluoride and the level of children's intelligence: a dose-response meta-analysis. Chen, X; Duan, Q; Jiao, J; Wang, X, 2018)	0.48
" The dose-response meta-analysis suggested a significant association between water fluoride dosage and intelligence (P < 0."	( Association between water fluoride and the level of children's intelligence: a dose-response meta-analysis. Chen, X; Duan, Q; Jiao, J; Wang, X, 2018)	0.48
"To compare and explore the dose-response of phytate-containing 1150 ppm fluoride toothpastes on model caries lesions and to determine the impact of zinc ions."	( Effect of phytate and zinc ions on fluoride toothpaste efficacy using an in situ caries model. Budhawant, C; Burnett, GR; Creeth, JE; Hara, AT; Lippert, F; Lynch, RJM; Parkinson, CR; Zero, DT, 2018)	0.48
" No differences between fluoride toothpastes were observed for any measure with little evidence of a dose-response for phytate."	( Effect of phytate and zinc ions on fluoride toothpaste efficacy using an in situ caries model. Budhawant, C; Burnett, GR; Creeth, JE; Hara, AT; Lippert, F; Lynch, RJM; Parkinson, CR; Zero, DT, 2018)	0.48
" We examined the dose-response effects of low-to-moderate fluoride exposure on dental fluorosis (DF) and intelligence quotient (IQ), and evaluated the potential relationships between DF grades and intelligence levels using piecewise linear regression and multiple logistic regression, respectively."	( Threshold effects of moderately excessive fluoride exposure on children's health: A potential association between dental fluorosis and loss of excellent intelligence. Chen, J; Cui, Y; Dong, L; Hou, C; Li, P; Li, Y; Liu, H; Liu, L; Pang, S; Tang, S; Tian, K; Wang, A; Xu, C; Yu, X; Zeng, Q; Zhang, S; Zhang, X; Zhao, L; Zhao, Q; Zhou, Z, 2018)	0.48
" Which sugar-reducing strategy is best for caries prevention? To answer this question, this manuscript discusses the shape of the dose-response association between sugar intake and caries, the influence of fluoridated toothpaste on the association of sugar intake and caries and the relative contribution of frequency and amount of sugar intake to caries levels."	( Sugar Restriction for Caries Prevention: Amount and Frequency. Which Is More Important? van Loveren, C, 2019)	0.51
" However, there is a lack of global consensus regarding trace elements provision and dosing in pediatric parenteral nutrition."	( Trace Element Provision in Parenteral Nutrition in Children: One Size Does Not Fit All. Bines, JE; McCallum, Z; Zemrani, B, 2018)	0.48
" The aim of the present study was investigate the dose-response effect of SDF on demineralized dentine in basal medium mucin (BMM) saliva substitute and human saliva."	( Silver deposition on demineralized dentine surface dosed by silver diammine fluoride with different saliva. Botelho, MG; Matinlinna, JP; Peng, JY; Tsoi, JKH, 2019)	0.51
" In addition to high-contrast imaging and consequently high sensitivity detection of bladder cancer cells, highly selective optoporation-assisted chemotherapy was accomplished using a dosage of chemotherapy agent significantly lower than any previous reports, within a clinically relevant incubation time window."	( Multifunctional nanoclusters of NaYF Cho, SK; Flaig, TW; Mao, C; Park, W; Su, LJ; Wolenski, CD, 2019)	0.51
" Evidence for the effects of different fluoride concentrations is more limited, but a dose-response effect was observed for D(M)FS in children and adolescents."	( Fluoride toothpastes of different concentrations for preventing dental caries. Glenny, AM; Jeroncic, A; Marinho, VC; Walsh, T; Worthington, HV, 2019)	0.51
" A dose-response pattern of association was observed between mean fluoride levels and dementia in women (1."	( Aluminium and fluoride in drinking water in relation to later dementia risk. Batty, GD; Deary, IJ; Hannah, J; Killin, LOJ; Russ, TC; Starr, JM, 2020)	0.56
" To explore the biological exposure limits for mixed exposures of fluoride and arsenic, we compared the contents of fluorine and arsenic in the environmental media of the control and fluoride-arsenic combined exposure areas and analyzed the dose-effect and dose-response relationship between fluoride, arsenic and the key proteins of Wnt signaling pathways."	( [Biological exposure limits caused by co exposure to fluoride and arsenic based on Wnt signaling pathway]. Hong, F; Tu, CL; Xu, YY; Yang, J; Yu, X; Zeng, QB, 2019)	0.51
"Although dietary fluoride (F) supplements (DFS) are recommended for children who use F-deficient drinking water, no studies have examined filled DFS prescriptions across multiple states to examine the dosage consistency with current recommendations or prescription length."	( Filled dietary fluoride supplement prescriptions for Medicaid-enrolled children living in states with high and low water fluoridation coverage. Espinoza, L; Gooch, BF; Griffin, SO; Li, CH, 2019)	0.51
" For 2011, the authors calculated the mean percentage of children with filled DFS prescriptions and the change since 2000 across states with high and low fluoridation coverage, the percentage of children with filled DFS prescriptions containing F dosage consistent with current recommendations, and filled DFS prescription length and cost across states."	( Filled dietary fluoride supplement prescriptions for Medicaid-enrolled children living in states with high and low water fluoridation coverage. Espinoza, L; Gooch, BF; Griffin, SO; Li, CH, 2019)	0.51
" Evidence for the effects of different fluoride concentrations was found to be more limited, but a dose-response effect was observed for D(M)FS in children and adolescents."	( What concentration of fluoride toothpaste should dental teams be recommending? Levine, RS, 2019)	0.51
"001) for the lowly cariogenic model, indicating a fluoride dose-response for both."	( Effects of Dentifrices Differing in Fluoride Content on Remineralization Characteristics of Dentin in vitro. Apel, C; Esteves-Oliveira, M; Meyer-Lueckel, H; Rupp, K; Wierichs, RJ, 2020)	0.56
"For both pH-cycling conditions a dose-response for fluoride could be revealed."	( Effects of Dentifrices Differing in Fluoride Content on Remineralization Characteristics of Dentin in vitro. Apel, C; Esteves-Oliveira, M; Meyer-Lueckel, H; Rupp, K; Wierichs, RJ, 2020)	0.56
"All the UAE available infant formulae tested had lower than the maximum daily recommended dosage of fluoride."	( Fluoride concentration of commercially available infant formulae in the United Arab Emirates. Agha, Y; Al-Halabi, M; AlSalami, A; Hussein, I; Kowash, M, 2020)	0.56
"Bone is the main target of fluorosis, and it has been perfectly elaborated that a moderate dosage of calcium (Ca) can alleviate bone fluorosis."	( Calcium relieves fluoride-induced bone damage through the PI3K/AKT pathway. Cheng, X; Ma, H; Manthari, RK; Ommati, MM; Wang, J; Xu, H; Yan, Z; Yang, J; Zhao, Y, 2020)	0.56
" It concludes that fluoride has a dose-response effect on BMP-2 in fluorosis rats, and fluoride-induced hypomethylation of specific CpGs may play an essential role in the regulation of BMP-2 and BMP-7 expression in rats."	( The dose-time effects of fluoride on the expression and DNA methylation level of the promoter region of BMP-2 and BMP-7 in rats. Angwa, LM; Ma, Y; Pei, J; Yao, Y; Zhong, N, 2020)	0.56
" Additional evidence is needed to assess the dose-response relationship between fluoride exposure and blood pressure."	( Fluoride Exposure and Blood Pressure: a Systematic Review and Meta-Analysis. Dong, N; Fan, Y; Feng, J; Gao, Y; Li, M; Liu, P; Qiu, Y; Tian, F; Tian, X; Xie, J; Yan, X; Zhao, Y, 2021)	0.62
" This study was aimed to evaluate the dose-response effect of fluoride on DNA methylation in human and rat blood."	( Effect of fluoride in drinking water on the level of 5-methylcytosine in human and rat blood. Alphonse, S; Ma, Y; Meng, X; Pei, J; Yao, Y; Zhong, N, 2021)	0.62
" In conclusion, a dose-response F effect was observed, and the high-fluoride dentifrice was effective in enhancing root dentine remineralization in this short-term in situ study."	( Dose-Response Effect of Fluoride Dentifrices on De-/Remineralization of Root Dentine in situ. Ferreira, R; Leal, J; Lingström, P; Tabchoury, C; Vale, G, 2020)	0.56
" Furthermore, the low dosage of fluoride could promote the growth of beneficial gut microbiota, including Faecalibacterium and Lactobacillus."	( The beneficial or detrimental fluoride to gut microbiota depends on its dosages. Cai, H; Chen, G; Hu, P; Peng, C; Wan, X; Wang, Y; Xu, Z, 2021)	0.62
" It was demonstrated that a fraction of the TL signal in LiF:Mg,Ti is generated in the supralinear dose-response range, due to the high local doses generated by photon-induced tracks."	( MICRODOSIMETRIC UNDERSTANDING OF DOSE RESPONSE AND RELATIVE EFFICIENCY OF THERMOLUMINESCENCE DETECTORS. Bilski, P; Olko, P, 2020)	0.56
" This study aimed to evaluate the dose-response of fluoride on fecal microbes as well as the link between fluorosis and fecal microbes."	( Effect of Fluoride in Drinking Water on Fecal Microbial Community in Rats. Gao, Y; Huang, W; Ma, Y; Meng, X; Pei, J; Sowanou, A; Wu, L; Zhong, N, 2022)	0.72
" No deviation from linearity was detected in the dose-response relationships, but boys showed lower BMC values than girls."	( A Benchmark Dose Analysis for Maternal Pregnancy Urine-Fluoride and IQ in Children. Bashash, M; Budtz-Jørgensen, E; Flora, D; Grandjean, P; Green, R; Hu, H; Lanphear, B; Song, PXK; Tellez-Rojo, MM; Till, C, 2022)	0.72
" The results of single-factor tests showed that the optimal reaction conditions included a reaction temperature of 35°C, Citrobacter dosage of 35% (volume ratio) in the particles and hybrid material dosage of 300 mL; under these conditions, the removal rates of SO42-, Cr(VI), total chromium and F- were 70."	( Remediation of chromium- and fluoride-contaminated groundwater by immobilized Citrobacter sp. on a nano-ZrO2 hybrid material. Chang, J; Fan, M; Li, J; Li, X; Liu, L; Yi, F; Zhang, Y, 2021)	0.62
"In vitro biofilm models have been extensively used, but only few of the models available to date had been validated in terms of the dose-response effect of anti-caries and/or antimicrobial substances."	( Validation of a cariogenic biofilm model by evaluating the effect of fluoride on enamel demineralization. Cury, JA; Marin, LM; Siqueira, WL, 2022)	0.72
" A dose-response effect was observed."	( Topical Fluoride Effectiveness in High Caries Risk Adults. Cabral, HJ; Gibson, G; Jones, JA; Jurasic, MM; Orner, MB; Wehler, CJ, 2022)	0.72
" However, to delineate its exact formulation, dosage or frequency, there is need for more well conducted randomised controlled trials."	( Effectiveness of topical fluorides in prevention of radiation caries in adults: A systematic review and meta- analysis. Agarwal, D; Kumar, V; Priya, H; Purohit, B; Ravi, P, 2022)	1.02
" However, the dose-response of fluoride on oxidative DNA damage is barely studied in organisms."	( Effect of Fluoride on the Expression of 8-Hydroxy-2'-Deoxyguanosine in the Blood, Kidney, Liver, and Brain of Rats. Li, A; Li, H; Ma, Y; Meng, X; Pei, J; Sowanou, A; Wang, J; Yao, Y; Zhong, N, 2023)	0.91
"01 mg/g at initial concentration range of 5 to 100 mg/L when 1 g/100 mL adsorbent dosage was used at initial pH of 6 ± 0."	( Synthesis of porous hydroxysodalite from aluminosilicate rich clay soils: application towards fluoride and pathogen removal. Gitari, WM; Mudzielwana, R; Obijole, OA, 2023)	0.91
" Further studies are necessary to examine the extended effect of Resveratrol with increased dosage or time of treatment."	( Resveratrol thyro-protective role in fluorosis rat model (histo-morphometric, biochemical and ultrastructural study). Amin, MA; Hassan, NH, 2023)	0.91
" Twenty-eight adult Wistar rats were divided equally and randomly into four groups: group one received distilled water; group two received NMO at a dosage of 250 mg/kg/body weight; group three received NaF at a dosage of 10 mg/kg/body weight; and group four received NaF and NMO."	( Ameliorative effects of nano Moringa on fluoride-induced testicular damage via down regulation of the StAR gene and altered steroid hormones. Abd-Allah, ER; El-Rahman, HAA, 2023)	0.91
" The aim of this systematic review and meta-analysis was to characterize this relation through a dose-response approach, by comparing the intelligence quotient (IQ) scores in the highest versus the lowest fluoride exposure category with a random-effects model, within a one-stage dose-response meta-analysis based on a cubic spline random-effects model."	( Fluoride exposure and cognitive neurodevelopment: Systematic review and dose-response meta-analysis. Birnbaum, LS; Consolo, U; Filippini, T; Generali, L; Giannone, ME; Mazzoleni, E; Veneri, F; Vinceti, M, 2023)	0.91
" At present, it is not possible to quantify health risks due to MPs because dose-response and toxicity assessments are not available."	( Drinking hot beverages from paper cups: Lifetime intake of microplastics. Goel, S; Joseph, A; Parveen, N; Ranjan, VP, 2023)	0.91
" Adsorption maxima are obtained over a wide pH range from 4 to 9, with a contact time of 15 minutes at a dosage of 4 g/L."	( Efficient removal of fluoride on aluminum modified activated carbon: an adsorption behavioral study and application to remediation of ground water. Korra, MR; Kuntaiah, K; Nandakishore, SS; Thomas, AM, 2023)	0.91
" The optimum treatment dosage of the isolated seed polysaccharides was determined using aqueous fluoride solutions of various ppm concentrations (1, 2, 3, 4, and 5 ppm)."	( Defluoridation of potable water employed by natural polysaccharide isolated from Tamarindus indica L. Alarifi, S; Ali, D; C, T; Chang, SW; D, S; Jones, S; Ramanujam, GM; Ravindran, B; Rembulan, GD; S T, A; Sahayarayan, JJ; Yadav, KK, 2023)	0.91
"We observed a dose-response relation between F concentrations in the gels without TMP for %SHR and ΔKHN."	( Effect of fluoride gels with nano-sized sodium trimetaphosphate on the in vitro remineralization of caries lesions. Báez-Quintero, LC; Danelon, M; Delbem, ACB; Monteiro, DR; Nagata, ME; Pessan, JP; Sampaio, C; Wiegand, A, 2023)	0.91
" The Central Composite Design (CCD), which uses four input variables including dosage (2-5 g/L), solution pH (4-8), contact time (30-70 min), and initial concentration (10-20 mg/L), was used to design the experiments."	( Synthesis and application of lanthanum-doped magnetic biochar composite adsorbent for removal of fluoride from water. Majamo, SL; Teju, MD, 2023)	0.91

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Class	Description
halide anion	A monoatomic monoanion resulting from the addition of an electron to any halogen atom.
monoatomic fluorine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
glycolysis IV (plant cytosol)	13	47
D-sorbitol biosynthesis I	1	15
superpathway of cytosolic glycolysis (plants), pyruvate dehydrogenase and TCA cycle	28	56
phytate degradation I	3	16
Rubisco shunt	6	32
superpathway of anaerobic sucrose degradation	33	60
fluoroacetate and fluorothreonine biosynthesis	0	16
fluoroacetate and fluorothreonine biosynthesis	4	22
superpathway of cytosolic glycolysis (plants), pyruvate dehydrogenase and TCA cycle	24	59
superpathway of glycolysis and the Entner-Doudoroff pathway	23	58
Rubisco shunt	8	32
superpathway of glycolysis, pyruvate dehydrogenase, TCA, and glyoxylate bypass	39	89
(aminomethyl)phosphonate degradation	12	31
photosynthetic 3-hydroxybutanoate biosynthesis (engineered)	63	73
L-tryptophan degradation I (via anthranilate)	1	26
phenylacetate degradation I (aerobic)	15	30
D-galactarate degradation I	5	30
superpathway of L-lysine degradation	33	112
L-lysine degradation V	1	33
superpathway of sulfate assimilation and cysteine biosynthesis	12	41
superpathway of microbial D-galacturonate and D-glucuronate degradation	35	92
fluoroacetate degradation	1	5
L-serine biosynthesis I	11	15
trehalose degradation IV	0	23
4-hydroxymandelate degradation	6	38
D-glucarate degradation I	5	31
hexitol fermentation to lactate, formate, ethanol and acetate	7	36
superpathway of aromatic compound degradation via 2-hydroxypentadienoate	50	95
phytate degradation I	0	21
superpathway of aromatic compound degradation via 3-oxoadipate	36	81
superpathway of N-acetylneuraminate degradation	39	79
gluconeogenesis I	28	62
superpathway of hexitol degradation (bacteria)	29	60
glycogen degradation I	8	50
mannitol cycle	3	15
superpathway of L-serine and glycine biosynthesis I	9	20
protocatechuate degradation II (ortho-cleavage pathway)	5	18
alkylnitronates degradation	3	50
glycolysis II (from fructose 6-phosphate)	21	49
glycolysis I (from glucose 6-phosphate)	37	51
glycolysis IV (plant cytosol)	7	47
glycolysis III (from glucose)	37	25
aromatic compounds degradation via u03B2-ketoadipate	11	27
guanosine nucleotides degradation III	14	25
superpathway of D-glucarate and D-galactarate degradation	6	37
Entner-Doudoroff pathway I	16	39
superpathway of anaerobic sucrose degradation	26	61
rutin degradation	2	30
trehalose biosynthesis I	7	19
trehalose biosynthesis	4	14
Ethanol metabolism resulting in production of ROS by CYP2E1	1	17
Ethanol metabolism production of ROS by CYP2E1	1	17

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase 1	Homo sapiens (human)	Ki	180,024.8800	0.0000	1.3726	10.0000	AID1798763; AID1803484
Carbonic anhydrase 2	Homo sapiens (human)	Ki	180,024.8800	0.0000	0.7236	9.9200	AID1798763; AID1803485
Carbonic anhydrase 4	Homo sapiens (human)	Ki	150,031.1000	0.0002	1.9720	9.9200	AID1798763
Carbonic anhydrase	Methanosarcina thermophila	Ki	21,300.0000	0.0600	0.9714	8.5000	AID1803493
Carbonic anhydrase 15	Mus musculus (house mouse)	Ki	150,031.1000	0.0009	1.8846	10.0000	AID1798763
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
one-carbon metabolic process	Carbonic anhydrase 1	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Homo sapiens (human)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Homo sapiens (human)
secretion	Carbonic anhydrase 2	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 2	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 2	Homo sapiens (human)
carbon dioxide transport	Carbonic anhydrase 2	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 2	Homo sapiens (human)
bicarbonate transport	Carbonic anhydrase 4	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
arylesterase activity	Carbonic anhydrase 1	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
protein binding	Carbonic anhydrase 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 1	Homo sapiens (human)
hydro-lyase activity	Carbonic anhydrase 1	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 4	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	Carbonic anhydrase 1	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 1	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
rough endoplasmic reticulum	Carbonic anhydrase 4	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment	Carbonic anhydrase 4	Homo sapiens (human)
Golgi apparatus	Carbonic anhydrase 4	Homo sapiens (human)
trans-Golgi network	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
external side of plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
cell surface	Carbonic anhydrase 4	Homo sapiens (human)
membrane	Carbonic anhydrase 4	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
transport vesicle membrane	Carbonic anhydrase 4	Homo sapiens (human)
secretory granule membrane	Carbonic anhydrase 4	Homo sapiens (human)
brush border membrane	Carbonic anhydrase 4	Homo sapiens (human)
perinuclear region of cytoplasm	Carbonic anhydrase 4	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1803485	ChEMBL_158305 (CHEMBL763190) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1803487	ChEMBL_158307 (CHEMBL763192) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1803254	CA Inhibition Assay from Article 10.3109/14756366.2011.649268: \\Inhibition of the alpha- and beta-carbonic anhydrases from the gastric pathogen Helycobacter pylori with anions.\\	2013	Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 28, Issue:2	Inhibition of the alpha- and beta-carbonic anhydrases from the gastric pathogen Helycobacter pylori with anions.
AID1798763	CA Inhibition Assay from Article 10.1016/j.bmcl.2008.12.082: \\Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions.\\	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions.
AID1803486	ChEMBL_158306 (CHEMBL763191) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1803484	ChEMBL_158304 (CHEMBL763189) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1803493	ChEMBL_158313 (CHEMBL763370) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1803491	ChEMBL_158311 (CHEMBL763368) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	11974 (46.99)	18.7374
1990's	3211 (12.60)	18.2507
2000's	3439 (13.49)	29.6817
2010's	4818 (18.91)	24.3611
2020's	2042 (8.01)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,456 (5.23%)	5.53%
Reviews	1,711 (6.15%)	6.00%
Case Studies	293 (1.05%)	4.05%
Observational	18 (0.06%)	0.25%
Other	24,365 (87.51%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (501)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride Varnish on Remineralization of White Spot Lesion in Primary Teeth (Randomized Clinical Trial) [NCT03865680]	Phase 2	180 participants (Actual)	Interventional	2019-04-28	Completed
Randomized Double-blind Placebo-controlled Trial of Silver Diamine Fluoride for Caries Prevention in Removable Partial Dentures Wearers [NCT03185104]		196 participants (Actual)	Interventional	2013-11-01	Active, not recruiting
Phase 1 Safety and Pharmacokinetics of Methane Sulfonylfluoride (MSF or SNX-001) After Single and Multiple Oral Dose Administration in Healthy Adult Aged Volunteers [NCT01269476]	Phase 1	27 participants (Actual)	Interventional	2009-12-31	Completed
A Medical Device Study to Measure the Efficacy of a Toothpaste Containing Calcium-silicate/Phosphate on Dentinal Hypersensitivity Compared to a Control Toothpaste Containing Fluoride. [NCT03244618]		272 participants (Actual)	Interventional	2017-06-19	Completed
The Clinical Investigation of a New Toothpaste Containing SnF as Compared to Colgate Fluoride Toothpaste in Reducing Plaque and Gingivitis - a Six-month Study in China [NCT03852056]	Phase 3	98 participants (Actual)	Interventional	2017-05-25	Completed
The Effectiveness of Casein Phosphopeptide Amorphous Calcium Phosphate (MI Varnish) and 5% Sodium Fluoride Plus Xylitol (PreviDent Varnish) on Non Cavitated Interproximal Lesions. Randomised Clinical Trial [NCT03925740]	Phase 4	90 participants (Anticipated)	Interventional	2019-01-01	Active, not recruiting
Remineralization of Molar Incisor Hypomineralization (MIH) With a Hydroxyapatite Toothpaste - an in Situ Study [NCT05485662]		15 participants (Anticipated)	Interventional	2022-09-06	Recruiting
[NCT00497029]		219 participants (Actual)	Interventional	2004-06-30	Completed
Comparison of Cariostatic Effect of Nano-Silver Fluoride Versus Silver Diamine Fluoride in a Group of Preschool Children [NCT05941429]	Phase 1	78 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Preventive Treatment Approach of Early Caries Lesions With Contemporary Methods of Remineralization [NCT03780270]		90 participants (Actual)	Interventional	2014-06-16	Completed
18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans [NCT03501940]		0 participants	Expanded Access		No longer available
Efficacy of Fluoride Varnish Containing Xylitol Coated Calcium Phosphate Versus Conventional Fluoride Varnish in Management of Hypersensitivity of Exposed Root Surfaces in Adult Patients: A Randomized Clinical Trial [NCT04472182]	Phase 1	105 participants (Actual)	Interventional	2020-12-20	Completed
Grape Seeds Versus Standard Measures for Prevention of Caries Incidence in Young Egyptian Adults: A Randomized Controlled Trial [NCT03724578]	Phase 1	80 participants (Anticipated)	Interventional	2019-01-01	Not yet recruiting
Comparative Study on the Outcomes of Restoring Untreated and SDF-treated Dentine Caries Lesions in Primary Teeth of Preschool Children [NCT03657862]		195 participants (Actual)	Interventional	2017-09-15	Active, not recruiting
Postoperative Pain After Application of Silver Diamine Fluoride and Glass Ionomer Versus Glass Ionomer Alone Following Minimal Caries Removal Technique in Asymptomatic Young Permanent Teeth With Deep Caries. A Randomized Pilot Study. [NCT03568474]	Phase 4	40 participants (Anticipated)	Interventional	2018-10-31	Not yet recruiting
Effect of a Triclosan Containing Dentifrice on Oral Bacteria and Postoperative Complications Following Third Molar Surgery [NCT01292343]		141 participants (Actual)	Interventional	2008-02-29	Completed
A Randomized Trial Evaluating the Efficacy of a Gum Health Formulation on Gingival Inflammation, Oral Malodor and Tooth Whitening [NCT03196648]		39 participants (Actual)	Interventional	2015-05-01	Completed
Effectiveness of Different Fluoride Varnishes on Salivary Bacteria Levels in Children With Early Childhood Caries [NCT03625310]		88 participants (Actual)	Interventional	2016-11-30	Completed
Radiographic Assessment of Glass Ionomer Restorations With and Without Prior Application of Nano Silver Fluoride in Occlusal Carious Molars Treated With Partial Caries Removal Technique (Randomized Clinical Trial) [NCT03193606]		22 participants (Actual)	Interventional	2018-07-03	Completed
Enhancing the Fluoride Retention in the Mouth by Chewing a Calcium Supplement Before Fluoride Rinse [NCT04620252]	Early Phase 1	18 participants (Actual)	Interventional	2021-02-01	Completed
Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity [NCT02705716]		409 participants (Actual)	Interventional	2016-03-01	Completed
Comparison of MI Paste Plus and Resin Infiltration in Improvement of White Spot Lesions Following Fixed Orthodontic Treatment: A Randomized Controlled Trial [NCT05733676]		62 participants (Anticipated)	Interventional	2023-05-30	Recruiting
Clinical Research Study to Evaluate the Antibacterial Effect 12 Hours After 4-week Use of a Toothpaste Containing Amine Base, Sodium Fluoride and Zinc Lactate [NCT05628571]	Phase 3	130 participants (Anticipated)	Interventional	2023-02-01	Not yet recruiting
Phase 1 Trial to Determine Safety and Feasibility in Treating Biochemical Recurrence Post-Prostatectomy With PSMA PET Guided External Beam Radiotherapy Followed by Consolidative Radioligand Therapy [NCT06105918]	Phase 1	10 participants (Anticipated)	Interventional	2023-11-29	Recruiting
Effect of CPP-ACP Pastes With/Without Fluoride on White Spot Lesion Progression, Salivary pH and Fluoride Release in High Caries Risk Patients A Randomized Clinical Trial [NCT03656432]	Phase 3	42 participants (Anticipated)	Interventional	2018-10-31	Not yet recruiting
Motivational Effect of Choosing the Taste of te Fluoride Varnish on Acceptance and Behavior During Dental Visit in Children - a Single Blind RCT [NCT05285228]		70 participants (Anticipated)	Interventional	2022-03-31	Not yet recruiting
Effect of pH and Fluoride Concentration of Liquid Dentifrices on Caries Control in a Fluoridated Area: a Randomized Clinical Trial [NCT01049503]	Phase 3	315 participants (Actual)	Interventional	2009-11-30	Completed
Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model [NCT03383783]	Phase 3	28 participants (Actual)	Interventional	2017-12-19	Completed
Assessment of a Potassium Oxalate-Containing Formulation for the Relief of Dentinal Hypersensitivity [NCT01345292]		226 participants (Actual)	Interventional	2011-04-30	Completed
18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules [NCT03824535]	Phase 2	50 participants (Anticipated)	Interventional	2019-02-04	Recruiting
Effect of Water Rinsing After APF Application on Dental Plaque Acidogenicity [NCT01569165]		25 participants (Actual)	Interventional	2011-02-28	Completed
A Randomized, 8 Week Clinical Study to Evaluate the Efficacy of an Experimental Stannous Fluoride Dentifrice in the Relief of Dentinal Hypersensitivity [NCT03310268]		185 participants (Actual)	Interventional	2017-11-18	Completed
A Pilot Study of FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents [NCT02055586]		10 participants (Actual)	Observational	2013-10-22	Completed
Clinical Feasibility Study of Hypoxia Imaging -Guided IMRT on the Individualized Radiotherapy of Nasopharyngeal Carcinoma [NCT02089204]		300 participants (Anticipated)	Observational	2010-06-30	Enrolling by invitation
A Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice [NCT04123665]	Phase 3	98 participants (Actual)	Interventional	2013-05-28	Completed
Postoperative Pain After Application of Silver Diamine Fluoride Verses Sodium Fluoride Varnish in Treatment of Carious Primary Teeth (A Randomized Clinical Trial) [NCT03554980]	Phase 4	46 participants (Anticipated)	Interventional	2018-12-01	Not yet recruiting
A Method Development Clinical Study Investigating the Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity [NCT03238352]	Phase 2	89 participants (Actual)	Interventional	2017-08-07	Completed
A Proof of Principal Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices [NCT03160703]		220 participants (Actual)	Interventional	2017-07-10	Completed
Post-operative Pain After Silver Diamine Fluoride Application in Primary Molars With Deep Caries Versus Interim Restorative Therapy [NCT03563534]	Phase 4	20 participants (Anticipated)	Interventional	2017-09-15	Recruiting
Discoloration of Carious Primary Teeth After Application of Silver Diamine Fluoride Versus Sodium Fluoride Varnish: A Randomized Clinical Trial [NCT03557996]	Phase 4	42 participants (Anticipated)	Interventional	2018-12-01	Not yet recruiting
A Study to Evaluate the Efficacy of an Experimental Occlusion Technology Dentifrice in the Relief of Dentinal Hypersensitivity [NCT02861664]		135 participants (Actual)	Interventional	2016-09-21	Completed
"Randomized Clinical Trial to Evaluate the Impact on Oral Health of the Oral Health Package Law (School Daily Brushing Program) Combined, or Not, With Fluor Varnish Application on Schoolchildren of Mérida, Mexico." [NCT05960110]	Phase 3	900 participants (Anticipated)	Interventional	2023-06-22	Recruiting
The PET-EVAR Study - Predicting Endoleaks Following Endovascular Aortic Aneurysm Repair Using 18F-Sodium Fluoride [NCT04577716]		102 participants (Actual)	Observational	2021-04-01	Active, not recruiting
Evaluation Of Changes in Children's Oral Health-Related Quality of Life Following Treatment of Early Childhood Caries With Caries Arrest Technique Using Silver Diamine Fluoride Versus Conventional Drill and Fill Technique A Randomized Clinical Trial [NCT05337449]		40 participants (Anticipated)	Interventional	2022-07-15	Not yet recruiting
A Pilot Study to Evaluate Gingivitis Using Traditional and Molecular Methods [NCT05326373]		40 participants (Actual)	Interventional	2022-04-11	Completed
Study to Investigate the Impact on Oral Health Related Quality of Life of Managing Dentine Hypersensitivity With a Daily Use Anti-Sensitivity Toothpaste [NCT02752958]		75 participants (Actual)	Interventional	2016-05-23	Completed
A Clinical Study Investigating the Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity [NCT02753075]		240 participants (Actual)	Interventional	2015-09-08	Completed
18F Sodium Fluoride PET/CT in Acute Aortic Syndrome [NCT03647566]		76 participants (Actual)	Observational	2018-10-01	Completed
Clinical Efficacy of an Experimental Toothpaste [NCT01079910]	Phase 1	0 participants (Actual)	Interventional	2009-12-09	Withdrawn
A Randomized, Controlled, Examiner-Blind Clinical Study Investigating the Effects of a Dentifrice Containing 0.454% w/w Stannous Fluoride on Gingivitis Treatment and Plaque Reduction When Used Twice Daily for 12 Weeks [NCT06143670]		160 participants (Anticipated)	Interventional	2023-11-29	Recruiting
"Immediate And Sustained Treatment Response Of Commercially Available BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In Dentin Hypersensitivity - A Randomized Clinical Trial" [NCT04249336]	Phase 3	140 participants (Actual)	Interventional	2019-09-27	Completed
Miswak Versus Standard Measures to Prevent the Incidence of Caries Young Egyptian Adults: A Randomized Controlled Clinical Trial [NCT03732040]		82 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Clinical Evaluation of Clinpro™ 2.1% Sodium Fluoride Aqueous Solution in the Treatment of Dentin Hypersensitivity [NCT05768373]		101 participants (Actual)	Interventional	2023-04-04	Completed
"Quantitative Evaluation of Silver Diamine Fluoride Modified Restoration In Treating Hypomineralized First Permanent Molar In A Group Of Children-A Clinical Study" [NCT05931822]		42 participants (Actual)	Interventional	2020-09-01	Completed
Clinical Effectiveness of Silver Diamine Fluoride on Arresting Caries Lesions in Children [NCT05872542]	Phase 4	60 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Efficacy of a Novel Fluoride Varnish Formula in Preventing White Spot Lesions During and After Treatment With Fixed Orthodontic Appliances [NCT03725020]		180 participants (Actual)	Interventional	2014-06-01	Active, not recruiting
Evaluation of a Low-fluoride Anticaries Toothpaste Containing an Innovative Calcium Technology [NCT01094210]		30 participants (Actual)	Observational	2010-09-30	Completed
PET Imaging as a Biomarker of Systemic Treatment Response for Men With Metastatic Castration-Resistant Prostate Cancer [NCT02169063]		0 participants (Actual)	Interventional	2015-12-31	Withdrawn
Different Concentrations of Potassium Nitrate in In-office Tooth Bleaching Sensitivity: a Randomized Clinical Trial [NCT03323372]	Phase 2	56 participants (Actual)	Interventional	2016-12-21	Completed
A Randomized Clinical Trial of Silver Diamine Fluoride to Arrest Early Childhood Caries in Young Children [NCT04054635]		84 participants (Actual)	Interventional	2019-10-01	Completed
In Vivo Comparison of Genotoxic and Cytotoxic Effects of Different Brands of Toothpaste - Without and With Fluoride [NCT03325400]		40 participants (Actual)	Interventional	2016-01-01	Completed
Efficacy of Silver Diamine Fluoride (SDF) and Fluoride Varnish in Arresting and Preventing Dental Caries in Primary School Children: Randomized Controlled Clinical Trial [NCT03480516]		300 participants (Actual)	Interventional	2017-09-01	Completed
A Clinical Study Investigating the Gingivitis Efficacy of a Stannous Fluoride Dentifrice [NCT02750943]		253 participants (Actual)	Interventional	2015-11-01	Completed
"Combined One Stop Shop NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients: A Pilot Study" [NCT02429804]	Phase 1	4 participants (Actual)	Interventional	2015-04-30	Terminated(stopped due to Accrual factor)
PET MRI for Evaluation of Knee Osteoarthritis in Patients With Bilateral Knee OA [NCT03174080]		150 participants (Anticipated)	Observational	2017-07-16	Not yet recruiting
Clinical Evaluation of Silver Nanoparticles in Comparison to Silver Diamine Fluoride in Management of Deep Carious Lesions [NCT05231330]		36 participants (Actual)	Interventional	2020-03-01	Completed
Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer [NCT05575440]		24 participants (Anticipated)	Observational	2022-04-22	Recruiting
Impact of a Triclosan-containing Toothpaste During the Progression of Experimental Peri-implant Mucositis: Clinical Parameters and Local Pattern of Osteo-immunoinflammatory Mediators in Peri-implant Fluid [NCT03145610]		22 participants (Actual)	Interventional	2013-06-01	Completed
Study on Children's Dental Caries Prevention and Mechanism [NCT02341352]	Phase 3	500 participants (Anticipated)	Interventional	2013-04-30	Active, not recruiting
Principal Investigator,Resident at Cairo University [NCT05948228]	Phase 1	330 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
A Prospective, Open Label, Randomized Control Trial to Study the Effect of Different Remineralizing Agents on White Spot Lesions and Dental Plaque During Orthodontic Retention [NCT04788550]		30 participants (Anticipated)	Interventional	2021-03-17	Recruiting
A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Immediate and Short Term Relief From Dentinal Hypersensitivity [NCT03072719]	Phase 3	120 participants (Actual)	Interventional	2012-03-01	Completed
The Evaluation of Resin Infiltration or Fluoride Varnish Effect on Non-cavited Proximal Caries Lesion Progress at Individuals Modarate/High Caries Risk [NCT05202665]		60 participants (Actual)	Interventional	2017-09-26	Active, not recruiting
Clinical Evaluation of the Efficacy of SPR-G (Surface Pre-reacted Glass Ionomer) Barrier Coat Versus Fluoride Varnish Versus the MI Paste (CPP-ACP) in the Treatment of Early White Spot Lesions in Pediatric Patients [NCT05202821]	Phase 1	60 participants (Anticipated)	Interventional	2021-01-01	Recruiting
Probiotics That Moderate pH and Antagonize Pathogens to Promote Oral Health [NCT02999230]		170 participants (Actual)	Interventional	2017-02-22	Active, not recruiting
Effect of Calcium Fluoride Nanoparticles in Prevention of Demineralization During Orthodontic Fixed Appliance Treatment: a Randomized Clinical Trial [NCT04994314]	Phase 3	31 participants (Anticipated)	Interventional	2021-02-15	Recruiting
Cost Effectiveness of Sodium Fluoride Varnish Application in Prevention of Dental Caries in School Children Between Age of 6 and 7 Years [NCT03571815]		328 participants (Actual)	Interventional	2015-01-02	Completed
An Open-Label Study to Investigate the AMPAɣ8 Receptor Occupancy of JNJ-64140284 With the Newly Developed TARP-γ8 PET Tracer [18F]JNJ-64511070 in Healthy Men [NCT03693391]	Phase 1	22 participants (Actual)	Interventional	2018-10-17	Terminated(stopped due to stopped because of a business decision)
A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity [NCT02751450]		263 participants (Actual)	Interventional	2016-02-01	Completed
A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity [NCT02832375]	Phase 3	242 participants (Actual)	Interventional	2016-03-01	Completed
Pharmacokinetics of Advantage Arrest in Healthy Children 13-Months to 13-Years of Age [NCT05670743]	Phase 2	23 participants (Actual)	Interventional	2023-03-01	Active, not recruiting
Non-invasive Detection of Bicuspid Aortic Valve-Related Thoracic Aortopathy [NCT04083118]		95 participants (Actual)	Observational	2019-04-01	Completed
Effect of Silver Diamine Fluoride on the Treatment of Gingivitis in Geriatric Patients [NCT03445286]		48 participants (Actual)	Interventional	2019-01-29	Completed
Clinical Study of an Ascorbic Acid Derivative Dentifrice in Patients With Gingivitis [NCT02102295]	Phase 3	300 participants (Actual)	Interventional	2006-09-30	Completed
18F-Fluoride Assessment of Aortic Bioprosthesis Durability and Outcome [NCT02304276]		80 participants (Actual)	Interventional	2015-01-31	Active, not recruiting
Comparative Evaluation of Remineralizing Efficacy of Fluoride Varnish and Its Combination Varnishes on White Spot Lesions in Children With ECC: A Randomized Clinical Trial [NCT03360266]		60 participants (Actual)	Interventional	2016-03-21	Completed
Randomized Metabolic Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma FDOPA PET-CT [NCT02176720]	Phase 1	31 participants (Actual)	Interventional	2014-05-31	Terminated(stopped due to PI left HMRI)
Effects of Aloe Vera Toothpaste on Periodontal Parameters of Patients With Gingivitis [NCT02235532]		20 participants (Actual)	Interventional	2013-09-30	Completed
Clinical Study to Evaluate Dental Plaque [NCT00758290]	Phase 3	23 participants (Actual)	Interventional	2008-05-31	Completed
A Feasibility Study to Determine Whether a Randomised Controlled Trial of Silver Diamine Fluoride Compared to Usual Care for the Management of Caries in Children's Primary Teeth is Feasible in UK Primary Dental Care [NCT06092151]		80 participants (Anticipated)	Interventional	2023-06-22	Recruiting
Clinical Investigation to Assess the Efficacy of an Antimicrobial Mouthrinse in the Reduction of Established Plaque and Gingivitis: a 6-month Clinical Study [NCT06048627]	Phase 3	90 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Comparison of the Remineralization Potential of an Optimized Fluoride Dentifrice With a Control Fluoride Dentifrice Using an in Situ Caries Model [NCT06010732]	Phase 3	65 participants (Anticipated)	Interventional	2023-10-02	Recruiting
18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes [NCT03530176]		98 participants (Actual)	Interventional	2015-01-01	Completed
Effect of Fluoride and Casein Phosphopeptide-amorphous Calcium Phosphate on Remineralization of Early Caries Lesions in Primary Teeth: an in Vivo Study [NCT03526276]		118 participants (Actual)	Interventional	2016-03-31	Completed
Effect of an Amine Fluoride/Stannous Fluoride Containing Mouthrinse on Gingival Inflammation,Plaque Development, Discoloration and Bacterial Plaque Composition Over Six Months. [NCT01317446]	Phase 4	180 participants (Actual)	Interventional	2010-11-30	Completed
Clinical and Laboratory Effectiveness of Different Toothpastes in Treating White Spot Lesions [NCT06128434]		21 participants (Anticipated)	Interventional	2023-11-30	Recruiting
A Real-World Evidence Study Evaluating Oral Health Related Quality Of Life With Use Of A Stannous Fluoride Anti-Sensitivity Toothpaste For Dentin Hypersensitivity Management [NCT06045026]		536 participants (Actual)	Interventional	2023-09-21	Active, not recruiting
Comparison of Silver Modified and Conventional Atraumatic Restorative Treatment Modalities in Primary Molars in a Group of Egyptian School Children. A Randomized Controlled Trial [NCT03881020]	Phase 4	100 participants (Actual)	Interventional	2020-08-03	Completed
Maintaining Oral Health With Bio-products: a Randomized, Cross-over, in Situ Study [NCT04033263]		45 participants (Anticipated)	Interventional	2022-09-30	Not yet recruiting
Effect of Low-level Light Therapy Associated With Potassium Nitrate in the Control of Post-bleaching Dental Sensitivity: a Randomized, Double-blind, Split-mouth, Controlled Trial [NCT03434782]	Phase 1	50 participants (Actual)	Interventional	2017-04-24	Completed
Dental Fluorosis Risk by the Use of Acidulated Fluoride Dentifrice: Clinical Trial - Epidemiological Study With Children Residing in an área Without Public Water Fluoridation [NCT03761485]	Phase 4	452 participants (Actual)	Interventional	2015-01-15	Completed
A Clinical Method Development Study to Characterise The Efficacy of An Experimental Dual Active Combination Dentifrice For The Relief Of Dentin Hypersensitivity [NCT03361774]	Phase 2	0 participants (Actual)	Interventional	2018-10-01	Withdrawn(stopped due to Cancelled before Active)
Effectiveness of Silver Diamine Fluoride as Cavity Disinfectant After Atraumatic Restorative Treatment in Primary Teeth: A Randomized Clinical Trial [NCT03855527]	Phase 2	60 participants (Actual)	Interventional	2018-01-12	Completed
"Parental Perception and Acceptance of the Utilization of Silver Diamine Fluoride on Their Child's Anterior and Posterior Teeth Before and After Masking the Colour With Glass Ionomer" [NCT04509232]		82 participants (Actual)	Interventional	2019-10-12	Completed
A Clinical Study Investigating the Gingivitis Efficacy of a Stannous Fluoride Dentifrice in a Chinese Population. [NCT02937636]		128 participants (Actual)	Interventional	2017-09-19	Completed
Clinical Efficacy of Giomer Versus Sodium Fluoride Varnish for Management of Hypersensitivity: Randomized Control Trail [NCT03818945]	Phase 4	104 participants (Anticipated)	Interventional	2019-03-01	Recruiting
Optimizing Fluoride Retention in the Mouth of Older Adults With Distinct Salivary Flow Rates [NCT04239872]	Phase 1	20 participants (Actual)	Interventional	2020-03-11	Completed
Comparison of the Effect of Fluoride Remineralizer Gel and Foam: a Randomized Clinical Trial [NCT02490592]	Phase 4	58 participants (Actual)	Interventional	2014-03-31	Completed
Retention of Fluoride Formed on Enamel by Fluoride Gel or Varnish Application and Its Release to Dental Biofilm Fluid - in Vivo Study [NCT02486458]	Early Phase 1	62 participants (Actual)	Interventional	2015-04-30	Completed
Effect of Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised Study [NCT02724592]	Phase 1/Phase 2	70 participants (Actual)	Interventional	2013-02-28	Completed
A Pilot Study of rhPSMA-PET MRI Imaging for the Detection of Clinically Actionable Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance [NCT05852041]	Early Phase 1	40 participants (Anticipated)	Interventional	2023-08-07	Recruiting
Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on Plaque, Gingival Inflammation and Bleeding Upon Probing [NCT05258721]	Phase 2	60 participants (Actual)	Interventional	2021-07-06	Completed
Effectiveness of Nano-silver Fluoride and Silver Diamine Fluoride for Arresting Early Childhood Caries (a Randomized Clinical Trial) [NCT05255913]		360 participants (Actual)	Interventional	2022-03-15	Completed
Effectiveness in Dental Plaque Reduction of Two Mouthwashes Containing Fatty Acids Compounds (F.A.G.) or Stannous Fluoride: a Comparative Study [NCT04977778]		34 participants (Actual)	Interventional	2021-09-01	Completed
Evaluating Commercial Anti-Plaque Products and Oral Rinse [NCT01014143]	Phase 2	26 participants (Actual)	Interventional	2007-08-31	Completed
Comparison of Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging of Spine and Sacroiliac Joints for Detection of Inflammatory Lesions in Patients Affected by Spondyloarthritis [NCT02869100]		26 participants (Actual)	Interventional	2013-01-31	Completed
Utility of 18F-DOPA PET/MRI Metrics as a Biomarker for Treatment Response Assessment in Sarcoma Patients: A Pilot Study [NCT05560009]		10 participants (Anticipated)	Observational	2022-11-10	Recruiting
"Effect of Single Rinsing With Three Different Types of Mouthwash on VSC Levels in Morning Breath; Randomized Clinical Trial, Double-blind Cross-sectional Study" [NCT04279106]		36 participants (Actual)	Interventional	2018-09-03	Completed
Periodontal Disease and Cardiovascular Disease [NCT00763165]	Phase 3	438 participants (Actual)	Interventional	2000-11-30	Active, not recruiting
Effect of Weekly Professional Oral Care, During 12 Months, on the Composition of the Oral Flora and Related Variables in Dependent Elderly Residents [NCT02627469]		68 participants (Actual)	Interventional	2007-08-31	Completed
Effectiveness of Silver Diamine Fluoride/ Potassium Iodide in Indirect Pulp Capping of Young Permanent Molars (a Randomized Controlled Clinical Trial) [NCT04236830]	Phase 2/Phase 3	108 participants (Actual)	Interventional	2019-11-01	Completed
Effect of Toothpaste Containing Novamin on Streptococcous Mutans Count in Dental Plaque of High Caries Risk Children (Randomized Controlled Clinical Trial) [NCT05979636]		36 participants (Actual)	Interventional	2022-12-06	Completed
Efficacy, Cost-efficacy and Parental Acceptability of Using Diammine Silver Fluoride in Arresting Enamel Caries Lesions on Babies' Occlusal Surfaces [NCT02789202]		100 participants (Anticipated)	Interventional	2014-10-31	Active, not recruiting
Clinical Study of Tooth Enamel Remineralization Using DoReMin Product [NCT06166849]		40 participants (Anticipated)	Interventional	2023-03-28	Recruiting
Phase II Study of Short Course Hypofractionated Proton Beam Therapy Incorporating 18F-DOPA-PET/MRI for Elderly Patients With Newly Diagnosed Glioblastoma [NCT03778294]	Phase 2	43 participants (Actual)	Interventional	2019-03-28	Completed
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases [NCT00375830]	Phase 2	114 participants (Actual)	Interventional	2006-01-31	Completed
A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer [NCT06179303]	Phase 2	60 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
Is 18F-EF5 PET Imaging Useful in Determining the Prognosis of Newly Diagnosed Head and Neck Squamous Cell Carcinoma? [NCT01020097]		5 participants (Actual)	Interventional	2009-03-31	Completed
Train New Examiners Via Modified Gingival Margin Plaque [NCT00758563]	Phase 3	15 participants (Actual)	Interventional	2008-03-31	Completed
Long-term Bi-center Trial to Compare the Radiological Cavity Progression of Approximal Caries Following Infiltration or Standard Treatment [NCT02191943]		0 participants (Actual)	Interventional	2014-11-30	Withdrawn
Efficacy of Two Protocols for Applying Fluorine Varnish to Initial Active Lesions of Deciduous Teeth: a Randomized Clinical Trial [NCT03827889]		168 participants (Anticipated)	Interventional	2024-01-01	Suspended(stopped due to Outbreak of COVID-19.)
A Prospective, Randomized Clinical Study on the Effects of CPP-ACP Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 2 [NCT00670618]		325 participants (Actual)	Interventional	2008-10-01	Completed
Assessment of Unstable Carotid Plaque Using PET and MR Imaging in Patient Referred to Endarterectomy: The CAROTEP Study [NCT03353103]	Phase 2	20 participants (Anticipated)	Interventional	2018-09-03	Recruiting
An 8-week, Randomised, Controlled, Examiner-Blind, Proof of Principle Study Investigating the Ability of a 3% Methyl Vinyl Ether/Maleic Anhydride Co-Polymer (PVM/MA) + 5% Potassium Nitrate (KNO3) Combination Toothpaste to Protect From Dentine Hypersensiti [NCT05243745]		120 participants (Actual)	Interventional	2022-02-28	Completed
Evaluation of Effectiveness of a Novel Remineralizing Agent: A Randomized Controlled Clinical Trial [NCT06131294]		23 participants (Actual)	Interventional	2023-02-24	Active, not recruiting
Change in Oral Health-Related Quality of Life Following Minimally Invasive Aesthetic Treatment of Anterior Teeth in Children With Molar Incisor Hypomineralization: A Prospective Clinical Study. [NCT05727475]		156 participants (Actual)	Interventional	2021-11-12	Completed
Effect of Curodont™ Repair in Patients With Early Approximal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised, Split-mouth, Post-marketing Study [NCT02101255]		25 participants (Actual)	Interventional	2014-07-31	Completed
EFFECTIVENESS OF A HOMECARE DESENSITIZER FOR PATIENTS WITH DENTIN HYPERSENSITIVITY [NCT02128633]	Phase 2/Phase 3	126 participants (Actual)	Interventional	2009-11-30	Completed
A Pilot Study to Evaluate the Effect of Livionex on Reducing Plaque Accumulation and Improving Oral Health in Children [NCT04368533]		78 participants (Actual)	Interventional	2019-02-08	Completed
Effect of a Triclosan-containing Toothpaste as a Preventive Strategy of Peri-implant Experimental Mucositis in Cigarette Smokers: Clinical and Osteo-immunoinflammatory Response in a Randomized Crossover Study. [NCT03241407]		26 participants (Actual)	Interventional	2013-07-01	Completed
Effects of a Toothpaste Containing 0.3% Triclosan in the Maintenance Phase of Peri-implantitis Treatment. [NCT03191721]	Phase 3	102 participants (Actual)	Interventional	2010-06-30	Completed
A Randomized Clinical Trial on the Use of Sodium Fluoride Varnish and Silver Diamine Fluoride Solution for Arresting Active Dental Caries in Preschool Children [NCT02426619]	Phase 2/Phase 3	371 participants (Actual)	Interventional	2012-09-30	Completed
FISSURE-Project. Improved Dental Decay Management in Dental Service for Children: Fissure Sealants or Fluoride Varnish? [NCT03315312]	Phase 4	410 participants (Actual)	Interventional	2017-02-01	Active, not recruiting
Comparison of the Clinical Efficacy From the Retention Phase of Fluoride Delivery of Fluoride Toothpastes Using an in Situ Caries Model [NCT00708123]	Phase 3	60 participants (Actual)	Interventional	2007-11-30	Completed
A Prospective, Randomized, Clinical Study on the Effects of Casein Phosphopeptide Amorphous Calcium Phosphate Paste, Fluoride and a Combination on the Evolution of White Spot Lesions in Orthodontic Patients After Debonding. [NCT05710874]		107 participants (Actual)	Interventional	2016-09-23	Completed
Effectiveness of Toothpaste Containing the Active Ingredient of Galla Chinensis Extract on Treating Dentin Hypersensitivity '' A Randomized Clinical Trial '' [NCT05483062]		90 participants (Actual)	Interventional	2021-05-20	Completed
A Pilot Study to Evaluate the Sensitivity of a Novel Molecular Method for Plaque Toxicity [NCT02574221]		60 participants (Actual)	Interventional	2015-08-31	Completed
Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study [NCT00723515]	Phase 4	45 participants (Actual)	Interventional	2007-02-28	Completed
A Three-Month Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices [NCT06140784]		120 participants (Anticipated)	Interventional	2023-09-02	Active, not recruiting
A Three-Month Clinical Study to Assess the Gingivitis Effects of Various Dentifrices [NCT06140771]		115 participants (Actual)	Interventional	2021-10-20	Completed
Evaluation of the Anticaries Efficacy of Various Dentifrice Formulations Using an In-situ Model [NCT06140758]		12 participants (Anticipated)	Interventional	2023-07-31	Active, not recruiting
Evaluation of Efficacy of Experimental Dentifrice Formulations With Different Forms of Fluoride and/or Other Agents to Remineralize Enamel and Dentine Subsurface Lesions in a Double-Blind Randomized In-Situ Clinical Trial [NCT06140745]		10 participants (Actual)	Interventional	2020-10-05	Completed
A Randomized, Controlled Clinical Study to Evaluate the Efficacy of a Range of Dental/Denture Products for Improved Oral Health, Compared to Existing Oral Hygiene, in a Population of Partial Denture Wearers With Generalized Mild-moderate Plaque-induced Gi [NCT04290624]	Phase 4	58 participants (Actual)	Interventional	2020-10-14	Completed
A Review of Meta-Analyses on Bioavailable Stannous Fluoride Dentifrices: Effects on Dental Plaque [NCT04006483]		2,359 participants (Actual)	Observational	2018-01-08	Completed
Bioavailable Stannous Fluoride Dentifrice Meta-Analyses: Effects on Dentine Hypersensitivity and Enamel Erosion [NCT04006470]		172 participants (Actual)	Observational	2018-01-08	Completed
Training and Calibration of Dental Examiners [NCT00765167]	Phase 3	18 participants (Actual)	Interventional	2007-11-30	Completed
Non-invasive Therapy With Fluoridated Toothpastes for Root Caries in Independently-living Older Adults [NCT02647203]	Phase 1/Phase 2	345 participants (Actual)	Interventional	2014-07-31	Completed
Arrest of Interproximal Caries Lesion in Primary Molars With 38% Silver Diamine Fluoride Solution and 5% Sodium Fluoride Varnish: A Randomized Clinical Trial [NCT05791669]	Phase 3	45 participants (Actual)	Interventional	2021-08-01	Completed
Antimicrobial Effect of Casein Phosphopeptide Amorphous Calcium Phosphate on Streptococcus Mutans in Children [NCT03526315]		127 participants (Actual)	Interventional	2016-03-31	Completed
Is Xylitol Toothpaste Effective in Preventing Dental Caries Among Young Children With Moderate-to-high Caries Risk? - a Randomized Controlled Trial [NCT04096599]		579 participants (Actual)	Interventional	2018-11-18	Active, not recruiting
Assessment of Prevident Sodium Fluoride 1.1% Toothpaste Using an Intra-oral Remineralization-demineralization Model [NCT02708160]	Phase 2	0 participants (Actual)	Interventional	2016-03-31	Withdrawn(stopped due to Withdrawn due to business reasons)
Effectiveness of Fluoride Varnish in the Prevention of Early Childhood Caries in Non-fluoridated Areas: A 24-month Randomized Controlled Trial [NCT02742038]		275 participants (Actual)	Interventional	2012-03-31	Completed
Assessment of Symptomatic and Asymptomatic Carotid Plaques Using Hybrid Imaging 18F-sodium Fluoride PET/MR [NCT02726984]		15 participants (Actual)	Interventional	2016-01-15	Completed
Clinical and Radiographic Evaluation of Nano Silver Fluoride Versus Calcium Hydroxide in Indirect Pulp Treatment of Deep Carious Second Primary Molars, Randomized Clinical Trial [NCT04005872]		40 participants (Actual)	Interventional	2019-10-01	Completed
Development and Validation of a Multi-Mineral Fluoride Mouthrinse [NCT00642252]	Phase 1	30 participants (Actual)	Interventional	2012-01-31	Completed
An 8 Week, Randomised, Examiner-blind, Controlled Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Dentifrice in the Relief of Dentinal Hypersensitivity in a Chinese Population [NCT04950465]		271 participants (Actual)	Interventional	2021-07-27	Completed
Validation of Imaging-Based Biomarkers of Treatment Response in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide [NCT02677376]		7 participants (Actual)	Observational	2016-06-27	Completed
Effectiveness of the Use of Desensitizing Dentifrices Based on Nanocrystals of Hydroxyapatite / 5% Potassium Nitrate / 1450ppm Sodium Monofluorophosphate and Potassium Nitrate 5% / 1426ppm Sodium Floride in the Treatment of Dentine Hypersensitivity. Test [NCT04156152]		32 participants (Anticipated)	Interventional	2020-04-10	Not yet recruiting
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being [NCT02536352]	Early Phase 1	43 participants (Actual)	Interventional	2015-10-31	Completed
The Influence of Preventive Regimens Containing Different Toothpastes on Caries Risk of High Risk Patients: A Randomized Clinical Trial [NCT04032210]		66 participants (Anticipated)	Interventional	2019-10-01	Not yet recruiting
Comparison of the Potential for Dentine Discoloration of Silver Diamino Fluoride and Silver Diamino Fluoride Associated With Potassium Iodide [NCT04001959]		40 participants (Anticipated)	Interventional	2019-05-02	Recruiting
Clinical and Microbiological Effects of Three Different Mouth Rinses Made of Sodium Fluoride, Guava Leaves Extract or Pomegranate Peel Extract on Dental Plaque in Children [NCT06013735]		40 participants (Actual)	Interventional	2020-02-17	Completed
Assessment of Effect of an Experimental Pregabalin Gel in Reducing Post-operative Tooth Sensitivity Surgery Caused by Bleaching With 35% Hydrogen Peroxide [NCT06180707]	Phase 3	75 participants (Anticipated)	Interventional	2024-01-05	Not yet recruiting
A Randomized Clinical Trial on the Effectiveness of Oral Health Preventive Programmes in School Children in Uganda [NCT06081868]		610 participants (Anticipated)	Interventional	2024-09-01	Not yet recruiting
Preventing Early Childhood Caries With Silver Diamine Fluoride - a Randomised Clinical Trial [NCT04075474]	Phase 2	730 participants (Anticipated)	Interventional	2020-10-27	Recruiting
Treatment of White Spot Lesions After Orthodontic Treatment: A Practice-based Randomized Controlled Trial [NCT01059058]		240 participants (Anticipated)	Interventional	2010-03-31	Completed
Reducing Disease Burden and Health Inequalities Arising From Chronic Dental Disease Among Indigenous Children: an Early Childhood Caries Intervention [NCT02151916]	Phase 3	544 participants (Actual)	Interventional	2011-06-30	Active, not recruiting
Assessment of Dentine Tubule Occlusion in a Modified in Situ Model [NCT02768194]		26 participants (Actual)	Interventional	2016-07-06	Completed
Remineralization Potential of MI Varnish(CPP-ACP and Fluoride) Versus Fluoride Varnish in Controlling White Spot Lesions in Maxillary Primary Incisors: A Randomized Clinical Trial [NCT03731403]		60 participants (Actual)	Interventional	2019-03-01	Completed
Caries Management by Risk Assessment in Children [NCT01310283]		120 participants (Anticipated)	Interventional	2010-04-30	Completed
Assessing Hypoxia by 18F-EF5 PET Scanning and Glycolysis by 18FFDG PET Scanning in Subjects With Non-Small Cell Lung Cancer [NCT01017133]	Phase 1	56 participants (Anticipated)	Interventional	2009-05-31	Completed
The Efficacy of a Toothpaste to Reduce Sensitivity [NCT00763269]	Phase 3	626 participants (Actual)	Interventional	2008-09-30	Completed
Desensitizing Efficacy of Polymeric Nano Calcium Fluoride Containing Varnish Versus Casein Phosphopeptide Amorphous Calcium Phosphate Containing Fluoride Varnish: Randomized Clinical Trial [NCT04614727]		50 participants (Anticipated)	Interventional	2021-02-10	Not yet recruiting
Clinical Study to Compare Dental Plaque Control [NCT00758394]	Phase 3	29 participants (Actual)	Interventional	2007-09-30	Completed
Medical Management of Caries in the Primary Dentition Using Silver Nitrate: A Pilot Study [NCT02604134]	Early Phase 1	122 participants (Actual)	Interventional	2014-07-31	Completed
The Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration [NCT05758662]		180 participants (Anticipated)	Observational	2023-04-30	Not yet recruiting
The Anticariogenic Effect of Miswak (Silvadora Persica) and Grape Seed Extract [NCT04136639]		30 participants (Actual)	Interventional	2019-06-01	Completed
Imaging for Prostate Cancer Metastasis Detection - Traditional Imaging (Bone Scan and CT) Versus PSMA-PET-CT, SPECT-CT and Whole-Body MRI [NCT03537391]		80 participants (Actual)	Interventional	2018-03-01	Completed
The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics [NCT00763256]	Phase 3	33 participants (Actual)	Interventional	2006-05-31	Completed
Early Childhood Caries in Jordanian Children: Prevalence, Risk Factors and Prevention Using Silver Diamine Fluoride [NCT05748054]		159 participants (Actual)	Interventional	2019-11-01	Completed
Prevention of Dental Caries Lesions With Fluoride Varnish in Erupting First Permanent Molars [NCT02592278]	Phase 4	180 participants (Actual)	Interventional	2015-03-31	Completed
Caries Preventive Effect of Salt Fluoridation in Preschool Children in The Gambia [NCT02585882]		441 participants (Actual)	Interventional	2012-03-31	Completed
An Observational Pilot Study of 18F-Sodium Fluoride (Na18F) Whole Body PET Scans in Patients for Whom 99m Tc MDP Bone Scans Would Normally be Indicated. [NCT00922519]		9,999 participants (Anticipated)	Observational	2009-06-30	Recruiting
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer [NCT00928252]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2009-06-30	Completed
The Effect of Periodontal Treatment and the Use of a Triclosan/Copolymer/Fluoride Toothpaste on Glycaemic Control in Diabetics. [NCT00762762]	Phase 3	60 participants (Actual)	Interventional	2006-03-31	Completed
EVALUATION OF AN ALTERNATIVE TECHNIQUE FOR THE APPLICATION OF SODIUM FLUOROPHOSPHATE: A 2-YEARS DOUBLE-BLIND RCT [NCT05810389]	Phase 4	300 participants (Actual)	Interventional	2017-04-01	Completed
Arresting Active Dentine Lesions and Quality of Life Among a Group of Preschool Children in Mansoura City. [NCT05314660]	Phase 4	135 participants (Actual)	Interventional	2020-01-15	Completed
A Randomised Controlled Trial to Measure Effectiveness of Sodium Fluoride Varnish to Prevent Dental Caries in School Children Between Age of 6 and 7 Years [NCT02877888]	Phase 1/Phase 2	320 participants (Actual)	Interventional	2016-08-31	Completed
In Vivo Evaluation of the Antimicrobial Activity of Diamine Silver Fluoride and Potassium Iodide on Dentin Carious Lesions in Kuwaiti Subjects. [NCT02771704]		5 participants (Actual)	Interventional	2015-10-31	Completed
Randomized Clinical Trial on Preventing and Arresting Root Surface Caries Using Silver Diammine Fluoride Solution in Older Adults Living in Fluoridated and Non-fluoridated Areas [NCT02742142]	Phase 2/Phase 3	534 participants (Actual)	Interventional	2012-10-31	Completed
A Phase 2, Multicenter Evaluation of 18F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant Prostate Cancer and Bone Metastases (BMS #180-279) [NCT00936975]	Phase 2	18 participants (Actual)	Interventional	2009-09-30	Completed
Effectiveness Silver Diamine Fluoride Versus Sodium Fluoride in Arresting Caries Around Crown Margins in Older Adults [NCT04255251]	Early Phase 1	200 participants (Anticipated)	Interventional	2021-06-26	Recruiting
A Randomized Controlled Clinical Trial to Evaluate Late First to Mid-Second Trimester Introduction of Advanced Daily Oral Hygiene on Gingivitis and Maternity Outcomes [NCT01549587]		746 participants (Actual)	Interventional	2012-02-29	Completed
Treatment of Initial Caries Lesions on Proximal Surfaces of Primary and Permanent Posterior Teeth: a Randomized Placebo-controlled Study. [NCT01477385]		183 participants (Anticipated)	Interventional	2012-01-31	Recruiting
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques [NCT00882609]	Phase 3	550 participants (Anticipated)	Interventional	2009-01-31	Recruiting
A Randomised, Controlled, Examiner Blind, Methodology Development Study to Evaluate the Effect of a Stannous Fluoride Toothpaste on the Oral Microbiome [NCT06048809]		50 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
Clinical Efficacy of Different Remineralizing Agents in Treatment of White Spot Lesions Among a Group of Egyptian Children : A Randomized Clinical Trial [NCT05064137]		30 participants (Anticipated)	Interventional	2022-03-31	Not yet recruiting
Effectiveness of Silver Diamine Fluoride Versus Sodium Fluoride Varnish With Parental Behavior Modification for Arresting Early Childhood Caries: A Randomized Clinical Trial [NCT05761041]	Phase 3	140 participants (Actual)	Interventional	2022-03-28	Completed
Comprehensive Oral Health Center for Discovery: New Strategies for Enhancing Tissue Integrity and Repair Early Childhood Caries: Prevention and Treatment Outcomes [NCT00066963]	Phase 3	376 participants (Actual)	Interventional	2002-10-31	Completed
Phase 2 Efficacy & Safety Evaluation of Advantage Anti-Caries Varnish for Primary Prevention [NCT04947527]	Phase 2	274 participants (Actual)	Interventional	2022-06-04	Active, not recruiting
The Use of Silver Diamine Fluoride and Papain-Based Gel for Management of MIH-affected Molar in Paediatric Patients: A Randomised Controlled Trial [NCT04710927]		38 participants (Actual)	Interventional	2019-12-01	Completed
A Pilot Study to Evaluate the Sensitivity of a Novel Molecular Method for Plaque Toxicity When Comparing Two-step Toothpaste to a Regular Dentifrice [NCT02543060]		60 participants (Actual)	Interventional	2015-06-30	Completed
[NCT02613130]		60 participants (Actual)	Interventional	2015-11-30	Completed
Comparison of the Clinical Effectiveness of 8% Arginine/1450 Ppm Sodium Monofluorophosphate Versus 5% Potassium Nitrate/2500 Ppm Sodium Fluoride in Dentin Hypersensitivity Therapy: A Randomized Controlled Clinical Trial [NCT02829879]	Phase 3	50 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Investigation of Dental Plaque and Gingival Index [NCT00759031]	Phase 3	19 participants (Actual)	Interventional	2008-02-29	Completed
Total Salivary Fluoride Concentration of Healthy Adult Subjects Following Toothbrushing With Different Formulations of Fluoridated Toothpastes With and Without Post-brushing Water Rinsing. A Double Blinded Randomised Controlled Trial [NCT02740803]		120 participants (Actual)	Interventional	2016-04-30	Completed
Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer [NCT04206319]	Phase 2	26 participants (Anticipated)	Interventional	2020-09-22	Recruiting
Clinical and Radiographic Evaluation of Silver Diamine Fluoride Versus Mineral Trioxide Aggregate as Indirect Pulp Capping Agents in Deeply Carious Young Permanent Molars Randomized Controlled Clinical Trial [NCT05425368]		30 participants (Anticipated)	Interventional	2022-08-01	Not yet recruiting
Reducing Oral Health Disparities of Older Adults: Comparative Effectiveness of 2 Treatments [NCT03916926]		590 participants (Anticipated)	Interventional	2019-09-18	Active, not recruiting
F-18 NaF PET for Detection of Bone Metastases in Men With Prostate Cancer: Exploratory Study [NCT00956163]	Early Phase 1	50 participants (Actual)	Interventional	2010-03-31	Completed
Randomized Controlled Examiner-Blind Phase II Exploratory Clinical Study to Characterize the Efficacy Profile of an Experimental Dual Active Combination Dentifrice for the Relief of Dentin Hypersensitivity, in Subjects With Clinically Diagnosed Dentin Hyp [NCT03943095]	Phase 2	123 participants (Actual)	Interventional	2019-05-13	Completed
The Behavioural Engagement of Dental Nurses Applying the Fluoride Varnish to Young Children: the BEHAVE Study [NCT00881790]		509 participants (Actual)	Observational	2009-04-30	Completed
A Randomised Controlled Trial Investigating a Comparison of Fluoride Varnish vs Self-Etching Dentine Bonding Agent in the Reduction of Cervical Dentine Sensitivity in Patients Attending a General Dental Practice in West Sussex, UK. [NCT02919202]		26 participants (Actual)	Interventional	2016-10-26	Completed
Bioavailable Stannous Fluoride Dentifrice Meta-Analyses: Effects on Dentine Hypersensitivity and Enamel Erosion [NCT04005417]		1,036 participants (Actual)	Observational	2018-01-08	Completed
Role of the Serotoninergic System in Impulse Control Disorders in Parkinson's Disease [NCT03970239]		45 participants (Anticipated)	Interventional	2019-05-13	Recruiting
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer [NCT04981509]	Phase 2	65 participants (Anticipated)	Interventional	2022-06-10	Recruiting
Effects of DIammine SIlver Fluoride Placed Over Cervical Lesions of Permanent Teeth to Reduce Tooth Sensitivity [NCT01063530]		144 participants (Anticipated)	Interventional	2010-02-28	Not yet recruiting
Randomized Clinical Trial on Resin Infiltration Versus Fluoride Varnish Treatment of Early Smooth-surface Caries Lesions in Deciduous Teeth [NCT01881100]		81 participants (Actual)	Interventional	2011-01-31	Completed
18F- Sodium Fluoride PET Imaging as a Replacement for Bone Scintigraphy [NCT01930812]	Phase 3	286 participants (Actual)	Interventional	2014-07-31	Completed
Cariostatic and Remineralizing Effects of Three Different Dental Varnishes (A Clinical Trial) [NCT04887389]	Phase 4	115 participants (Anticipated)	Interventional	2021-08-01	Active, not recruiting
Clinical and Laboratory Assessments of Effectiveness of Silver Diamine Fluoride (SDF) in Arresting Caries Among Children and Parental Satisfaction [NCT04642846]		155 participants (Anticipated)	Interventional	2020-11-21	Recruiting
Preventive Therapy of White Spot Lesions Using Different Remineralizing Agents in Children From 3 to 12 Years Old [NCT04705428]		75 participants (Actual)	Interventional	2021-01-01	Completed
Phase III RCT of the Effectiveness of Silver Diamine Fluoride in Arresting Cavitated Caries Lesions [NCT03649659]	Phase 3	831 participants (Actual)	Interventional	2018-10-08	Completed
Effect of Therapeutic Measures in Dental Caries Reduction in Children With Primary Dentition From Metropolitan Area Sorrounded Medellín City. A Clinical Trial [NCT00475618]	Phase 3	180 participants (Actual)	Interventional	2007-05-31	Completed
Fluoride Bioavailability in Plasma and Saliva After Ingestion of Water or Foods Prepared With Fluoridated Water [NCT01978041]	Phase 1	20 participants (Actual)	Interventional	2013-01-31	Completed
Clinical and Cost-effectiveness of Fluoride Varnish Versus Resin Based Fissure Sealant in Newly Erupted Permanent Molars in Group of Egyptian Children : A Randomized Clinical Trial ( Part 1) [NCT04603573]		91 participants (Anticipated)	Interventional	2021-07-10	Recruiting
Efficacy of a Fluoride Varnish and a Glass Ionomer Sealant on Cervical Dentin Hypersensitivity: A Randomized Clinical Trial [NCT04591444]	Phase 3	121 participants (Actual)	Interventional	2017-01-31	Completed
Fluoride Varnish Trial in High Caries Preschoolers [NCT00067353]	Phase 3	500 participants	Interventional	2003-11-30	Completed
Identification of Effective Fluoride Concentration In Toothpaste For Dental Caries Prevention; A Randomized Controlled Trial [NCT02016001]		380 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Effectiveness of Biannual Application of Silver Nitrate Solution Followed by Sodium Fluoride Varnish in Arresting Early Childhood Caries in Preschool Children: a 30-month, Randomised, Double-blind, Non-inferiority Trial [NCT02019160]	Phase 3	1,070 participants (Actual)	Interventional	2014-09-30	Completed
Effect of Curodont Repair or Placebo on the Remineralisation in Patients With Class 5 Carious Lesions: A Mono-centre, Split-mouth, Double-blinded, Placebo Controlled, Randomised, Post Marketing Clinical Study [NCT02020681]		40 participants (Actual)	Interventional	2013-09-30	Completed
Impact of Maternal Xylitol Consumption on Mutans Sterptococci ,Plaque and Caries Levels in Children [NCT02036151]	Phase 4	60 participants (Actual)	Interventional	2009-02-28	Completed
Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity [NCT02773758]	Phase 4	143 participants (Actual)	Interventional	2016-01-01	Completed
Preventing Caries in Preschoolers: Testing a Unique Service Delivery Model in American Indian Head Start Programs [NCT01116739]	Phase 3	2,060 participants (Actual)	Interventional	2011-04-30	Completed
Nanosilver Fluoride: a Microbiological and Clinical Trial [NCT01950546]	Phase 1	30 participants (Actual)	Interventional	2014-09-30	Completed
To Access the Effects of Mucositis in Adults With Dental Implants [NCT01072201]	Phase 3	60 participants (Actual)	Interventional	2007-06-30	Completed
Positron Emission Tomography Study in Patients With Non-Hodgkin Lymphoma [NCT00712556]		55 participants (Actual)	Observational	2008-05-31	Completed
A Pilot Study of Utility of 18F-FDOPA-PET for Neurosurgical Planning and Radiotherapy Target Delineation in Glioma Patients: Biopsy Validation of 18F-FDOPA-PET Uptake and Biodistribution in Brain Tumors [NCT01165632]	Early Phase 1	24 participants (Actual)	Interventional	2010-07-26	Active, not recruiting
An Observational Multi-cite Study to Evaluate and Compare the Effectiveness of Various Tooth Specific Treatments in the Management of Early Caries Lesions [NCT04933331]		744 participants (Anticipated)	Observational	2020-12-07	Active, not recruiting
Clinical Evaluation of the Effect of an Experimental Toothpaste on the Reduction of Dental Plaque and Gingival Inflammation [NCT02552589]		241 participants (Actual)	Interventional	2015-09-30	Completed
A Review of Meta-Analyses on Bioavailable Stannous Fluoride Dentifrices: Effects on Gingival Health [NCT03970759]		2,890 participants (Actual)	Observational	2018-01-08	Completed
[NCT02637830]		12 participants (Actual)	Interventional	2012-01-31	Completed
Glass Ionomer Sealant Versus Fluoride Varnish Application to Prevent Occlusal Caries Among Preschool Children - a Randomized Controlled Trial [NCT04163354]		348 participants (Anticipated)	Interventional	2018-04-11	Enrolling by invitation
Impact of Basic Periodontal Therapy in the Levels of Porphyromonas Gingivalis and Aggregatibacter Actinomycetemcomitans Subgingival and Its Association With Vascular Function [NCT02716259]		120 participants (Anticipated)	Interventional	2016-03-31	Recruiting
Sodium Fluoride, Chlorhexidine and Vancomycin Effect in the Inhibition of Mutans Streptococci in Children With Dental Caries: a Randomized, Double-Blind Clinical Trial [NCT00612469]		69 participants (Actual)	Interventional	2005-10-31	Completed
Parental Perception of Silver Diamine Fluoride Staining and Its Efficacy on Caries Arrestment in Comparison to Sodium Fluoride With Casein Phosphopeptide-amorphous Calcium Phosphate [NCT04213573]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2020-01-21	Suspended(stopped due to because of corona virus epidemic)
Assessment of the Oral Tissue Tolerance of a Potassium Oxalate Containing Mouthrinse [NCT01009554]		96 participants (Actual)	Interventional	2009-10-31	Completed
Clinical Efficacy of Fluoride Toothpastes Using an in Situ Caries Model [NCT01005966]	Phase 3	65 participants (Actual)	Interventional	2008-11-30	Completed
Determination of the Oral Irritation and Sensitization Potential of Two Experimental Potassium Oxalate Containing Mouthrinses [NCT01156376]		80 participants (Actual)	Interventional	2010-06-30	Completed
Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma [NCT02876991]		110 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Effectiveness of Different Preventive Regimens in Cariogram Parameters and DMF Scores of High Caries Risk Patients: A Randomized Control Trial [NCT04032184]		66 participants (Anticipated)	Interventional	2019-10-01	Not yet recruiting
An in Situ Clinical Trial to Evaluate the Efficacy of a Calcium and Phosphate Enriched Sodium Monofluorophosphate Toothpaste on Enamel Lesion Remineralisation [NCT04155658]		55 participants (Actual)	Interventional	2019-11-25	Completed
Remineralization Potential of Curodont Repair Flouride Plus Versus CPP-ACP in Management of White Spot Lesions: Randomized Clinical Trial [NCT04245787]		48 participants (Anticipated)	Interventional	2020-02-29	Not yet recruiting
Effectiveness of Silver Diamine Fluoride in Arresting Early Approximal Carious Lesion Progression: A Pilot Study [NCT02591147]		41 participants (Actual)	Interventional	2016-01-07	Completed
Pharmacokinetics of Advantage Arrest in Children [NCT04186663]	Phase 2	59 participants (Actual)	Interventional	2019-08-01	Completed
Prevention of Transmission of Mutans Streptococci From Mother to Child [NCT00066040]		280 participants	Interventional	2001-01-31	Completed
Medical Treatment of Early-Enamel Carious Lesion Using Different Remeneralizing Agents: 2-years Randomized Clinical Trial [NCT05296213]		45 participants (Actual)	Interventional	2019-12-01	Completed
A Prospective Study of the RefleXion [18F]- DCFPyL PET-CT Subsystem Imaging Performance in Patients With Prostate Cancer [NCT05470699]		30 participants (Actual)	Interventional	2022-08-29	Active, not recruiting
18F-fluoride (18F-NaF) Positron Emission Tomography (PET) for Identification of Ruptured and High-Risk Coronary Atherosclerotic Plaques [NCT02607748]	Phase 4	41 participants (Actual)	Interventional	2015-11-13	Completed
Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis [NCT00926328]	Phase 3	120 participants (Actual)	Interventional	2007-06-30	Completed
A Randomized Controlled Trial on the Effectiveness of Fissure Sealant and Topical Fluoride Application in Preventing Dental Caries [NCT01446107]		502 participants (Actual)	Interventional	2007-12-31	Completed
The Effect of Brushing With Fluoride Toothpaste on Dental Plague Control for Elementary School Students [NCT06116825]		400 participants (Actual)	Interventional	2022-10-20	Completed
Organizing Family-based Health Promotion for Young Children in Public Dental Service [NCT01854502]		804 participants (Actual)	Interventional	2008-01-31	Completed
Salivary Levels of Fluoride and Silver 7 Days After Treatment With Diammine Silver Fluoride [NCT01860391]		6 participants (Actual)	Interventional	2012-12-31	Completed
FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients [NCT01864083]	Early Phase 1	30 participants (Actual)	Interventional	2013-05-31	Completed
Comparative Evaluation of Giomer Varnish vs Fluoride Varnish as Desensitizing Agents Among a Group of Children With Molar Incisor Hypomineralization : A Controlled Clinical Trial [NCT05542667]	Phase 3	24 participants (Anticipated)	Interventional	2025-02-28	Not yet recruiting
Imaging Cell Proliferation With FLT PET: A Pilot Study in Paediatric Lymphoma Patients With Equivocal FDG PET Findings [NCT04028804]		8 participants (Actual)	Observational	2011-07-31	Completed
Phase 3 Randomized Trial Of PSMA PET Prior to Definitive Radiation Therapy for Unfavorable Intermediate-Risk or High-Risk Prostate Cancer [PSMA dRT] [NCT04457245]	Phase 3	54 participants (Actual)	Interventional	2020-08-14	Terminated(stopped due to accrual)
Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction [NCT01040169]		79 participants (Actual)	Interventional	2008-05-31	Completed
Effectiveness of Sylc Air Abrasion Bioactive Glass Technology Versus Fluoride Varnish Application in Management of Hypersensitivity of Non-Carious Cervical Lesions: Randomized Clinical Trial. [NCT03285360]	Phase 1	50 participants (Actual)	Interventional	2017-10-01	Completed
Plaque Removal Efficacy of Four Dentifrices in a Single Brushing Model [NCT03285984]		56 participants (Actual)	Interventional	2012-03-27	Completed
Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children [NCT00435500]	Phase 3	1,320 participants	Interventional	2003-06-30	Active, not recruiting
Assessing Three Oral Care Regimen on Plaque, Gingivitis, and Tooth Whitening [NCT02940821]		142 participants (Actual)	Interventional	2016-05-30	Completed
Comparative Study Using Biomimetic Remineralization Versus Fluoride Varnish In Management Of White Spot Lesion In Post Orthodontic Treated Patient: (Split Mouth Technique ) A Randomized Clinical Trial [NCT02913885]	Phase 2	64 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
The Biodistribution of N-{4-[3'-[F-18] Fluoroethylphenyl)Amino]-6-quinazolinyl}-Acrylamide ([F-F18]FEQA) in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and in Healthy Subjects: A Pilot Study [NCT00444223]		3 participants (Actual)	Interventional	2004-05-04	Terminated(stopped due to poor recruitment)
Clinical Evaluation of Silver Diamine Fluoride Combined With Potassium Iodide Versus Silver Diamine Fluoride in Management of Class I Carious Lesions Over a Period of 12 Months Follow-up: A Randomized Controlled Clinical Trial [NCT05485272]		42 participants (Anticipated)	Interventional	2022-02-01	Recruiting
A 12-Week, Randomised, Controlled, Examiner-blind, Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste for the Relief of Dentine Hypersensitivity in a Chinese Population [NCT05750745]		245 participants (Actual)	Interventional	2023-05-08	Completed
Eficácia de dentifrício Com Sistema de liberação Controlada de flúor Para remineralização de lesões Iniciais de cárie: Estudo clínico Randomizado. [NCT05139966]	Phase 2/Phase 3	21 participants (Actual)	Interventional	2017-08-03	Completed
Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy [NCT02149173]		29 participants (Actual)	Interventional	2010-09-15	Terminated(stopped due to Terminated due to low accrual)
Efficacy of Salivary Bacteria and Post Brushing [NCT00981825]	Phase 3	22 participants (Actual)	Interventional	2007-10-31	Completed
Evaluation of the Antibacterial Effect of Nano Silver Fluoride Versus Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique: A Randomized Clinical Trial [NCT03186261]	Phase 3	44 participants (Actual)	Interventional	2018-04-01	Completed
Phase 4 Study Prevention of Incipient Carious Lesions (White Spot Lesions) in Patients With Fixed Orthodontic Appliances Following the Application of Elmex Gel [NCT00268138]	Phase 4	314 participants (Anticipated)	Interventional	2006-04-30	Recruiting
Comparison of Dentin Hypersensitivity Reduction Over a 1-month Period Between a Single Topical Application of a Dentin-desensitizing Agent (Gluma) and Other Materials: A Randomized Clinical Trial [NCT04351412]		55 participants (Actual)	Interventional	2020-01-10	Completed
The Antibacterial Effect of Nanosilver Fluoride in Relation to Caries Activity in Primary Teeth: a Randomized Controlled Clinical Trial [NCT05221749]	Phase 3	50 participants (Actual)	Interventional	2022-03-15	Terminated(stopped due to Only the 1 month follow-up was completed. The principal investigator could not complete the 3 month follow-up appointments and was not calibrated with other dentists who were available at the time.)
An Investigation of the Role of 18F-Sodium Fluoride and 18F-Flurodeoxyglucose PET CT and USPIO Enhanced MRI in Imaging Carotid Artery Inflammation and Mineralization. [NCT01674257]		60 participants (Anticipated)	Observational	2013-01-31	Recruiting
Comparative Effectiveness of Treatments to Prevent Dental Caries Given to Rural Children in School-based Settings: Protocol for a Cluster Randomized Controlled Trial [NCT03448107]		3,960 participants (Anticipated)	Interventional	2017-09-20	Recruiting
Fluoride Administered and Retained After Topical Fluoride Varnish [NCT01754831]	Early Phase 1	6 participants (Actual)	Interventional	2011-12-31	Completed
A Randomized, Crossover, Controlled, Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101 in Healthy Adult Subjects [NCT06182267]	Phase 1	30 participants (Anticipated)	Interventional	2023-11-27	Active, not recruiting
Effect of Vitamin D Supplementation on Salivary Biomarkers; Certain Proteins and Cariogenic Oral Microbiome for Medical Management of Dental Caries: A Randomized Controlled Trial [NCT06172764]	Phase 4	90 participants (Anticipated)	Interventional	2023-12-12	Recruiting
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT [NCT03604315]	Phase 1	120 participants (Anticipated)	Interventional	2018-12-18	Recruiting
Phase 2 Efficacy Evaluation Of Advantage Anti-Caries Varnish [NCT03082196]	Phase 2	284 participants (Actual)	Interventional	2017-03-30	Completed
Effectiveness and Retention of Pit and Fissure Sealants in Rural Setup: A School-based Clinical Trial in Nepal [NCT05894200]		377 participants (Anticipated)	Observational [Patient Registry]	2023-08-10	Enrolling by invitation
Clinical Efficacy of Caries Infiltration (Icon) - A Randomized, Blinded and Controlled Pilot Study of Early Caries Progression Detection [NCT01796106]		12 participants (Actual)	Interventional	2015-03-31	Terminated(stopped due to Recruitment slower than expected.)
Effect on Bacterial Glycolytic Acid Formation on Plaque [NCT00762450]	Phase 3	6 participants (Actual)	Interventional	2008-04-30	Completed
Compare Anti-inflammatory Dentifrices [NCT00762528]	Phase 4	49 participants (Actual)	Interventional	2009-02-28	Completed
Investigation of Clinical Efficacy of a New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems as Compared to a Control Mouthwash - a Six-month Study in Italy [NCT05821712]	Phase 3	80 participants (Actual)	Interventional	2021-03-08	Completed
Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste [NCT01072188]	Phase 3	45 participants (Actual)	Interventional	2008-07-31	Completed
Progression of Active Microcavitated Carious Lesions on Primary Teeth Occlusal Surfaces: Randomize Clinical Trial [NCT04127357]		22 participants (Actual)	Interventional	2015-03-05	Completed
Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion [NCT01128972]	Phase 2	36 participants (Actual)	Interventional	2009-08-31	Completed
Glass Ionomer Sealant and Fluoride Varnish Randomized Clinical Trial [NCT01129440]	Phase 2	597 participants (Actual)	Interventional	2011-06-30	Completed
Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer [NCT01541358]		2 participants (Actual)	Interventional	2012-05-31	Terminated(stopped due to Low accrual and no funding)
Effectiveness of Nano-hydroxyapetite Care Paste in Reducing Dentinhypersenstitivity: A Double Blind Randomized Control Trial [NCT02936830]	Phase 4	63 participants (Actual)	Interventional	2016-10-31	Completed
Evaluation of the Efficacy of Two Potassium Oxalate Containing Mouthrinses for Relieving Dentinal Hypersensitivity [NCT01133379]		174 participants (Actual)	Interventional	2010-05-31	Completed
Compare the Clinical Efficacy of Prototype Toothpastes [NCT00926029]	Phase 3	98 participants (Actual)	Interventional	2008-01-31	Completed
Effectiveness of Silver Diamine Fluoride in Arresting Early Childhood Caries: Randomized Controlled Clinical Trial [NCT04514094]		100 participants (Actual)	Interventional	2018-01-01	Completed
A Long-term Retrospective Cohort Study in Children With Autism Spectrum Disorders on the Effectiveness of Dental Sealants and Fluoride Varnish to Prevent the Occurrence of New Caries [NCT05146479]		232 participants (Actual)	Observational	2006-01-01	Completed
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapies [NCT01516866]		58 participants (Actual)	Observational	2011-11-30	Completed
Effectiveness of Remineralization Agents on the Prevention of Dental Bleaching Induced Sensitivity [NCT04855279]		64 participants (Actual)	Interventional	2019-01-07	Completed
Evaluation of the Efficacy of Fluoride Therapies on Hypersensitive Carious Lesions in Primary Teeth [NCT04804423]	Phase 2/Phase 3	30 participants (Actual)	Interventional	2020-01-13	Completed
Comparative Evaluation of Two-Year Clinical Performance of Three Universal Adhesives in Posterior Restorations [NCT05696431]		30 participants (Anticipated)	Interventional	2022-11-05	Recruiting
The Effect of Fluoride Varnish, Casein Phosphopeptide-Amorphous Calcium Phosphate, and Resin Infiltration in the Treatment of White Spot Lesions After Orthodontic Therapy: A Randomized Controlled Trial [NCT06051981]	Phase 4	88 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Stereotactic Accelerated Radiotherapy in GlioblastomA (SAGA) [NCT05781321]	Phase 2	170 participants (Anticipated)	Interventional	2023-03-23	Recruiting
Clinical and Radiographic Evaluation of Deep Occlusal Carious Molars Treated With Partial Caries Removal With and Without Using Silver Diamine Fluoride (SDF) Prior to Resin Composite Restoration. (A Randomized Clinical Trial) [NCT04561934]	Phase 1	40 participants (Anticipated)	Interventional	2020-12-01	Not yet recruiting
Effectiveness of Using Nano-Silver Fluoride Varnish Versus Sodium Fluoride Varnish in Management of Cervical Dentin Hypersensitivity in Adult Patients: A Randomized Clinical Trial. [NCT04731766]		42 participants (Anticipated)	Interventional	2021-11-01	Not yet recruiting
Combination Osteogenic Therapy in Established Osteoporosis [NCT00018447]	Phase 2	0 participants	Interventional	1998-11-30	Completed
Clinical Efficacy of Combined Application of Diode Laser and Different Remineralizing Agents on Combined Application of Diode Laser and Different Remineralizing Agents on White Spot Lesions [NCT05871619]		45 participants (Actual)	Interventional	2022-05-05	Completed
NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy Using [F18] Fluorothymidine (FLT) As a Marker of Proliferation in Patients With Primary Brain Tumors [NCT00276770]		12 participants (Actual)	Interventional	2006-02-28	Completed
Minimally Invasive Treatment Approach for Early Childhood Caries Using Silver Diammine Fluoride and Sodium Fluoride With Functionalized Tricalcium Phosphate and Their Effects on Oral Health Related Quality of Life: A Pragmatic Randomized Control Trial [NCT05772039]	Phase 4	72 participants (Anticipated)	Interventional	2022-01-18	Enrolling by invitation
F-18 Sodium Fluoride PET/CT Guided Robotic Arm-assisted Pain Palliation in Chronic Nociceptive Low Backache [NCT05560165]		30 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Clinical Efficiency and Treatment Failure of Hall Versus SDF Techniques in the Management of Carious Primary Molar: Randomized Clinical Trial. [NCT04765904]		120 participants (Anticipated)	Interventional	2021-08-01	Not yet recruiting
Evaluation of the Remineralizing and Antibacterial Effect of Natural Versus Synthetic Materials on Deep Carious Dentin [NCT04145102]		80 participants (Actual)	Interventional	2019-01-01	Completed
Evaluate Clinical Research From Commerical Oral Care Products [NCT00759187]	Phase 3	25 participants (Actual)	Interventional	2008-01-31	Completed
Clinical Study to Examine Brushing on Dental Implants [NCT00762619]	Phase 3	105 participants (Actual)	Interventional	2007-04-30	Completed
Development of Clinical Method to Triclosan Retention in Plaque Following Brushing [NCT00762853]	Phase 3	20 participants (Actual)	Interventional	2008-05-31	Completed
Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes [NCT00762515]	Phase 3	44 participants (Actual)	Interventional	2008-02-29	Completed
[NCT02513212]		24 participants (Actual)	Interventional	2015-07-31	Completed
Xylitol for Caries Prevention in Inner-City Children [NCT01901250]		562 participants (Actual)	Interventional	2007-08-31	Completed
F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer [NCT01967862]		54 participants (Actual)	Interventional	2013-12-31	Completed
Randomized Clinical Trial on Preventing and Arresting Dental Root Surface Caries Using Silver Diamine Fluoride Solution in Community-dwelling Older Adults [NCT02360124]	Phase 2/Phase 3	323 participants (Actual)	Interventional	2012-01-31	Completed
Efficacy of Miswak When Compared to Fluoridated Toothpaste for the Maintenance of Oral Hygiene in Young Adults [NCT04561960]	Phase 4	30 participants (Actual)	Interventional	2020-09-30	Completed
The Effect of Light-cured Fluoride Varnish to Remineralize Post-orthodontic White Spot Lesions and Change the Oral Microbiome: a Double-blind, Split-mouth Randomized Clinical Trial [NCT04528134]		120 participants (Anticipated)	Interventional	2022-02-07	Recruiting
NUPRO(r) Sensodyne Prophylaxis Paste With NovaMin(r) for the Treatment of Dentin Hypersensitivity. [NCT01610167]		151 participants (Actual)	Interventional	2011-09-30	Completed
Pilot Clinical Study to Evaluate Efficacy of a Professionally Delivered Fluoride Varnish on Erosive Tooth Wear in an In-Situ Mode [NCT06136754]	Phase 3	24 participants (Actual)	Interventional	2022-04-08	Completed
Prospective Cohort Study: Efficacy of the Use of 38% Silver Diamine Fluoride and 5% Sodium Fluoride Varnish in Patients 4 to 12 Years for the Treatment of Caries and Its Association With Other Aspects of Relevance [NCT05638217]		199 participants (Actual)	Observational	2022-11-07	Completed
Evaluation of Silver Diamine Fluoride Application in Molar-Incisor Hypomineralisation-Affected Molars [NCT06165042]		120 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Cost-efficacy of Silver Diammine Fluoride to Control Caries Lesions in Erupting Permanent First Molars - Randomized Clinical Trial. [NCT01508611]		192 participants (Actual)	Interventional	2015-02-28	Active, not recruiting
Low-fluoride Acidic Liquid Dentifrice in Non-fluoridated Communities: a Randomized Clinical Trial [NCT01623362]	Phase 3	212 participants (Actual)	Interventional	2010-09-30	Completed
Comparison of Fluoride Varnish With Two Different Desensitizers in Reducing Dentinal Hypersensitivity [NCT03177109]	Phase 3	60 participants (Anticipated)	Interventional	2017-05-03	Recruiting
Characterization of Fluoride and Silver Pharmacokinetics of Diammine Silver Fluoride Applied Topically to Teeth of Adults [NCT01664871]	Phase 1	6 participants (Actual)	Interventional	2011-07-31	Completed
Comparison of 18-F Sodium Fluoride Uptake in Culprit Plaques Between Acute Coronary Syndrome and Stable Angina [NCT01665248]		20 participants (Actual)	Interventional	2012-08-31	Terminated
Assessment of the Cytotoxic and Genotoxic Effect of Toothpastes With Different Forms of Fluoride on the Buccal Mucosa [NCT05596149]		80 participants (Anticipated)	Interventional	2022-11-01	Recruiting
Assessment of 1450 Ppm Fluoride/Arginine Toothpaste Using an Intra-oral Remineralization-demineralization Model. [NCT02388178]	Phase 2	0 participants (Actual)	Interventional	2015-04-30	Withdrawn(stopped due to The study was stopped due to business reasons.)
Fluoride Bioavailability in Saliva After Use of Prescription and Over-the-counter Toothpastes Followed by Fluoride Mouthrinses [NCT05601154]	Early Phase 1	20 participants (Anticipated)	Interventional	2023-03-23	Enrolling by invitation
Prevention Management Model for Early Childhood Caries [NCT00066950]	Phase 3	361 participants (Actual)	Interventional	2003-03-31	Completed
Effect of Fluoride Varnish and CPP-ACP Paste on Oral and Salivary Symptoms of Patients Under Chemotherapy: A Double-blind Clinical Trial [NCT01737307]	Phase 2	30 participants (Actual)	Interventional	2011-03-31	Completed
Masking and Therapeutic Effect of Different Mouth Rinses in Patients With Oral Malodor. [NCT01747226]		96 participants (Anticipated)	Interventional	2013-03-31	Not yet recruiting
Caries-preventive Effectiveness of a Dentifrice Containing 5.000 Ppm Fluoride - a Randomized Controlled Trial in Adolescents With Fixed Orthodontic Appliances [NCT01768390]	Phase 4	500 participants (Actual)	Interventional	2008-01-31	Completed
Three Month Clinical Efficacy of an Ethyl Lauroyl Arginate HCL (LAE) Mouth Rinse: Effect on Gingivitis [NCT01821261]		0 participants (Actual)	Interventional	2014-04-30	Withdrawn(stopped due to Business Decision)
A Comparative Study on the Cost-effectiveness of Four Methods in Preventing Fissure Caries in Permanent Teeth [NCT01829334]	Phase 2	329 participants (Actual)	Interventional	2006-06-30	Completed
Clinical Efficacy in Reducing Established Dental Plaque and Gingivitis of a Toothpaste Containing 0.3% Triclosan, 2% Copolymer / Sodium Fluoride and a Manual Toothbrush as Compared to an Oral Hygiene Multi-component Regimen Encompassing the Use of a Manua [NCT02366689]	Phase 4	179 participants (Actual)	Interventional	2014-06-30	Completed
[NCT02613117]		104 participants (Actual)	Interventional	2015-11-30	Completed
Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes [NCT00708305]	Phase 3	65 participants (Actual)	Interventional	2008-06-30	Completed
A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity [NCT02731833]	Phase 4	229 participants (Actual)	Interventional	2016-04-01	Completed
Clinical Efficiency and Child's Behavior of Hall Versus SDF Techniques in the Management of Carious Primary Molar: [NCT04737057]		72 participants (Anticipated)	Interventional	2021-05-01	Not yet recruiting
Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer [NCT00928174]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2009-06-30	Completed
A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity [NCT02923895]	Phase 4	197 participants (Actual)	Interventional	2016-10-11	Completed
Pilot Trial of Oral Cabozantinib/XL184 in Metastatic Castrate Resistant Prostate Cancer to Explore the Changes in Bone and Tumor Imaging Related Pathways [NCT01812668]		20 participants (Actual)	Interventional	2013-03-31	Completed
Pharmacokinetics of Advantage Arrest [NCT04184271]	Phase 2	16 participants (Actual)	Interventional	2017-08-01	Completed
Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1 [NCT03007719]	Phase 2	4 participants (Actual)	Interventional	2017-03-07	Terminated(stopped due to Low Accrual)
Evaluation of Caries Prevention Based on Genetic Etiology and Risk: Protocol for a Multicenter Randomized Controlled and Adaptive Trial for Oral Personalized Care (PRECARIES) [NCT05600517]		520 participants (Anticipated)	Interventional	2021-08-25	Recruiting
Assessment of a Potassium Oxalate Containing Formulation for the Relief of Dentinal Hypersensitivity [NCT02113579]		375 participants (Actual)	Interventional	2014-03-31	Completed
Changes in Streptococcus Mutans Colonization With Different Oral Hygiene Protocols in Adult Patients With Fixed Orthodontic Appliance:A Randomized Clinical Trial [NCT05016713]		27 participants (Anticipated)	Interventional	2021-06-01	Recruiting
The Effect of Toothpastes Based on Alkaline Thermal Water With and Without Fluorinated Derivative on Gingivitis, Dentin Hypersensitivity, and Oral Hygiene: a Randomized Clinical Trial [NCT05623761]	Phase 4	84 participants (Actual)	Interventional	2022-11-01	Completed
18F-FMAU for Imaging in Cancer Patients [NCT02079181]		30 participants (Anticipated)	Interventional	2014-01-31	Recruiting
The Effectiveness of Sealants in Prevention of Occlusal Caries on Primary Molars [NCT01438866]	Phase 4	148 participants (Actual)	Interventional	2011-10-31	Completed
Efficacy and Cost-effectiveness of Different Caries Preventive Protocols in a High -Risk Group of Young Egyptian Adults: A Randomized Control Trial [NCT05962632]	Early Phase 1	44 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Comparing Chlorhexidine Gluconate Rinse, Sodium Fluoride Rinse, Water Rinse, and Chewing Gum in Regard to Streptococcus Mutans Reduction [NCT02598778]	Phase 2	12 participants (Actual)	Interventional	2015-11-01	Terminated(stopped due to Study discontinued early due to time constraints and lack of selectivity in agar used in the identification of the target (Streptococcus mutans). Only 12 participants out of a planned 40 were enrolled.)
Short- and Long Term Antibacterial Effects of a Single Rinse With Different Mouthwashes: a Randomized Clinical Trial [NCT05178823]	Phase 4	171 participants (Actual)	Interventional	2017-06-01	Completed
Evaluation of Remineralization Potential of Self Assembling Peptide P11-4 Combined With Fluoride Compared to Fluoride Varnish in Management of Incipient Carious Lesions Using Laser Fluorescence: Randomized Clinical Trial [NCT05094492]		58 participants (Anticipated)	Interventional	2021-10-30	Not yet recruiting
Remineralization Effect of NaF, NaF With TCP, NaF With CPP-ACP, and NaF With CXP Varnishes on Newly Erupted First Permanent Molars: a Randomised Controlled Trial [NCT04124887]		40 participants (Actual)	Interventional	2017-02-03	Completed
The Efficiency and Gingival Health Status of Hall Versus SDF Techniques in the Management of Carious Primary Molars: Randomized Clinical Trial [NCT04889196]	Phase 3	40 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
Avaliação da Carga do vírus SARS-CoV-2 na Cavidade Oral e na Saliva após desinfecção Com soluções Antimicrobianas Orais e dentifrícios. [NCT04537962]		202 participants (Actual)	Interventional	2020-07-14	Completed
A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity [NCT02612064]		488 participants (Actual)	Interventional	2015-11-01	Completed
Open-label Clinical Trial on the Safety and Efficacy of 18F-sodium Fluoride (NaF) PET Imaging in Patients in Need of a Standard 99mTc Bone Scintigraphy [NCT04842071]	Phase 3	2,500 participants (Anticipated)	Interventional	2008-01-01	Recruiting
Effectiveness of a Bonding and a Fluoride Varnish for Long-term Dentin Hypersensitivity Treatment: a Split-mouth Randomized Clinical Trial [NCT04813848]		38 participants (Actual)	Interventional	2020-01-07	Completed
Post-operative Pain and Child Behavior of Hall Technique Versus Silver Diamine Fluoride in the Management of Carious Primary Molars: Randomized Clinical Trial [NCT04794426]	Phase 3	40 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
Clinical and Cost-effectiveness of Fluoride Varnish Versus Resin Based Sealant in Newly Erupted Permanent Molars in Group of Egyptian Children: A Randomized Clinical Trial(Part 2). [NCT04793256]		91 participants (Anticipated)	Interventional	2021-04-30	Not yet recruiting
A Randomized, Open-Label, Crossover, Controlled, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases of Malignant Tumors Compared With 99mTc⁃MDP-BS±SPECT [NCT05614518]	Phase 3	280 participants (Actual)	Interventional	2021-03-29	Completed
NUPRO Sensodyne Prophylaxis Paste With NovaMin for the Treatment of Dentin Hypersensitivity. [NCT01669785]		139 participants (Actual)	Interventional	2012-03-31	Completed
Comparison of the Salivary Levels of Streptococcus Mutans in Pediatric Patients With Early Childhood Caries After the Application of Silver Diamine Fluoride or 5% Sodium Fluoride Varnish [NCT03089567]	Early Phase 1	0 participants (Actual)	Interventional	2017-09-15	Withdrawn(stopped due to Study was not conducted. No participants were enrolled)
A Prospective Randomized Controlled Trial for Prevention of Enamel White Spot Lesions During Fixed Orthodontic Treatment [NCT04342858]	Phase 2	99 participants (Actual)	Interventional	2017-09-15	Active, not recruiting
An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy [NCT01665911]		28 participants (Actual)	Interventional	2012-08-31	Completed
PET Imaging of Lung Cancer and Indeterminate Pulmonary Nodules With 18F-FSPG [NCT02448225]	Phase 2	46 participants (Actual)	Interventional	2015-06-16	Completed
A Clinical Study Investigating the Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity [NCT02542943]		240 participants (Actual)	Interventional	2015-09-30	Completed
Clinical Evaluation of Oral Hygiene Products in an In Situ Caries Model [NCT02399163]		80 participants (Actual)	Interventional	2015-04-30	Completed
A Placebo Controlled Study to Evaluate the Effectiveness of Experimental Foaming Gel Toothpastes Using an In-situ Erosion Remineralization Model [NCT01657903]		56 participants (Actual)	Interventional	2011-11-30	Completed
Clinical Investigation Examining the Anticaries Efficacy of Three Dentifrices (1.5% Arginine in a Calcium Base, 8.0% Arginine in a Calcium Base, and 0.32% Sodium Fluoride in a Silica Base): a Two-year Caries Clinical Study [NCT05560945]	Phase 3	6,000 participants (Actual)	Interventional	2019-04-15	Completed
Phase II Study to Evaluate the Performance of PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Clinically Significant Prostate Cancer in Men Presenting Following a Positive Screen for Prostate Cancer [NCT04910425]	Phase 2	106 participants (Anticipated)	Interventional	2023-06-17	Not yet recruiting
Evaluation of Remineralizing Efficacy of Grape Seed Extract Oil Versus Fluoride Mouthwash in Management of Post-Orthodontic White Spot Lesions: Randomized Clinical Trial [NCT04357093]		40 participants (Anticipated)	Interventional	2021-02-28	Not yet recruiting
A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity [NCT02924350]		205 participants (Actual)	Interventional	2016-11-07	Completed
Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients [NCT05527483]		40 participants (Anticipated)	Observational	2022-04-21	Recruiting
Clinical Effectiveness of Early Treatments for Preventing Occlusal Caries Lesions in Erupting Permanent Molars [NCT05969756]		114 participants (Anticipated)	Interventional	2023-07-31	Recruiting
Role of Aloe Vera Versus Fluoride Toothpaste in Changing High to Low Salivary Bacterial Count :Randomized Controlled Trial [NCT03108313]	Phase 2	58 participants (Anticipated)	Interventional	2017-03-03	Recruiting
Effiacacy of Desensitizing Agent,After an In-office Vital Tooth Bleaching. A Randomized Double Blind Clinical Trial Trial. [NCT05569590]		90 participants (Actual)	Interventional	2021-05-14	Completed
Quantitative-imaging in Cardiac Transthyretin Amyloidosis [NCT05776212]		140 participants (Anticipated)	Observational	2021-08-25	Recruiting
Evaluation Of Fluoride Uptake By Dentine Following Pretreatment With Silver Diamine Fluoride And Potassium Iodide Under Resin Modified Glass Ionomer Restoration Versus Resin Modified Glass Ionomer Restoration Alone In Carious Primary Molars: (In Vitro Stu [NCT04777968]	Phase 4	20 participants (Actual)	Interventional	2020-08-01	Completed
A Proof of Concept Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in the Relief of Dentinal Hypersensitivity [NCT01831817]	Phase 2	140 participants (Actual)	Interventional	2013-01-31	Completed
Fissure Caries Inhibition Study With Solea CO2-9.3μm Short-pulsed Laser - A Randomized, Single Blind, Prospective, Split Mouth Controlled, Clinical Trial [NCT02357979]		60 participants (Actual)	Interventional	2018-02-08	Completed
The Effect of Fluoride in an Experimental Dentifrice on Remineralization of Erosive Lesions In-Situ [NCT01641237]	Phase 3	72 participants (Actual)	Interventional	2012-03-31	Completed
MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study [NCT02424097]	Phase 4	40 participants (Actual)	Interventional	2013-05-31	Completed
The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ [NCT02195583]		62 participants (Actual)	Interventional	2014-06-30	Completed
The Clinical Investigation of Colgate Total Toothpaste as Compared to Crest Pro-Health Toothpaste and Crest Pro-Health Mouthwash, and Crest Cavity Protection Toothpaste and Crest Fluoride Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical St [NCT02360995]	Phase 4	129 participants (Actual)	Interventional	2014-06-30	Completed
A Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity [NCT02371616]		304 participants (Actual)	Interventional	2014-09-29	Completed
A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity [NCT01827670]	Phase 3	119 participants (Actual)	Interventional	2013-02-28	Completed
A Randomized Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal Hypersensitivity [NCT03965039]		120 participants (Actual)	Interventional	2019-07-08	Completed
A Clinical Study to Evaluate the Efficacy of Pre-procedural and Pre-surgical Rinsing With an Antimicrobial Agent in Reducing Bacteria in Dental Aerosols and in the Oral Cavity [NCT02319668]	Phase 4	38 participants (Actual)	Interventional	2015-02-01	Completed
A Pharmacodynamic Study Using NaF PET/CT Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Metastatic Castrate Resistant Prostate Cancer to Bone [NCT01816048]	Phase 2	8 participants (Actual)	Interventional	2013-05-31	Terminated(stopped due to Study supporter (Takeda) ended study drug for prostate cancer; enrollment ended prematurely.)
Parental Satisfaction of Hall Technique Versus Silver Diamine Fluoride (SDF) in the Management of Carious Primary Molars Randomized Clinical Trial [NCT05249231]		22 participants (Anticipated)	Interventional	2022-04-30	Not yet recruiting
The Effectiveness of Silver Diamine Fluoride as a Treatment for Caries in Comparison to Traditional Restorative Techniques: A 12 Month Randomized Controlled Trial [NCT02601833]	Phase 3	98 participants (Actual)	Interventional	2016-01-31	Completed
Evaluating the Impact of 18F-DOPA-PET on Neurosurgical Planning for Gliomas [NCT02020720]	Early Phase 1	72 participants (Actual)	Interventional	2014-01-22	Active, not recruiting
Imaging Using the Novel Radiotracer [18F] FluorThanaTrace([18F]FTT) by PET/CT in Patients With Breast Cancer [NCT05226663]	Phase 2	36 participants (Anticipated)	Interventional	2022-04-01	Recruiting
Study to Investigate the Initial Stages of Enamel Erosion in Vivo [NCT02533466]		30 participants (Actual)	Interventional	2015-10-01	Completed
Pragmatic Trial of Topical Diammine Silver Fluoride for Dental Caries Arrest [NCT02536040]	Phase 3	66 participants (Actual)	Interventional	2016-01-31	Completed
Clinical Study to Assess Therapeutic Delay and Resolution of Induced Gingivitis [NCT05731778]	Phase 4	26 participants (Actual)	Interventional	2018-12-22	Completed
A Six Month Clinical Study Based in the US to Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms [NCT02207400]	Phase 2	246 participants (Actual)	Interventional	2014-08-25	Completed
Effect of Sodium Fluoride at 1.1%, Associated or Not With the Low-level Light Therapy in the Prevention of Post-bleaching Sensitivity: a Randomized, Double-blind, Controlled Trial [NCT03044171]	Phase 1	25 participants (Actual)	Interventional	2016-08-01	Completed
The Effect of Silver Diamine Fluoride (SDF) on Bacteria Involved in Root or Cervical Carious Lesions Using HOMINGS Technology. A Clinical Study [NCT02953886]	Phase 4	21 participants (Actual)	Interventional	2016-11-30	Completed
Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream [NCT02918617]	Phase 2	203 participants (Actual)	Interventional	2015-05-31	Completed
A Randomized, Examiner Blind, Crossover, in Situ Erosion Study to Investigate the Efficacy of an Experimental Dentifrice in Remineralization of Previously Softened Enamel Compared to a Placebo Dentifrice [NCT03296072]	Phase 3	62 participants (Actual)	Interventional	2017-11-13	Completed
Effectiveness of Silver Diamine Fluoride in Arresting Dental Caries in Deciduous Molars: a Controlled and Randomized Clinical Trial [NCT03063307]		119 participants (Actual)	Interventional	2016-09-20	Completed
A Pilot Clinical Study to Compare Professional Treatments for Dentinal Hypersensitivity [NCT03405259]		22 participants (Actual)	Interventional	2013-06-26	Completed
Effectiveness of Silver Diamine Fluoride in Arresting Dental Caries in Preschool Children: a Randomized Clinical Trial With Different Periodicity and Concentration. [NCT02385474]	Phase 3	888 participants (Actual)	Interventional	2013-03-31	Completed
Compare the Efficacy of the Remineralization Agents on the White Enamel Lesions [NCT02341872]		32 participants (Actual)	Interventional	2013-08-31	Completed
Evaluation of Prevention Potential of Preventive Regimens Containing Herbal-based and Fluoride-based Toothpastes Versus Fluoride Varnish and Fluoride Toothpaste Only in High Caries Risk Patients: A Randomized Clinical Trial [NCT04436913]		54 participants (Actual)	Interventional	2021-01-16	Completed
A Pilot Study to Evaluate Stannous Fluoride in GCF and Subgingival Plaque [NCT03296657]		20 participants (Actual)	Interventional	2017-08-23	Completed
Caries Inhibition With CO2-Laser During Orthodontic Treatment [NCT04903275]		41 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
Quantitative Clinical Assessment of Bifluorid 10 Versus Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient: A Randomized Clinical Trial [NCT04485299]	Phase 2/Phase 3	68 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
Caries-preventing Effect of a Hydroxyapatite-toothpaste in Adults [NCT04756557]		192 participants (Actual)	Interventional	2021-01-01	Completed
Clinical Efficacy of Fluoride Toothpastes Using an in Situ Caries Model [NCT00708097]	Phase 3	57 participants (Actual)	Interventional	2008-04-30	Completed
Antibacterial Effect of Miswak Toothpaste Compared to Fluoride Toothpaste in High Caries Risk Patients: Randomized Clinical Trial [NCT05109299]		32 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
Clinical Efficacy of SDF and Laser in Preventing Initial Caries Progression With and Without Fissure Sealants in Primary and Permanent Molars [NCT06119126]	Phase 2	23 participants (Actual)	Interventional	2020-06-01	Completed
A Phase 2 Randomized, Double-blind, Active-controlled Multi-center Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices With 1.5%, 4.0% and 8.0% Arginine Each in Comparison With 0.24% Sodium Fluor [NCT04750902]	Phase 2	2,000 participants (Actual)	Interventional	2021-01-21	Active, not recruiting
Silver Diamine Fluoride: Novel Addition to the Prophylactic Bundle for Dental Management of Radiation-Induced Dental Caries in Oral and Pharyngeal Cancer Patients [NCT05403125]		60 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
A Three-Month Bleeding-Model Clinical Study [NCT05916521]		90 participants (Actual)	Interventional	2021-11-15	Completed
A One-Month Bleeding-Model Clinical Study [NCT05916508]		90 participants (Actual)	Interventional	2020-10-19	Completed
Efficacy of Dentifrices Containing Arginine Versus Fluoride on Microbial Acid Using Chair Side(Potential of Hydrogen) pH Meter Assessment Method in Adult Population: Randomized Clinical Trial [NCT03143023]		28 participants (Anticipated)	Interventional	2017-06-30	Not yet recruiting
A Study to Measure the Effect of Two Fluoride Toothpastes on Gingival Health Over a Six Month Period [NCT03027908]		239 participants (Actual)	Interventional	2016-10-19	Completed
Cost-efficacy and Applicability of the Treatment of Moderate Caries Using Sealants as an Alternative to the Restorations on Occlusal Surfaces of Deciduous Teeth: a Randomized Controlled Trial [NCT03005405]		96 participants (Anticipated)	Interventional	2015-02-28	Active, not recruiting
A Randomized Clinical Study of the Safety and Effectiveness of Two Dentinal Hypersensitivity Treatments Used With Normal Oral Hygiene [NCT02221349]		30 participants (Actual)	Interventional	2014-08-31	Completed
A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model [NCT01607411]	Phase 3	55 participants (Actual)	Interventional	2012-02-29	Completed
A Six Month Clinical Study Based in the US to Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste [NCT02207907]	Phase 2	247 participants (Actual)	Interventional	2014-08-31	Completed
Assessment of Osteoblastic Activity With 18F-Fluoride in Aortic Bioprosthesis Structural Valve Dysfunction (SVD) [NCT03015818]	Phase 4	25 participants (Actual)	Interventional	2017-01-30	Completed
The Comparative Efficacy of Three Oral Hygiene Multi-component Regimens Encompassing the Use of a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Established Dental Plaque and Gingivitis. [NCT02193165]	Phase 3	120 participants (Actual)	Interventional	2014-07-31	Completed
Root Caries Prevention Using Fluoride Varnish Fortified With Strontium-doped Bioactive Glass Ceramic: a Randomized Double-blind Controlled Clinical Trial [NCT06131957]		540 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Pilot Study to Evaluate Sampling Methods for Subgingival Plaque [NCT02841839]		20 participants (Actual)	Interventional	2016-06-30	Completed
Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by Coronary CTA (CCTA) and Microcalcification by F18-NaF PET: A Phase 3 Study [NCT03689946]	Phase 3	55 participants (Actual)	Interventional	2019-03-19	Completed
Evaluation of an Experimental Mouth Rinse Device for Relieving Dentinal Hypersensitivity [NCT01727258]		153 participants (Actual)	Interventional	2012-12-31	Completed
Clinical Investigation of a Toothpaste Containing Stannous Fluoride as Compared to Colgate Fluoride Toothpaste in Reducing Plaque and Gingivitis - a Three Month Study [NCT04033575]	Phase 4	88 participants (Actual)	Interventional	2019-03-06	Completed
The Pharmacokinetics of Silver Diamine Fluoride (SDF) in Healthy Children [NCT04766775]		15 participants (Actual)	Interventional	2020-07-03	Active, not recruiting
Comparative Evaluation of Staining Potential and Caries Arresting Effect of Silver Diamine Fluoride⁄Potassium Iodide and Silver Diamine Fluoride in Carious Primary Anterior Teeth [NCT04196829]	Phase 4	15 participants (Actual)	Interventional	2020-01-02	Active, not recruiting
Collection of Gingival Crevicular Fluid From Periodontitis Patients [NCT00763048]	Phase 3	39 participants (Actual)	Interventional	2008-03-31	Completed
Effect of a Dentifrice Containing Calcium Glycerophosphate and Fluoride on the pH of Dental Biofilm in Vivo [NCT00875212]	Phase 1	12 participants (Actual)	Interventional	2006-01-31	Completed
Esthetic Effect of Casein Phosphopeptide-Amorphous Calcium Phosphate Varnish Versus Tricalcium Phosphate Varnish on Postorthodontic White Spot Lesions: A Randomized Pilot Study [NCT03217084]	Phase 4	20 participants (Anticipated)	Interventional	2017-12-17	Recruiting
A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity [NCT01592864]	Phase 3	120 participants (Actual)	Interventional	2012-03-31	Completed
Non-invasive and Minimal Intervention in Dental Caries Management: Randomized Clinical Study [NCT04373356]		30 participants (Anticipated)	Interventional	2020-07-01	Not yet recruiting
Comparison Of The Caries-Protective Effect Of Fluoride Varnish (Duraphat®) With Treatment As Usual In Nursery School Attendees Receiving Preventive Oral Health Support Through The Childsmile Oral Health Improvement Programme: An RCT [NCT01674933]	Phase 4	1,610 participants (Anticipated)	Interventional	2012-10-31	Completed
Silver Diamine Fluoride Treatment of Active Root Caries Lesions in Older Adults: A Case Series [NCT04370080]		63 participants (Actual)	Interventional	2017-01-03	Completed
Evaluate Inflammation Caused by Gingivitis in Adults [NCT00941668]	Phase 4	49 participants (Actual)	Interventional	2007-01-31	Completed
Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse [NCT01024738]	Phase 3	22 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized Controlled Trial on the Remineralization Agents Used for the Treatment of White Spot Lesions [NCT04827966]		12 participants (Actual)	Interventional	2022-09-01	Terminated(stopped due to Funding issues)
Silver Diamine Fluoride Versus Therapeutic Sealants for the Arrest and Prevention of Dental Caries in Low-income Minority Children [NCT03442309]		7,418 participants (Actual)	Interventional	2019-02-01	Completed
Treatment of Interproximal Carious Lesions on Primary Molar Teeth With SDF and Super Floss Application Versus SDF Without Super Floss Versus Fluoride Varnish Alone: a Pilot Phase 3 Randomized Controlled Trial [NCT03770286]	Phase 3	60 participants (Anticipated)	Interventional	2019-01-22	Recruiting
Comparison of the Efficacy of Silver Diamine Fluoride Solution and Sodium Fluoride Varnish for the Prevention and Arrest of Root Caries in a Group of Older Adults [NCT04432415]		90 participants (Actual)	Interventional	2017-09-01	Suspended(stopped due to Coronavirus Pandemic)
Cost-effectiveness Analysis of Fluoride Foam and Fluoride Varnish in Preventing Dental Caries in the Primary Teeth of Preschool Children With High Caries Risk [NCT05025163]		1,083 participants (Actual)	Interventional	2016-07-01	Completed
Effectiveness of Self-assembling Peptide (P11-4) and Nano-silver Fluoride Varnish in Management of Enamel White Spot Lesions in Young People (Randomized Controlled Clinical Trial) [NCT04929509]		66 participants (Anticipated)	Interventional	2020-12-05	Recruiting
Enhancing Effect of the Application of 1% Chlorhexidine Varnish With Silane Fluoride and Oral Health Promotion on the Streptococcus Mutans Counts Reduction in Pregnant Women and on Early Mother-infant Transmission [NCT04868513]	Phase 4	58 participants (Actual)	Interventional	2015-01-31	Completed
Evaluation of the Response of Caries Lesions in Dentin After Application of Silver Diamine Fluoride Gel: A Case Series [NCT05395065]		235 participants (Actual)	Observational	2022-07-11	Active, not recruiting
Photobiomodulation and Glass Ionomer Sealant as Complementary Treatment for Hypersensitivity in Molars With MIH in Children - Protocol for a Blinded Randomized Clinical Trial. [NCT05370417]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2022-10-01	Not yet recruiting
A Prospective Pilot Study Investigating rhPSMA 7.3 PET/MRI in Detecting Recurrent Disease and Aid in Radiotherapy Planning in Patients With Biochemically Recurrent Prostate Cancer [NCT04978675]	Phase 1	25 participants (Anticipated)	Interventional	2021-08-04	Recruiting
Influence of Fluoride Varnish, Ozone and Octenidin on the Incidence of White Spot Lesions and Caries During Orthodontic Treatment - a Randomized Clinical Trial [NCT04992481]		150 participants (Actual)	Interventional	2013-02-01	Completed
Comparison of the Clinical Effectiveness of Self Etch Adhesive and Fluoride Varnish in Reducing Dentin Hypersensitivity in Patients With Gingival Recession: Randomized Clinical Trial [NCT05895526]		142 participants (Anticipated)	Interventional	2023-06-12	Not yet recruiting
Strategy to Reduce Bladder Activity With RhPSMA 7.3: Comparison of 18F-RhPSMA 7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer [NCT05779943]	Phase 2	20 participants (Anticipated)	Interventional	2023-04-27	Recruiting
A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Short Term Relief From Dentinal Hypersensitivity [NCT01592851]	Phase 3	113 participants (Actual)	Interventional	2012-04-30	Completed
Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia: a Multicentre Randomized Controlled Trial [NCT04872907]	Phase 3	60 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
Compare the Clinical Efficacy of Prototype Toothpastes. [NCT00761930]	Phase 3	103 participants (Actual)	Interventional	2008-03-31	Completed
A Proof of Concept Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in the Relief of Dentinal Hypersensitivity [NCT01691560]	Phase 2	140 participants (Actual)	Interventional	2012-08-31	Completed
PET Imaging of Hepatocellular Carcinoma With 18F-FSPG [NCT02379377]	Phase 1	80 participants (Anticipated)	Interventional	2022-02-15	Recruiting
The Effect of Sodium Fluoride Application on the Prevention of Radiation Caries in Nasopharyngeal Carcinoma Patients: A Prospective, Open, Randomized Controlled Phase II Trial [NCT06174012]	Phase 2	135 participants (Anticipated)	Interventional	2023-12-15	Not yet recruiting
Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing. [NCT00966953]	Phase 3	25 participants (Actual)	Interventional	2007-10-31	Completed
Effectiveness of Silver Diamine Fluoride in Preventing Occlusal Caries in Primary Teeth of Preschool Children: a 30-month Randomized Clinical Trial [NCT05084001]	Phase 2/Phase 3	769 participants (Anticipated)	Interventional	2020-03-01	Recruiting
A Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity [NCT02226562]	Phase 2	191 participants (Actual)	Interventional	2014-09-02	Completed
A Randomised, Controlled Trial to Assess the Effect of Different Modes of Fluoride Delivery on Enamel Demineralisation, During Orthodontic Treatment With Fixed Appliances [NCT05005689]	Phase 4	130 participants (Anticipated)	Interventional	2023-10-20	Recruiting
Remineralization of Dentine Caries Using Nanosilver Fluoride and Casein Phosphopeptides-amorphous Calcium Phosphate (A Randomized Clinical Trial) [NCT04930458]		135 participants (Anticipated)	Interventional	2021-08-10	Recruiting
Investigate Oral Bacteria in Adult Population [NCT00762177]	Phase 3	24 participants (Actual)	Interventional	2008-05-31	Completed
A Study to Evaluate the Effect of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Digluconate Tooth Staining [NCT01962493]	Phase 4	160 participants (Actual)	Interventional	2013-09-30	Completed
Diagnostic Value of 18F-Fluoride-PET/MRI in the Management of Suspected Facet Joint Arthropathy: A Prospective Cohort Study [NCT03317275]		50 participants (Actual)	Interventional	2017-05-26	Completed
Clinical Evaluation of Efficacy of Shield Force Plus Varnish Versus Sodium Fluoride on Cervical Dentin Hypersensitivity on Adult Patients: A Randomized Clinical Trial [NCT04484844]	Phase 2/Phase 3	68 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
Improving Caries Risk Using Propolis-containing Versus Fluoride-containing Toothpastes in High Caries Risk Patients: Randomized Clinical Trial [NCT03222960]		40 participants (Anticipated)	Interventional	2017-10-31	Not yet recruiting
Effectiveness of Self-assembling Peptide (p11-4) in Conjunction With Fluoride Varnish in the Management of White Spot Lesions in Primary Teeth (Randomized Controlled Clinical Trial) [NCT05721586]		24 participants (Actual)	Interventional	2020-06-01	Completed
A Real-World Evidence Study Evaluating Oral Health Related Quality of Life Following the Use of Antisensitivity Toothpaste for Dentine Hypersensitivity Management [NCT04964063]		655 participants (Actual)	Interventional	2021-08-31	Completed
A Study to Measure the Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride Using an In Situ Caries Model [NCT01563172]	Phase 4	65 participants (Actual)	Interventional	2009-01-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00066963 (1) [back to overview]	Number of Caries Incident Cases
NCT00375830 (9) [back to overview]	Cohort 2 - 18F-NaF/18F-FDG vs Whole-body MRI for Detection of Skeletal Lesions
NCT00375830 (9) [back to overview]	Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI/99mTc-MDP Bone Scintigraphy
NCT00375830 (9) [back to overview]	Cohort 3 - Skeletal Lesions Identified by 99mTc MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI
NCT00375830 (9) [back to overview]	Cohort 3 - Total Skeletal Lesions Identified, Tc-99m MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI
NCT00375830 (9) [back to overview]	Cohort 1 - 18F-NaF PET/CT vs 18F-FDG PET/CT
NCT00375830 (9) [back to overview]	Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy
NCT00375830 (9) [back to overview]	Cohort 2 - 18F-NaF/18F-FDG PET/CT vs Whole-body MRI for Detection of Extraskeletal Lesions
NCT00375830 (9) [back to overview]	Cohort 2 - 18F-NaF/18F-FDG vs 99mTc-MDP Bone Scintigraphy for Detection of Skeletal Lesions
NCT00375830 (9) [back to overview]	Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI
NCT00708097 (5) [back to overview]	Enamel Fluoride Uptake (Demineralized Specimens)
NCT00708097 (5) [back to overview]	Percentage SMHR of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (675ppmF) and Placebo Toothpaste (0ppmF)
NCT00708097 (5) [back to overview]	Enamel Fluoride Uptake (Sound Enamel Specimens)
NCT00708097 (5) [back to overview]	Percentage SMHR of Demineralized Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste(1450ppmF) and Placebo Toothpaste (0ppmF)
NCT00708097 (5) [back to overview]	Percentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF)
NCT00708123 (3) [back to overview]	Mean %SMHR of Enamel Specimens Exposed to NaF/Carbopol Toothpaste (1400 ppmF), NaF Toothpaste (1350ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (250ppmF) and Placebo Toothpaste (0ppmF)
NCT00708123 (3) [back to overview]	Adjusted Mean Change From Baseline in Enamel Fluoride Uptake
NCT00708123 (3) [back to overview]	Mean Percentage Surface Microhardness Recovery (%SMHR) of Enamel Specimens Exposed to NaF/Carbopol Toothpaste (1400 ppmF), NaF Toothpaste (1350ppmF) Compared to NaMFP/NaF Toothpaste (1450ppmF)
NCT00708305 (7) [back to overview]	Change From Baseline in Fluoride Concentration at 1 Hour Post Brushing With Study Treatments
NCT00708305 (7) [back to overview]	Change From Baseline in Fluoride Concentration at 15 Minutes After Brushing With Study Treatments
NCT00708305 (7) [back to overview]	Change From Baseline in Fluoride Concentration at 2 Hours Post Brushing With Study Treatments
NCT00708305 (7) [back to overview]	Change From Baseline in Fluoride Concentration at 30 Minutes Post Brushing With Study Treatments
NCT00708305 (7) [back to overview]	Change From Baseline in Fluoride Concentration at 4 Hours Post Brushing With Study Treatments
NCT00708305 (7) [back to overview]	Natural Log Transformed Area Under the Fluoride Concentration in Plaque Fluid by Time Curve (AUC) Between 0-4 Hours
NCT00708305 (7) [back to overview]	Natural Log Transformed AUC for Fluoride Concentration in Plaque Fluid Between 0-4 Hours
NCT00758290 (1) [back to overview]	Dental Plaque Index
NCT00758394 (1) [back to overview]	Dental Plaque Index
NCT00758563 (1) [back to overview]	Mean Gingival Plaque Units
NCT00759031 (1) [back to overview]	Gingival Margin Plaque Index
NCT00759187 (1) [back to overview]	Dental Plaque Index
NCT00761930 (3) [back to overview]	Gingivitis Score
NCT00761930 (3) [back to overview]	Dental Plaque
NCT00761930 (3) [back to overview]	Bleeding Index (EIBI)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Plaque(Actinomyces)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Plaque(Sulfur Bacteria)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Tongue(Fusobacteria)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Tongue(Oral Streptococci)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Saliva(Veillonella)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Saliva(Total Anaerobic)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Saliva(Sulfur Bacteria)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Saliva(Oral Streptococci)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Saliva(Fusobacteria)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Saliva(Actinomyces)
NCT00762177 (24) [back to overview]	Antimicrobial Species on the Cheek(Veillonella)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Plaque(Veillonella)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Plaque(Total Anaerobic)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Plaque(Oral Streptococci)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Plaque(Fusobacteria)
NCT00762177 (24) [back to overview]	Antimicrobial Species on the Tongue(Actinomycetes)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Tongue(Sulfur Bacteria)
NCT00762177 (24) [back to overview]	Antimicrobial Species on the Cheek(Total Anaerobic)
NCT00762177 (24) [back to overview]	Antimicrobial Species on the Cheek(Sulfur Bacteria)
NCT00762177 (24) [back to overview]	Antimicrobial Species on the Cheek(Oral Streptococci)
NCT00762177 (24) [back to overview]	Antimicrobial Species on the Cheek(Fusobacteria)
NCT00762177 (24) [back to overview]	Antimicrobial Species on the Cheek(Actinomyces)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Tongue(Veillonella)
NCT00762177 (24) [back to overview]	Antimicrobial Species in Tongue(Total Anaerobic)
NCT00762450 (1) [back to overview]	ph of Dental Plaque After Sucrose Challenge
NCT00762515 (2) [back to overview]	Control Established Plaque in Adults
NCT00762515 (2) [back to overview]	Control Gingivitis in Adults
NCT00762528 (8) [back to overview]	Interleukin - 1 Beta (IL-ß)
NCT00762528 (8) [back to overview]	Gingival Index (GI)
NCT00762528 (8) [back to overview]	Dental Plaque Index (PI)
NCT00762528 (8) [back to overview]	8-iso-prostaglandinF2α (8-iso-PGF2α)
NCT00762528 (8) [back to overview]	Prostaglandin E2 (PGE2)
NCT00762528 (8) [back to overview]	Nuclear Factor Kappa B Ligand (RANK-L)
NCT00762528 (8) [back to overview]	Interleukin-6 (IL-6)
NCT00762528 (8) [back to overview]	Bleeding on Probing (BOP)
NCT00762619 (68) [back to overview]	F.Nucleatum (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	A.Actinomycetemcomitans (DNA Probe Analysis)- Dental Implant
NCT00762619 (68) [back to overview]	F.Nucleatum (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	E.Saburreum (DNA Probe Analysis)- Natural Teeth
NCT00762619 (68) [back to overview]	E.Saburreum (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	P.Intermedia (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	E.Saburreum (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]	E.Saburreum (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]	E.Corrodens (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	E.Corrodens (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	E.Corrodens (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]	E.Corrodens (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]	Capnocytophaga sp. (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	Capnocytophaga sp. (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	Capnocytophaga sp. (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]	Capnocytophaga sp. (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]	C.Rectus (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	C.Rectus (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	C.Rectus (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]	C.Rectus (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]	A.Actinomycetemcomitans (DNA Probe Analysis)- Natural Teeth
NCT00762619 (68) [back to overview]	P.Gingivalis (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	A.Actinomycetemcomitans (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	A.Actinomycetemcomitans (DNA Probe Analysis)- Dental Implant
NCT00762619 (68) [back to overview]	Gingival Bleeding on Probing (BOP) Using Sulcus Bleeding Index for Teeth
NCT00762619 (68) [back to overview]	Veillonella sp.(DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	Veillonella sp.(DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	Veillonella sp.(DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	Veillonella sp.(DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	T.Forsythia (DNA Probe Analysis)-Natural Teeth
NCT00762619 (68) [back to overview]	T.Forsythia (DNA Probe Analysis)- Natural Teeth
NCT00762619 (68) [back to overview]	T.Forsythia (DNA Probe Analysis)- Dental Implants
NCT00762619 (68) [back to overview]	T.Forsythia (DNA Probe Analysis)- Dental Implants
NCT00762619 (68) [back to overview]	Streptococci (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	Streptococci (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	Streptococci (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	Streptococci (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	Solobacterium (S.Moorei)(DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	Solobacterium (S.Moorei)(DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	Solobacterium (S.Moorei)(DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	Solobacterium (S.Moorei)(DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	P.Melaninogenica (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	P.Melaninogenica (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	P.Melaninogenica (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	P.Melaninogenica (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	P.Intermedia (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	P.Intermedia (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	P.Intermedia (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	P.Gingivalis (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	P.Gingivalis (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	P.Gingivalis (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	Neissera sp. (DNA Probe Analysis) Natural Teeth
NCT00762619 (68) [back to overview]	Neissera sp. (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	Neissera sp. (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	Neissera sp. (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]	Mombelli Plaque Index (mPI) for Natural Teeth
NCT00762619 (68) [back to overview]	Mombelli Plaque Index (mPI) for Natural Teeth
NCT00762619 (68) [back to overview]	Mombelli Plaque Index (mPI) for Dental Implants
NCT00762619 (68) [back to overview]	Mombelli Plaque Index (mPI) for Dental Implants
NCT00762619 (68) [back to overview]	Löe-Silness Gingival Index Score (GI)- Dental Implants
NCT00762619 (68) [back to overview]	Löe-Silness Gingival Index Score (GI)- Dental Implants
NCT00762619 (68) [back to overview]	Löe-Silness Gingival Index Score (GI) - Natural Teeth
NCT00762619 (68) [back to overview]	Löe-Silness Gingival Index Score (GI) - Natural Teeth
NCT00762619 (68) [back to overview]	Gingival Bleeding on Probing (BOP) Using the Modified Sulcus Bleeding Index for Implants
NCT00762619 (68) [back to overview]	Gingival Bleeding on Probing (BOP) Using the Modified Sulcus Bleeding Index for Implants
NCT00762619 (68) [back to overview]	Gingival Bleeding on Probing (BOP) Using Sulcus Bleeding Index for Teeth
NCT00762619 (68) [back to overview]	F.Nucleatum (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]	F.Nucleatum (DNA Probe Analysis) - Natural Teeth
NCT00762762 (6) [back to overview]	HbA1c Levels in Blood
NCT00762762 (6) [back to overview]	TNF-α (Tumor Necrosis Factor - Alpha)
NCT00762762 (6) [back to overview]	IL-6 (Interleukin - 6)
NCT00762762 (6) [back to overview]	High Sensitivity CRP (C-Reactive Protein)
NCT00762762 (6) [back to overview]	HbA1c Levels in Blood
NCT00762762 (6) [back to overview]	C-Peptide
NCT00762853 (1) [back to overview]	Triclosan Concentration in Dental Plaque
NCT00763048 (10) [back to overview]	Metabolite Associated With Inflammation (Putrescine)
NCT00763048 (10) [back to overview]	Metabolite Associated With Inflammation (Cadaverine)
NCT00763048 (10) [back to overview]	Metabolite Associated With Inflammation (Choline)
NCT00763048 (10) [back to overview]	Metabolite Associated With Inflammation (Isoleucine)
NCT00763048 (10) [back to overview]	Metabolite Associated With Inflammation (Hypoxanthine)
NCT00763048 (10) [back to overview]	Metabolite Associated With Inflammation (Inosine)
NCT00763048 (10) [back to overview]	Metabolite Associated With Inflammation (Leucine)
NCT00763048 (10) [back to overview]	Metabolite Associated With Inflammation (Lysine)
NCT00763048 (10) [back to overview]	Metabolite Associated With Inflammation (Phenylalanine)
NCT00763048 (10) [back to overview]	Metabolite Associated With Inflammation (Xanthine)
NCT00763256 (5) [back to overview]	C-Peptide
NCT00763256 (5) [back to overview]	High Sensitivity CRP (C-Reactive Protein)
NCT00763256 (5) [back to overview]	HbA1c Levels in Blood
NCT00763256 (5) [back to overview]	P. Gingivalis
NCT00763256 (5) [back to overview]	Gingivitis Score (GI)
NCT00763269 (4) [back to overview]	Hypersensitivity Tactile (Yeaple Probe)
NCT00763269 (4) [back to overview]	Hypersensitivity Tactile(Yeaple Probe)
NCT00763269 (4) [back to overview]	Air Blast Hypersensitivity (4 Week)
NCT00763269 (4) [back to overview]	Air Blast Hypersensitivity (8 Week)
NCT00875212 (2) [back to overview]	Minimum pH After 14 Days of Use of Dentifrice
NCT00875212 (2) [back to overview]	Minimum pH
NCT00926029 (2) [back to overview]	Plaque Index
NCT00926029 (2) [back to overview]	Gingivitis Index
NCT00926328 (2) [back to overview]	Plaque Index
NCT00926328 (2) [back to overview]	Gingivitis Index
NCT00928174 (1) [back to overview]	Prostate Specific Antigen (PSA) Outcome Correspondence to Imaging Results With Fluorine-18 Fluorocholine PET/CT
NCT00928252 (3) [back to overview]	Metabolically Active Tumor Volume (MATV) Response
NCT00928252 (3) [back to overview]	Proportional Hazards Regression Analysis of Time to PSA Progression
NCT00928252 (3) [back to overview]	Time to PSA Progression
NCT00936975 (6) [back to overview]	Changes in 18F-fluoride PET SUV - Normal Bone
NCT00936975 (6) [back to overview]	Changes in 18F-fluoride PET (SUV) - Tumor Bone
NCT00936975 (6) [back to overview]	Changes in 18F-fluoride Ki - Normal Bone
NCT00936975 (6) [back to overview]	Changes in 18F-fluoride Ki - Tumor Bone
NCT00936975 (6) [back to overview]	Changes in 18F-fluoride Transport (by Patlak Flux) - Normal
NCT00936975 (6) [back to overview]	Changes in 18F-fluoride Transport (by Patlak Flux) - Tumor
NCT00941668 (2) [back to overview]	Level of Gingival Crevicular Fluid Interleukin - 6(GCF IL-6) at 2 Hours
NCT00941668 (2) [back to overview]	Level of Gingival Crevicular Fluid Interleukin - 1 (GCF IL-1) at 2 Hours
NCT00966953 (1) [back to overview]	Plaque Index
NCT00981825 (1) [back to overview]	CFU (Colony Forming Units)
NCT01005966 (3) [back to overview]	Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF)
NCT01005966 (3) [back to overview]	Percent SMH Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste (1400ppm F) and Placebo (0ppmF)
NCT01005966 (3) [back to overview]	Change From Baseline in Enamel Fluoride Uptake Potential
NCT01009554 (64) [back to overview]	Mean Stain Score for Interproximal (Mesial and Distal) Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Lingual Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Lingual Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Lingual Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score Over All Tooth Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score Over All Tooth Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score Over All Tooth Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Oral Tissue Tolerance
NCT01009554 (64) [back to overview]	Mean Stain Intensity For Interproximal (Mesial and Distal) Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Interproximal (Mesial and Distal) Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Change in Tooth Color as Represented by Δb at 4 Weeks Post Baseline From the CIElab Assessment
NCT01009554 (64) [back to overview]	Change in Tooth Color as Represented by Δb at 6 Weeks Post Baseline From the CIElab Assessment
NCT01009554 (64) [back to overview]	Change in Tooth Color as Represented by Δb at 8 Weeks Post Baseline From the CIElab Assessment
NCT01009554 (64) [back to overview]	Change in Tooth Color as Represented by ΔE at 4 Weeks Post Baseline From the CIElab Assessment
NCT01009554 (64) [back to overview]	Change in Tooth Color as Represented by ΔE at 6 Weeks Post Baseline From the CIElab Assessment
NCT01009554 (64) [back to overview]	Change in Tooth Color as Represented by ΔE at 8 Weeks Post Baseline From the CIElab Assessment
NCT01009554 (64) [back to overview]	Change in Tooth Color as Represented by ΔL at 4 Weeks Post Baseline From the CIElab Assessment
NCT01009554 (64) [back to overview]	Change in Tooth Color as Represented by ΔL at 6 Weeks Post Baseline From the CIElab Assessment
NCT01009554 (64) [back to overview]	Change in Tooth Color as Represented by ΔL at 8 Weeks Post Baseline From the CIElab Assessment
NCT01009554 (64) [back to overview]	Mean Stain Area for Body Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Body Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Body Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Facial Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Facial Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Facial Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Gingival Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Gingival Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Gingival Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Interproximal (Mesial and Distal) Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Interproximal (Mesial and Distal) Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Interproximal (Mesial and Distal) Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Lingual Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Lingual Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area for Lingual Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area Over All Tooth Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area Over All Tooth Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Area Over All Tooth Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Body Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Body Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Body Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Facial Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Facial Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Facial Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Gingival Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Gingival Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Gingival Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity For Interproximal (Mesial and Distal) Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity For Interproximal (Mesial and Distal) Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Lingual Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Lingual Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity for Lingual Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity Over All Tooth Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity Over All Tooth Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Intensity Over All Tooth Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Body Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Body Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Body Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Facial Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Facial Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Facial Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Gingival Sites at 4 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Gingival Sites at 6 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Gingival Sites at 8 Weeks
NCT01009554 (64) [back to overview]	Mean Stain Score for Interproximal (Mesial and Distal) Sites at 6 Weeks
NCT01014143 (1) [back to overview]	Plaque Index
NCT01024738 (1) [back to overview]	Plaque Index
NCT01040169 (2) [back to overview]	Tooth Hypersensivity Stimuli to Air
NCT01040169 (2) [back to overview]	Tooth Hypersensitity to Touch Stimuli (Tactile)
NCT01049503 (7) [back to overview]	Caries Progression in Caries-inactive Children After 1 Year, According to the Type of Dentifrice Used
NCT01049503 (7) [back to overview]	Caries Regression in Caries-active Children After 1 Year, According to the Type of Dentifrice Used
NCT01049503 (7) [back to overview]	Caries Progression in Caries-active Children After 1 Year, According to the Type of Dentifrice Used Assessed by the Quantitative Light Induced Method (QLF)(Fluorescence Change (∆F in %))
NCT01049503 (7) [back to overview]	Caries Progression in Caries-active Children After 1 Year, According to the Type of Dentifrice Used Assessed by the the Quantitative Light Induced Method (QLF) (Lesion Area (mm^2))
NCT01049503 (7) [back to overview]	Caries Progression in Caries-active Children After 1 Year, According to the Type of Dentifrice Used
NCT01049503 (7) [back to overview]	Evaluation of the Concentration of Fluoride Incorporated Into Participants' Toenails 6 Months After Initiation of the Dentifrices Use.
NCT01049503 (7) [back to overview]	Evaluation of the Concentration of Fluoride Incorporated Into the Biofilm Done 6 Months After Initiation of Dentifrices Use.
NCT01072188 (2) [back to overview]	Hypersensitivity to Touch (Tactile)
NCT01072188 (2) [back to overview]	Air Blast
NCT01072201 (3) [back to overview]	Bleeding on Probing
NCT01072201 (3) [back to overview]	Mean Percentage of Plaque Scores
NCT01072201 (3) [back to overview]	Mean Pocket Depth
NCT01116739 (7) [back to overview]	Evaluation of Decayed, Missing, and Filled Tooth Surfaces (Dmfs) at Year 3
NCT01116739 (7) [back to overview]	Acquisition of Dental Attitudes and Behaviors of the Caregivers of the Children
NCT01116739 (7) [back to overview]	Acquisition of Dental Knowledge of the Caregivers of the Children
NCT01116739 (7) [back to overview]	Evaluation of Caries Patterns
NCT01116739 (7) [back to overview]	Evaluation of Decayed, Missing, and Filled Tooth Surfaces (Dmfs) at Baseline
NCT01116739 (7) [back to overview]	Evaluation of Decayed, Missing, and Filled Tooth Surfaces (Dmfs) at Year 1
NCT01116739 (7) [back to overview]	Evaluation of Decayed, Missing, and Filled Tooth Surfaces (Dmfs) at Year 2
NCT01128972 (6) [back to overview]	Adjusted Mean Percentage Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to Test Dentifrice + Test MR Relative to: 1)Test Dentifrice+Sterile Water Rinse 2)Reference Dentifrice+Sterile Water Rinse 3)Placebo Dentifrice+ Sterile Water Rinse
NCT01128972 (6) [back to overview]	Adjusted Mean Percent NER of Enamel Specimens Exposed to a Treatment Regimen of Placebo Dentifrice + Test MR Relative to: 1) Test Dentifrice +Test MR 2) Test Dentifrice + Sterile Water Rinse 3) Reference Dentifrice +Sterile Water Rinse
NCT01128972 (6) [back to overview]	Adjusted Mean Percent NER of Enamel Specimens Exposed to Test Dentifrice +Sterile Water Rinse and Reference Dentifrice +Sterile Water Rinse
NCT01128972 (6) [back to overview]	Adjusted Mean Percent Net Erosion Resistance (NER) of Enamel Specimens Exposed to Test Dentifrice + Test MR Relative to: 1) Test Dentifrice+ Sterile Water Rinse 2) Reference Dentifrice+ Sterile Water Rinse 3) Placebo Dentifrice+ Sterile Water Rinse
NCT01128972 (6) [back to overview]	Adjusted Mean Percent SMH Recovery of Enamel Specimens Exposed to Test Dentifrice +Sterile Water Rinse and Reference Dentifrice +Sterile Water Rinse
NCT01128972 (6) [back to overview]	Adjusted Mean Percentage SMH Recovery of Enamel Specimens Exposed to Test Dentifrice + Test MR Relative to Following Treatment Regimens: 1) Test Dentifrice +Test MR 2) Test Dentifrice + Sterile Water 3) Reference Dentifrice +Sterile Water
NCT01129440 (6) [back to overview]	Retention of Glass Ionomer Sealants
NCT01129440 (6) [back to overview]	Caries Patterns
NCT01129440 (6) [back to overview]	Caries Increment
NCT01129440 (6) [back to overview]	Caries Incidence
NCT01129440 (6) [back to overview]	Adverse Event
NCT01129440 (6) [back to overview]	Salivary Fluoride Level
NCT01133379 (16) [back to overview]	Global Subjective VAS Score at Week 6
NCT01133379 (16) [back to overview]	Global Subjective VAS Score at Week 4
NCT01133379 (16) [back to overview]	Mean Tactile Sensitivity VAS Score at Week 6
NCT01133379 (16) [back to overview]	Mean Tactile Sensitivity VAS Score at Week 4
NCT01133379 (16) [back to overview]	Mean Tactile Sensitivity VAS Score at Week 2
NCT01133379 (16) [back to overview]	Mean Tactile Sensitivity Score at Week 6
NCT01133379 (16) [back to overview]	Mean Tactile Sensitivity VAS Score at Week 1
NCT01133379 (16) [back to overview]	Mean Cold Air Stimulus VAS Score at Week 6
NCT01133379 (16) [back to overview]	Mean Tactile Sensitivity Score at Week 1
NCT01133379 (16) [back to overview]	Mean Tactile Sensitivity Score at Week 2
NCT01133379 (16) [back to overview]	Mean Tactile Sensitivity Score at Week 4
NCT01133379 (16) [back to overview]	Mean Cold Air Stimulus VAS Score at Week 2
NCT01133379 (16) [back to overview]	Mean Cold Air Stimulus VAS Score at Week 1
NCT01133379 (16) [back to overview]	Global Subjective VAS Score at Week 2
NCT01133379 (16) [back to overview]	Global Subjective VAS Score at Week 1
NCT01133379 (16) [back to overview]	Mean Cold Air Stimulus VAS Score at Week 4
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Mucobuccal Fold at Screening
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Mucobuccal Fold at Day 5
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Mucobuccal Fold at Day 3
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Labial Mucosa at Day 3
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Uvula/Oropharynx at Day 3
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Uvula/Oropharynx at Screening
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Uvula/Oropharynx at Day 5
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Uvula/Oropharynx at Day 25
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Uvula/Oropharynx at Day 24 - Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Uvula/Oropharynx at Day 24 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Uvula/Oropharynx at Day 1 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Uvula/Oropharynx at Day 1 - Baseline/Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Tongue at Screening
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Tongue at Day 5
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Tongue at Day 3
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Tongue at Day 25
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Tongue at Day 24 - Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Tongue at Day 24 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Tongue at Day 1 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Tongue at Day 1 - Baseline/Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Sublingual Mucosa at Screening
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Sublingual Mucosa at Day 5
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Sublingual Mucosa at Day 3
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Sublingual Mucosa at Day 25
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Labial Mucosa at Day 5
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Sublingual Mucosa at Day 24 - Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Sublingual Mucosa at Day 24 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Labial Mucosa at Day 25
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Sublingual Mucosa at Day 1 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Labial Mucosa at Screening
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Mucobuccal Fold at Day 1 - Baseline/Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Sublingual Mucosa at Day 1 - Baseline/Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Mucobuccal Fold at Day 1 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Mucobuccal Fold at Day 24 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Mucobuccal Fold at Day 24 - Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Mucobuccal Fold at Day 25
NCT01156376 (72) [back to overview]	Percentage of Participants With an Abnormal Condition by Anatomical Site at Day 1 - Baseline/Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Participants With an Abnormal Condition by Anatomical Site at Day 1 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Participants With an Abnormal Condition by Anatomical Site at Day 24 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Participants With an Abnormal Condition by Anatomical Site at Day 24 - Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Participants With an Abnormal Condition by Anatomical Site at Day 25
NCT01156376 (72) [back to overview]	Percentage of Participants With an Abnormal Condition by Anatomical Site at Day 3
NCT01156376 (72) [back to overview]	Percentage of Participants With an Abnormal Condition by Anatomical Site at Day 5
NCT01156376 (72) [back to overview]	Percentage of Participants With an Abnormal Condition by Anatomical Site at Screening
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Buccal Mucosa at Day 1 - Baseline/Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Buccal Mucosa at Day 1 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Buccal Mucosa at Day 24 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Buccal Mucosa at Day 24 - Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Buccal Mucosa at Day 25
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Buccal Mucosa at Day 3
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Buccal Mucosa at Day 5
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Buccal Mucosa at Screening
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Gingiva at Day 1 - Baseline/Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Gingiva at Day 1 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Gingiva at Day 24 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Gingiva at Day 24 - Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Gingiva at Day 25
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Gingiva at Day 3
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Gingiva at Day 5
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Gingiva at Screening
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Hard/Soft Palate at Day 1 - Baseline/Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Hard/Soft Palate at Day 1 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Hard/Soft Palate at Day 24 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Hard/Soft Palate at Day 24 - Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Hard/Soft Palate at Day 25
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Hard/Soft Palate at Day 3
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Hard/Soft Palate at Day 5
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Hard/Soft Palate at Screening
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Labial Mucosa at Day 1 - Baseline/Pretreatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Labial Mucosa at Day 1 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Labial Mucosa at Day 24 - Post-treatment
NCT01156376 (72) [back to overview]	Percentage of Subjects in Irritation Score Category for Labial Mucosa at Day 24 - Pretreatment
NCT01345292 (8) [back to overview]	Mean Tactile Sensitivity Score at Week 4
NCT01345292 (8) [back to overview]	Mean Tactile Sensitivity Score at Week 2
NCT01345292 (8) [back to overview]	Mean Cold Air Stimulus VAS Score at Week 4
NCT01345292 (8) [back to overview]	Mean Cold Air Stimulus VAS Score at Week 2
NCT01345292 (8) [back to overview]	Global Subjective VAS Score at Week 4
NCT01345292 (8) [back to overview]	Global Subjective VAS Score at Week 2
NCT01345292 (8) [back to overview]	Mean Tactile Sensitivity Visual Analog Scale (VAS) Score at Week 2
NCT01345292 (8) [back to overview]	Mean Tactile Sensitivity VAS Score at Week 4
NCT01541358 (3) [back to overview]	Total Number of Lesions Identified by F-18 NaF PET/CT in Patients With Suspected Skeletal Malignancy
NCT01541358 (3) [back to overview]	Specificity of F-18 NaF PET/CT to Detect Bone Lesions in Patients With Suspected Skeletal Malignancy
NCT01541358 (3) [back to overview]	Sensitivity of F-18 NaF PET/CT to Detect Bone Lesions in Patients With Suspected Skeletal Malignancy
NCT01549587 (6) [back to overview]	Gestational Age (Weeks)
NCT01549587 (6) [back to overview]	Neonate Birth Weight (Grams)
NCT01549587 (6) [back to overview]	Preterm Birth (Gestational Age < 37 Weeks)
NCT01549587 (6) [back to overview]	Change From Baseline in Löe-Silness Gingivitis Index
NCT01549587 (6) [back to overview]	Change From Baseline in Löe-Silness Gingivitis Index
NCT01549587 (6) [back to overview]	Change From Baseline in Löe-Silness Gingivitis Index
NCT01563172 (10) [back to overview]	Percentage Surface Micro Hardness (% SMH) Recovery , of Brushing for 2 Minutes vs. Brushing for 45 Seconds With 0.5g of Experimental Dentifrice.
NCT01563172 (10) [back to overview]	Percentage Surface Micro Hardness (% SMH) Recovery, of Brushing for 2 Minutes With 0.5g of Experimental Dentifrice vs. Brushing for 2 Minutes With 1.5g of Experimental Dentifrice.
NCT01563172 (10) [back to overview]	Percentage Surface Micro Hardness Recovery (% SMH), of Brushing for 2 Minutes Versus (vs.) Brushing for 45 Seconds With 1.5g of Experimental Dentifrice.
NCT01563172 (10) [back to overview]	Percentage Surface Micro-hardness Recovery (% SMH), of Brushing for 45 Seconds With 0.5g of Experimental Dentifrice vs. Brushing for 45 Seconds With 1.5g of Experimental Dentifrice.
NCT01563172 (10) [back to overview]	Enamel Fluoride Uptake (EFU) After Brushing for 2 Minutes vs. Brushing for 45 Seconds With 0.5g of Experimental Dentifrice.
NCT01563172 (10) [back to overview]	Enamel Fluoride Uptake (EFU) After Brushing for 2 Minutes vs. Brushing for 45 Seconds With 1.5g of Experimental Dentifrice.
NCT01563172 (10) [back to overview]	Enamel Fluoride Uptake (EFU) After Brushing for 2 Minutes With 0.5g of Experimental Dentifrice vs. Brushing for 2 Minutes With 1.5g of Experimental Dentifrice.
NCT01563172 (10) [back to overview]	Enamel Fluoride Uptake (EFU) After Brushing for 2 Minutes With 1.5g of Experimental Dentifrice vs. Brushing for 2 Minutes With 1.5g of Control Dentifrice.
NCT01563172 (10) [back to overview]	Enamel Fluoride Uptake (EFU) After Brushing for 45 Seconds With 0.5g of Experimental Dentifrice vs. Brushing for 45 Seconds With 1.5g of Experimental Dentifrice.
NCT01563172 (10) [back to overview]	Percent Surface Micro-hardness (% SMH) Recovery, of Brushing for 2 Minutes With 1.5g of Experimental Dentifrice vs. Brushing for 2 Minutes With 1.5g of an Control Dentifrice.
NCT01592851 (6) [back to overview]	Change From Baseline in Tactile Pain Threshold Score Immediately Post-treatment
NCT01592851 (6) [back to overview]	Change From Baseline in Tactile Pain Threshold Score at Day 14
NCT01592851 (6) [back to overview]	Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Day 14
NCT01592851 (6) [back to overview]	Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Day 3
NCT01592851 (6) [back to overview]	Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale Immediately Post-treatment
NCT01592851 (6) [back to overview]	Change From Baseline in Tactile Pain Threshold Score at Day 3
NCT01592864 (4) [back to overview]	Adjusted Mean Change From Baseline in Tactile Sensitivity Pain Response at Week 8
NCT01592864 (4) [back to overview]	Adjusted Mean Change From Baseline in Tactile Sensitivity Pain Response at Week 4
NCT01592864 (4) [back to overview]	Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 4
NCT01592864 (4) [back to overview]	Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 8
NCT01607411 (4) [back to overview]	Percent Net Acid Resistance (%NAR) of Enamel Specimens
NCT01607411 (4) [back to overview]	Enamel Fluoride Uptake
NCT01607411 (4) [back to overview]	%SMHR of Enamel Specimens Exposed to Test Treatments
NCT01607411 (4) [back to overview]	Percentage Surface Microhardness Recovery of Test Dentifrices Relative to Placebo Dentifrice
NCT01610167 (5) [back to overview]	Extended Sensitivity Relief. Tactile Sensitivity.
NCT01610167 (5) [back to overview]	Immediate Sensitivity Relief. Air Blast Sensitivity.
NCT01610167 (5) [back to overview]	Immediate Sensitivity Relief. Tactile Sensitivity.
NCT01610167 (5) [back to overview]	Adverse Events.
NCT01610167 (5) [back to overview]	Extended Sensitivity Relief. Air Blast Sensitivity.
NCT01641237 (4) [back to overview]	Enamel Fluoride Uptake (Corrected Data)
NCT01641237 (4) [back to overview]	Percentage Relative Erosion Resistance
NCT01641237 (4) [back to overview]	Percentage Surface Microhardness Recovery (%SMHR) Dose Response Relationship
NCT01641237 (4) [back to overview]	%SMHR
NCT01657903 (4) [back to overview]	Surface Microhardness (SMH) Recovery of Enamel Specimens Post 4 Hours of Treatment Exposure
NCT01657903 (4) [back to overview]	SMH Recovery of Enamel Specimens Post 2 Hours of Treatment Exposure
NCT01657903 (4) [back to overview]	RER of Enamel Specimens Post 2 Hours of Treatment Exposure
NCT01657903 (4) [back to overview]	Relative Erosion Resistance (RER) of Enamel Specimens Post 4 Hours of Treatment Exposure
NCT01665911 (3) [back to overview]	% Acid Resistance Score Per Each of Five Arms
NCT01665911 (3) [back to overview]	Enamel Fluoride Uptake Per Each of Five Arms
NCT01665911 (3) [back to overview]	% Surface Microhardness (SMH) Recovery Score Per Each of Five Arms
NCT01669785 (10) [back to overview]	Long-term Sensitivity Relief (Self-Assessment)
NCT01669785 (10) [back to overview]	Post-prophylaxis Sensitivity Relief (Self-Assessment)
NCT01669785 (10) [back to overview]	Sensitivity Relief (Self-Assessment)
NCT01669785 (10) [back to overview]	Post- Scaling Sensitivity Relief (Self-Assessment)
NCT01669785 (10) [back to overview]	Long-term Sensitivity Relief (Tactile Sensitivity)
NCT01669785 (10) [back to overview]	Baseline Pre-Prophy Assessment (Air Blast Sensitivity)
NCT01669785 (10) [back to overview]	Baseline Pre-Prophy Assessment (Tactile Sensitivity)
NCT01669785 (10) [back to overview]	Immediate Sensitivity Relief (Schiff Air Blast Sensitivity)
NCT01669785 (10) [back to overview]	Immediate Sensitivity Relief (Tactile Sensitivity)
NCT01669785 (10) [back to overview]	Long-term Sensitivity Relief (Schiff Air Blast Sensitivity)
NCT01691560 (6) [back to overview]	Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 8
NCT01691560 (6) [back to overview]	Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 4
NCT01691560 (6) [back to overview]	Change From Baseline in Evaporative Air Sensitivity Response on a Visual Rating Scale (VRS) at Week 4
NCT01691560 (6) [back to overview]	Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 8
NCT01691560 (6) [back to overview]	Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4
NCT01691560 (6) [back to overview]	Change From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8
NCT01727258 (6) [back to overview]	Mean Cold Air Stimulus VAS Score at Week 2
NCT01727258 (6) [back to overview]	Mean Tactile Sensitivity VAS Score at Week 4
NCT01727258 (6) [back to overview]	Mean Cold Air Stimulus VAS Score at Week 4
NCT01727258 (6) [back to overview]	Mean Tactile Sensitivity Score at Week 2
NCT01727258 (6) [back to overview]	Mean Tactile Sensitivity VAS Score at Week 2
NCT01727258 (6) [back to overview]	Mean Tactile Sensitivity Score at Week 4
NCT01796106 (1) [back to overview]	Validation of SFE Imaging for Lesion Size Assessment: SFE Imaging vs. Radiographic Imaging
NCT01812668 (6) [back to overview]	Time to Progression
NCT01812668 (6) [back to overview]	Number of Participants With Indicated Toxicities Grade 3 or Higher
NCT01812668 (6) [back to overview]	PET Response Based on the RECIST Criteria 1.1
NCT01812668 (6) [back to overview]	Number of Participants With Indicated Clinical Response Based on the RECIST Criteria 1.1
NCT01812668 (6) [back to overview]	PSA Response Based on the RECIST Criteria 1.1
NCT01812668 (6) [back to overview]	Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment.
NCT01816048 (2) [back to overview]	Number of Participants With Change in the Number of Circulating Tumor Cells Using the Cell Search System (Veridex, LLC) Obtained Prior to Beginning Treatment With TAK 700, After Completing One Cycle and After Completing 3 Cycles
NCT01816048 (2) [back to overview]	Number of Subjects Who Experience Adverse Events While on Treatment With TAK 700
NCT01827670 (6) [back to overview]	Mean Change in Dentinal Hypersensitivity After 4 Weeks as Measured by Visual Analog Scale (VAS)
NCT01827670 (6) [back to overview]	Mean Change From Baseline in Tactile Sensitivity
NCT01827670 (6) [back to overview]	Mean Change From Baseline in Tactile Sensitivity
NCT01827670 (6) [back to overview]	Mean Change From Baseline in Schiff Sensitivity Score
NCT01827670 (6) [back to overview]	Mean Change From Baseline in Schiff Sensitivity Score
NCT01827670 (6) [back to overview]	Mean Change in Dentinal Hypersensitivity After 8 Weeks as Measured by Visual Analog Scale (VAS)
NCT01831817 (8) [back to overview]	Mean Change From Baseline in Schiff Sensitivity Score at Week 8
NCT01831817 (8) [back to overview]	Median Change From Baseline in Tactile Sensitivity at Week 8
NCT01831817 (8) [back to overview]	Median Change From Baseline in Tactile Sensitivity at Week 4
NCT01831817 (8) [back to overview]	Mean Change From Baseline in Visual Rating Scale Score at Week 8
NCT01831817 (8) [back to overview]	Mean Change From Baseline in Visual Rating Scale Score at Week 4
NCT01831817 (8) [back to overview]	Mean Change From Baseline in Schiff Sensitivity Score at Week 4
NCT01831817 (8) [back to overview]	Mean Change From Baseline in Dentine Hypersensitivity Experience Questionnaire Total Score at Week 4
NCT01831817 (8) [back to overview]	Mean Change From Baseline in Dentine Hypersensitivity Experience Questionnaire (DHEQ) Total Score at Week 8
NCT01901250 (1) [back to overview]	Change in the Number of Decayed or Filled Permanent Teeth (DFT) From Baseline (Beginning of Kindergarten) to the Middle of 2nd Grade
NCT01962493 (8) [back to overview]	Overall Interproximal MLSI at Week 3
NCT01962493 (8) [back to overview]	Overall Interproximal MLSI at Week 6
NCT01962493 (8) [back to overview]	Modified Lobene Stain Index (MLSI) at Week 6
NCT01962493 (8) [back to overview]	Overall Facial MLSI at Week 6
NCT01962493 (8) [back to overview]	Overall Gingival and Interproximal MLSI at Week 3
NCT01962493 (8) [back to overview]	Overall Facial MLSI at Week 3
NCT01962493 (8) [back to overview]	Overall Gingival and Interproximal MLSI at Week 6
NCT01962493 (8) [back to overview]	Overall MLSI at Week 3
NCT01967862 (1) [back to overview]	Number of Eligible Patients With Positive CT Scan/Bone Scan, MRI and PET Scan.
NCT02113579 (10) [back to overview]	Mean Cold Air Stimulus VAS Score at Week 2
NCT02113579 (10) [back to overview]	Mean Cold Air Stimulus VAS Score at Week 4
NCT02113579 (10) [back to overview]	Mean Tactile Sensitivity Score at Week 2
NCT02113579 (10) [back to overview]	Mean Tactile Sensitivity Score at Week 4
NCT02113579 (10) [back to overview]	Mean Tactile Sensitivity VAS Score at Week 4
NCT02113579 (10) [back to overview]	Percentage of Subjects With Reduction From Baseline by at Least 30% in Mean Cold Air VAS Stimulus Score at Week 4
NCT02113579 (10) [back to overview]	Percentage of Subjects With Reduction From Baseline by at Least 30% in Mean Cold Air VAS Stimulus Score at Week 2
NCT02113579 (10) [back to overview]	Mean Tactile Sensitivity VAS Score at Week 2
NCT02113579 (10) [back to overview]	Global Subjective VAS Score at Week 2
NCT02113579 (10) [back to overview]	Global Subjective VAS Score at Week 4
NCT02149173 (4) [back to overview]	Time to Disease Progression
NCT02149173 (4) [back to overview]	Proportion of Patients Experienced a Threshold in Percentage Change, or Surpassed a Targeted Follow-up F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV)
NCT02149173 (4) [back to overview]	Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV), Assessed by a One-sample Test of the Percent Change in FES SUV
NCT02149173 (4) [back to overview]	F-18 16 Alpha-fluoroestradiol (FES) Uptake
NCT02193165 (6) [back to overview]	Gingivitis Scores
NCT02193165 (6) [back to overview]	Gingivitis Scores
NCT02193165 (6) [back to overview]	Gingivitis Scores
NCT02193165 (6) [back to overview]	Dental Plaque Scores
NCT02193165 (6) [back to overview]	Dental Plaque Scores
NCT02193165 (6) [back to overview]	Dental Plaque Scores
NCT02195583 (4) [back to overview]	Percentage Comparative Acid Resistance (% CAR)
NCT02195583 (4) [back to overview]	Enamel Fluoride Uptake
NCT02195583 (4) [back to overview]	Percentage Surface Microhardness Recovery (% SMHR)
NCT02195583 (4) [back to overview]	Percentage Net Acid Resistance (% NAR)
NCT02207400 (7) [back to overview]	Number of Gingival Bleeding Sites at 24 Weeks
NCT02207400 (7) [back to overview]	Modified Gingival Index (MGI)) at 6 and 12 Weeks.
NCT02207400 (7) [back to overview]	Number of Gingival Bleeding Sites at 6 and 12 Weeks
NCT02207400 (7) [back to overview]	Plaque Control (Overall and Interproximal Dental Plaque Scores) at 6, 12 and 24 Weeks.
NCT02207400 (7) [back to overview]	Bleeding Index (BI) at 6, 12 and 24 Weeks
NCT02207400 (7) [back to overview]	Bacterial Count at Baseline, After 6, 12, 24 and 32 Weeks
NCT02207400 (7) [back to overview]	Modified Gingival Index (MGI) at 24 Weeks
NCT02207907 (6) [back to overview]	Bleeding Index at 6, 12 and 24 Weeks
NCT02207907 (6) [back to overview]	Modified Gingival Index (MGI) at 6 and 12 Weeks.
NCT02207907 (6) [back to overview]	Plaque Control (Overall and Interproximal Dental Plaque Scores) Using Turesky Modification of Quigley &Amp; Hein Plaque Index at 6, 12 and 24 Weeks.
NCT02207907 (6) [back to overview]	Number of Gingival Bleeding Sites at 6 and 12 Weeks.
NCT02207907 (6) [back to overview]	Number of Gingival Bleeding Sites at 24 Weeks
NCT02207907 (6) [back to overview]	Modified Gingival Index (MGI) at 24 Weeks
NCT02221349 (2) [back to overview]	Change From Baseline Visual Analog Scale
NCT02221349 (2) [back to overview]	Change From Baseline Air Challenge
NCT02226562 (6) [back to overview]	Mean Change From Baseline in Schiff Sensitivity Score at Week 4
NCT02226562 (6) [back to overview]	Mean Change From Baseline in Tactile Threshold at Week 4
NCT02226562 (6) [back to overview]	Mean Change From Baseline in Tactile Threshold at Week 8
NCT02226562 (6) [back to overview]	Mean Change From Baseline in Schiff Sensitivity Score at Week 8
NCT02226562 (6) [back to overview]	Mean Change From Baseline in Visual Rating Scale (VRS) at Week 8
NCT02226562 (6) [back to overview]	Mean Change From Baseline in VRS at Week 4
NCT02319668 (4) [back to overview]	Area Under the Curve (AUC) for the Total Number of Plaque Bacteria in the Mouth Post Implant Surgery
NCT02319668 (4) [back to overview]	Total Number of Recoverable Viable Bacteria in the Aerosol Generated During Dental Prophylaxis
NCT02319668 (4) [back to overview]	Total Number of Detectable Plaque Bacteria Sampled at Implant Surgery (at Pre-rinse, Pre, Mid and Post Implant Surgery) and Post Implant Surgery (at Day 1 and 7)
NCT02319668 (4) [back to overview]	Total Number of Detectable Plaque Bacteria Sampled 3 Days Post Implant Surgery
NCT02357979 (2) [back to overview]	International Caries Detection and Assessment System (ICDAS II) - Number of Molars With ICDAS Score of 3 or More - ICDAS Score 3, Cavity -
NCT02357979 (2) [back to overview]	Change in ICDAS Scores - International Caries Detection and Assessment System (ICDAS II) -
NCT02360124 (2) [back to overview]	Number of New Tooth Root Caries Lesions
NCT02360124 (2) [back to overview]	Proportion of Inactive Root Caries Lesions
NCT02360995 (6) [back to overview]	Gingivitis Scores
NCT02360995 (6) [back to overview]	Dental Plaque Scores
NCT02360995 (6) [back to overview]	Gingivitis Scores
NCT02360995 (6) [back to overview]	Gingivitis Scores
NCT02360995 (6) [back to overview]	Dental Plaque Scores
NCT02360995 (6) [back to overview]	Dental Plaque Scores
NCT02366689 (6) [back to overview]	Dental Plaque Scores
NCT02366689 (6) [back to overview]	Dental Plaque Scores
NCT02366689 (6) [back to overview]	Gingivitis Scores
NCT02366689 (6) [back to overview]	Gingivitis Scores
NCT02366689 (6) [back to overview]	Gingivitis Scores
NCT02366689 (6) [back to overview]	Dental Plaque Scores
NCT02371616 (4) [back to overview]	Mean Change From Baseline in Evaporative Air Sensitivity as Measured by Visual Analogue Score (VAS) at Week 8
NCT02371616 (4) [back to overview]	Mean Change From Baseline in Evaporative Air Sensitivity as Measured by Visual Analogue Score (VAS) at Week 4
NCT02371616 (4) [back to overview]	Mean Change From Baseline in Evaporative Air Sensitivity as Measured by Schiff Sensitivity Score at Week 4 and Week 8
NCT02371616 (4) [back to overview]	Change From Baseline in Tactile Threshold at Week 4 and Week 8
NCT02399163 (5) [back to overview]	Enamel Fluoride Uptake
NCT02399163 (5) [back to overview]	Change in Saliva Fluoride Concentration From Baseline (Pre-treatment) to Day 14
NCT02399163 (5) [back to overview]	Percentage Surface Microhardness Recovery (%SMHR) of Placebo Dentifrice/Fluoride Rinse Compared to Placebo Dentifrice/No Rinse
NCT02399163 (5) [back to overview]	Percentage Surface Microhardness Recovery (SMHR) of Placebo Dentifrice/Fluoride Rinse, Placebo Dentifrice/No Rinse, Fluoride Dentifrice/No Rinse and Fluoride Dentifrice/Fluoride Rinse
NCT02399163 (5) [back to overview]	Change in Saliva Fluoride Concentration From Baseline (Post-treatment) to Day 14
NCT02424097 (2) [back to overview]	Change in White Spot Lesions Count - Enamel Decalcification Index (EDI)
NCT02424097 (2) [back to overview]	Change in International Caries Detection and Assessment System (ICDAS II) to Score for Smooth Surfaces White Spot Lesions (WSL)
NCT02448225 (4) [back to overview]	Ability of 18F-FSPG PET/CT to Discriminate Benign From Malignant Nodules
NCT02448225 (4) [back to overview]	CD44 and xC- Expression Levels in Tissue Samples(0-3)
NCT02448225 (4) [back to overview]	Ability of 18F-FSPG PET/CT to Stage of Lung Cancer (Metastatic or Not)
NCT02448225 (4) [back to overview]	Uptake of 18F-FSPG (Expressed in Maximal Standardized Uptake Value [SUV] Within the Tumor)
NCT02513212 (2) [back to overview]	Change From Baseline Visual Analog Scale
NCT02513212 (2) [back to overview]	Change From Baseline Air Challenge
NCT02533466 (10) [back to overview]	Change From Baseline of Salivary Calcium Concentration 7 Hours Post Dietary Acid Challenge
NCT02533466 (10) [back to overview]	Change From Baseline of Salivary Calcium Concentration at 30 Mins Post Dietary Acid Challenge
NCT02533466 (10) [back to overview]	Change From Pre-acid Challenge (Baseline) Tooth Impression Grading Score Following 2 Hours Post Acid Challenge.
NCT02533466 (10) [back to overview]	Change From Pre-acid Challenge (Baseline) Tooth Impression Grading Score Following 4 Hours Post Acid Challenge
NCT02533466 (10) [back to overview]	Change From Baseline in Buffering Capacity at 30 Mins Post Dietary Acid Challenge
NCT02533466 (10) [back to overview]	Change From Baseline in Buffering Capacity 7 Hours Post Dietary Acid Challenge
NCT02533466 (10) [back to overview]	Change From Pre-acid Challenge (Baseline) Tooth Impression Grading Score Following 7 Hours Post Acid Challenge
NCT02533466 (10) [back to overview]	Change From Baseline of pH Measurement 7 Hours Post Dietary Acid Challenge
NCT02533466 (10) [back to overview]	Change From Pre-acid Challenge (Baseline) Tooth Impression Grading Score Immediately Following an Acid Challenge
NCT02533466 (10) [back to overview]	Change From Baseline of pH Measurement at 30 Mins Post Dietary Acid Challenge
NCT02536040 (1) [back to overview]	Dental Caries Activity
NCT02542943 (7) [back to overview]	Change From Baseline in Schiff Sensitivity Score of Experimental Oral Rinses 1 and 2 Against a Placebo Oral Rinse at Week 8
NCT02542943 (7) [back to overview]	Change From Baseline in Schiff Sensitivity Score of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse at Week 4
NCT02542943 (7) [back to overview]	Change From Baseline in Schiff Sensitivity Score of Two Experimental Oral Rinses 1 and 2 at Week 8
NCT02542943 (7) [back to overview]	Change From Baseline in Tactile Threshold (g) of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse at Week 8
NCT02542943 (7) [back to overview]	Change From Baseline in Visual Rating Scale (VRS) of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse) at Week 4
NCT02542943 (7) [back to overview]	Change From Baseline in VRS of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse) at Week 8
NCT02542943 (7) [back to overview]	Change From Baseline in Tactile Threshold (Gram [g]) of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse at Week 4
NCT02598778 (2) [back to overview]	Change in Salivary Streptococcus Mutans Levels After 30 Second Oral Rinse Time (Chlorhexidine Gluconate, Sodium Fluoride, or Deionized Water) or 2 Minute Chew Time (Paraffin Wax Chewing Gum)
NCT02598778 (2) [back to overview]	Change in Salivary Streptococcus Mutans Levels After 30 Second Oral Rinse Time (Chlorhexidine Gluconate, Sodium Fluoride, or Deionized Water) or 2 Minute Chew Time (Paraffin Wax Chewing Gum)
NCT02601833 (3) [back to overview]	Time of Treatment Procedures (Duration of Time in Minutes)
NCT02601833 (3) [back to overview]	Costs of Treatment (Dollars)
NCT02601833 (3) [back to overview]	Caries Arrest of Teeth in the SDF Group Measured by Change in Size
NCT02612064 (3) [back to overview]	Change From Baseline in Tactile Threshold Post First Treatment by Direct Application and on Day 3
NCT02612064 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score Post First Treatment by Direct Application
NCT02612064 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score on Day 3
NCT02613117 (1) [back to overview]	Did Participants Notice a Difference in the Areas Noted?
NCT02647203 (2) [back to overview]	Root Caries Activity
NCT02647203 (2) [back to overview]	Oral Health Related Quality of Life, Measured by the Oral Health Impact Profile (OHIP-14 Sp)
NCT02705716 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score on Day 14
NCT02705716 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score on Day 7
NCT02705716 (3) [back to overview]	Change From Baseline in Tactile Threshold on Day 7 and 14
NCT02724592 (4) [back to overview]	Caries Activity Assessment According to Nyvad Criteria
NCT02724592 (4) [back to overview]	ICDAS Classification Index
NCT02724592 (4) [back to overview]	Visual Analog Scale of Lesion Progression (VAS)
NCT02724592 (4) [back to overview]	Caries Activity and Progression Assessment Using LASER Fluorescence Readings by Diagnodent® Device.
NCT02731833 (4) [back to overview]	Change From Baseline in Schiff Sensitivity Score on Day 3
NCT02731833 (4) [back to overview]	Change From Baseline in Tactile Threshold Post First Treatment by Direct Application
NCT02731833 (4) [back to overview]	Change From Baseline in Tactile Threshold on Day 3
NCT02731833 (4) [back to overview]	Change From Baseline in Schiff Sensitivity Score Post First Treatment by Direct Application
NCT02750943 (5) [back to overview]	Bleeding Index (BI) at Week 4 and Week 12
NCT02750943 (5) [back to overview]	Number of Bleeding Sites at Week 4
NCT02750943 (5) [back to overview]	Number of Bleeding Sites at Week 12
NCT02750943 (5) [back to overview]	Number of Participants With Visible Blood in Expectorate (Presence [Trace, Substantial]/Absence) at Week4 and Week 12
NCT02750943 (5) [back to overview]	Modified Gingival Index (MGI) at Week 4 and Week 12
NCT02751450 (4) [back to overview]	Change From Baseline in Tactile Threshold Post First Treatment by Direct Application
NCT02751450 (4) [back to overview]	Change From Baseline in Tactile Threshold on Day 3
NCT02751450 (4) [back to overview]	Change From Baseline in Schiff Sensitivity Score Post First Treatment by Direct Application
NCT02751450 (4) [back to overview]	Change From Baseline in Schiff Sensitivity Score on Day 3
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 8
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questi 30 to 34) at Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questions 30 to 34) at Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questions 30 to 34) at Week 20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questions 30 to 34) at Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questions 30 to 34) at Week 8
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 8
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 8
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 8
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questions 30 to 34) at Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 8
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score DHEQ Section1 - Question (Q) No. 8 At Week 8
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 At Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of Dentine Hyersensitivity Experience Questionnaire (DHEQ) Section1 - Question (Q) No. 7 At Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 At Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 7 At Week 20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 at Week 8
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 8
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 7 At Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 7 At Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 7 At Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 7 At Week 8
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 8 At Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 8 At Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 8 At Week 24
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 8 At Week 4
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 8 At Week20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 At Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 At Week 16
NCT02752958 (66) [back to overview]	Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 At Week 20
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 12
NCT02752958 (66) [back to overview]	Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 8
NCT02753075 (7) [back to overview]	Change From Baseline in Visual Rating Scale (VRS) of Two Experimental Oral Rinses 1, 2 and a Placebo Oral Rinse at Week 4
NCT02753075 (7) [back to overview]	Change From Baseline in Schiff Sensitivity Score of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse at Week 4
NCT02753075 (7) [back to overview]	Change From Baseline in Schiff Sensitivity Score of Experimental Oral Rinses 1 and 2 Against a Placebo Oral Rinse at Week 8
NCT02753075 (7) [back to overview]	Change From Baseline in Schiff Sensitivity Score of Two Experimental Oral Rinses 1 and 2 at Week 8
NCT02753075 (7) [back to overview]	Change From Baseline in Tactile Threshold (g) of Two Experimental Oral Rinses 1, 2 and a Placebo Oral Rinse at Week 8
NCT02753075 (7) [back to overview]	Change From Baseline in Tactile Threshold (Gram [g]) of Two Experimental Oral Rinses 1, 2 and a Placebo Oral Rinse at Week 4
NCT02753075 (7) [back to overview]	Change From Baseline in VRS of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse) at Week 8
NCT02768194 (2) [back to overview]	Change From Baseline in Mean Occlusion Scores After 1, 4, & 10 Days Treatment Application
NCT02768194 (2) [back to overview]	Change From Baseline in Mean Occlusion Scores After 8 Days Treatment Application
NCT02773758 (3) [back to overview]	Change From Baseline in Tactile Threshold at Day 7 and Day 14
NCT02773758 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score at Day 7
NCT02773758 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score at Day 14
NCT02832375 (3) [back to overview]	Change From Baseline in Tactile Threshold Immediately After Single Use and on Day 3
NCT02832375 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score After Single Use
NCT02832375 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score on Day 3
NCT02861664 (3) [back to overview]	Change From Baseline in Tactile Threshold at Week 4 and 8
NCT02861664 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score at Week 8
NCT02861664 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score at Week 4
NCT02918617 (4) [back to overview]	Percentage Change From Baseline in VAS (Visual Analog Scale) With Cold Stimulation
NCT02918617 (4) [back to overview]	Percentage Change From Baseline in DPS (Dental Pain Scale) With Cold Stimulation
NCT02918617 (4) [back to overview]	Percentage Change From Baseline in DPS (Dental Pain Scale) With Air Stimulation
NCT02918617 (4) [back to overview]	Percentage Change From Baseline in VAS (Visual Analog Scale) With Air Stimulation
NCT02923895 (4) [back to overview]	Change From Baseline in Tactile Threshold on Day 3
NCT02923895 (4) [back to overview]	Change From Baseline in Tactile Threshold After a Single Use
NCT02923895 (4) [back to overview]	Change From Baseline in Schiff Sensitivity Score After a Single Use
NCT02923895 (4) [back to overview]	Change From Baseline in Schiff Sensitivity Score on Day 3
NCT02924350 (3) [back to overview]	Change From Baseline (Day 0 Pre-treatment) in Schiff Sensitivity Score on Day 0 (After 60 Seconds of Single Direct Application)
NCT02924350 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score on Day 3
NCT02924350 (3) [back to overview]	Change From Baseline (Day 0 Pre-treatment) in Tactile Threshold on Day 0 (After 60 Seconds of Single Direct Application) and Day 3
NCT02937636 (4) [back to overview]	Number of Bleeding Sites
NCT02937636 (4) [back to overview]	Mean Plaque Index (PI) (Overall and Interproximal)
NCT02937636 (4) [back to overview]	Mean Bleeding Index (BI)
NCT02937636 (4) [back to overview]	Mean Modified Gingival Index (MGI)
NCT02953886 (3) [back to overview]	Patient Assessment of Appearance of Treated Tooth (Concern With the Appearance of Study Tooth, Desire for the Study Tooth to be Filled)
NCT02953886 (3) [back to overview]	Change in Bacterial Composition Before and One Month After SDF Application to Root or Cervical Caries Lesions
NCT02953886 (3) [back to overview]	Caries Arrest of Teeth Measured by Change in Dentin Texture (Soft, Hard)
NCT03072719 (3) [back to overview]	Change From Baseline in Tactile (Yeaple) Pain Threshold on Post First Brushing (After 5 Minutes), Day 3 and Day 14
NCT03072719 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score on Post First Brushing (After 5 Minutes) and Day 3
NCT03072719 (3) [back to overview]	Change From Baseline in Schiff Sensitivity Score on Day 14
NCT03082196 (4) [back to overview]	Child Response to First Treatment
NCT03082196 (4) [back to overview]	Child Response to Fifth Treatment
NCT03082196 (4) [back to overview]	Dental Caries for All Primary Teeth Sound at Baseline
NCT03082196 (4) [back to overview]	Dental Caries for Primary Molars Sound at Baseline
NCT03160703 (1) [back to overview]	Overall Modified Lobene Stain Index (MLSI) Mean Score at Week 4
NCT03186261 (1) [back to overview]	Bacterial Count of Streptococus Mutans
NCT03238352 (2) [back to overview]	Change From Baseline in Tactile Threshold
NCT03238352 (2) [back to overview]	Change From Baseline in Schiff Sensitivity Score
NCT03244618 (6) [back to overview]	Thermo-evaporative (Schiff Air Blast) Stimuli
NCT03244618 (6) [back to overview]	Thermo-evaporative (Schiff Air Blast) Stimuli
NCT03244618 (6) [back to overview]	Visual Analogue Scale
NCT03244618 (6) [back to overview]	Visual Analogue Scale
NCT03244618 (6) [back to overview]	Tactile (Yeaple Probe) Stimuli
NCT03244618 (6) [back to overview]	Tactile (Yeaple Probe) Stimuli
NCT03285984 (2) [back to overview]	Mean Change From Baseline (Pre-brushing to Post Brushing) in Turesky Score After Single Supervised Use for Test Products 1, 2, 3 and 4 After 4 Weeks
NCT03285984 (2) [back to overview]	Mean Change From Baseline (Pre-brushing to Post-brushing) in Turesky Score After Single Supervised Use (Test Product 1 Versus [vs] Test Product 4) After 4 Weeks
NCT03296072 (6) [back to overview]	% Surface Micro Hardness Recovery (SMHR; Comparison of 1150 Ppm Fluoride and 5% KNO3 Dentifrice Relative to a Fluoride Free Placebo Dentifrice to Enhance Remineralization of Enamel)
NCT03296072 (6) [back to overview]	% Relative Erosion Resistance (RER; Comparison of 1150 Ppm Fluoride and 5% KNO3 Dentifrice Relative to a Fluoride Free Placebo Dentifrice to Inhibit Demineralization of Enamel)
NCT03296072 (6) [back to overview]	% RER (Comparison of 1150 Ppm Fluoride and 5% KNO3 Dentifrice Relative to Comparator Containing 1100 Ppm Fluoride)
NCT03296072 (6) [back to overview]	% SMHR (Comparison of 1150 Ppm Fluoride and 5% KNO3 Dentifrice Relative to Comparator Containing 1100 Ppm Fluoride)
NCT03296072 (6) [back to overview]	EFU (Comparison of 1150 Ppm Fluoride and 5% KNO3 Dentifrice Relative to Comparator Containing 1100 Ppm Fluoride)
NCT03296072 (6) [back to overview]	Enamel Fluoride Uptake (EFU; Comparison of 1150 Ppm Fluoride and 5% KNO3 Dentifrice Relative to a Fluoride Free Placebo Dentifrice to Promote Fluoride Uptake in Enamel)
NCT03310268 (2) [back to overview]	Change From Baseline in Tactile Threshold After 8 Weeks of Treatment
NCT03310268 (2) [back to overview]	Change From Baseline in Schiff Sensitivity Score After 8 Weeks of Treatment
NCT03383783 (7) [back to overview]	Net Acid Resistance (NAR)
NCT03383783 (7) [back to overview]	Transverse Microradiography (TMR) - Lesion Depth - L
NCT03383783 (7) [back to overview]	Transverse Microradiography (TMR) - Integrated Mineral Loss - ∆Z
NCT03383783 (7) [back to overview]	Comparative Acid Resistance (CAR)
NCT03383783 (7) [back to overview]	Enamel Fluoride Uptake (EFU)
NCT03383783 (7) [back to overview]	Percentage Surface Microhardness Recovery (%SMH)
NCT03383783 (7) [back to overview]	Transverse Microradiography (TMR) - Maximum Mineral Density at the Surface-zone
NCT03405259 (2) [back to overview]	Change From Baseline Air Challenge
NCT03405259 (2) [back to overview]	Change From Baseline Visual Analog Scale
NCT03778294 (2) [back to overview]	Progression Free Survival
NCT03778294 (2) [back to overview]	Overall Survival (OS)
NCT03943095 (20) [back to overview]	Number of Sensitive Teeth (Schiff Sensitivity Score >= 1) on Day 28
NCT03943095 (20) [back to overview]	Number of Sensitive Teeth (Schiff Sensitivity Score >= 1) on Day 14
NCT03943095 (20) [back to overview]	Mean Tactile Threshold (Average of the Two Selected Test Teeth) at Day 7
NCT03943095 (20) [back to overview]	Mean Tactile Threshold (Average of the Two Selected Test Teeth) at Day 56
NCT03943095 (20) [back to overview]	Mean Tactile Threshold (Average of the Two Selected Test Teeth) at Day 3
NCT03943095 (20) [back to overview]	Mean Tactile Threshold (Average of the Two Selected Test Teeth) at Day 28
NCT03943095 (20) [back to overview]	Number of Sensitive Teeth (Schiff Sensitivity Score >= 1) on Day 7
NCT03943095 (20) [back to overview]	Change From Baseline (Day 0) in Tactile Threshold on Day 56
NCT03943095 (20) [back to overview]	Change From Baseline in Schiff Sensitivity Score at Day 56
NCT03943095 (20) [back to overview]	Mean Tactile Threshold (Average of the Two Selected Test Teeth) at Baseline (Day 0)
NCT03943095 (20) [back to overview]	Mean Tactile Threshold (Average of the Two Selected Test Teeth) at Day 14
NCT03943095 (20) [back to overview]	Mean Schiff Sensitivity Score (Average of the Two Selected Test Teeth) at Day 7
NCT03943095 (20) [back to overview]	Mean Schiff Sensitivity Score (Average of the Two Selected Test Teeth) at Day 56
NCT03943095 (20) [back to overview]	Mean Schiff Sensitivity Score (Average of the Two Selected Test Teeth) at Day 3
NCT03943095 (20) [back to overview]	Mean Schiff Sensitivity Score (Average of the Two Selected Test Teeth) at Day 28
NCT03943095 (20) [back to overview]	Mean Schiff Sensitivity Score (Average of the Two Selected Test Teeth) at Baseline (Day 0)
NCT03943095 (20) [back to overview]	Number of Sensitive Teeth (Schiff Sensitivity Score Greater Than or Equal to [>=] 1) on Day 0 (Baseline)
NCT03943095 (20) [back to overview]	Number of Sensitive Teeth (Schiff Sensitivity Score >= 1) on Day 56
NCT03943095 (20) [back to overview]	Mean Schiff Sensitivity Score (Average of the Two Selected Test Teeth) at Day 14
NCT03943095 (20) [back to overview]	Number of Sensitive Teeth (Schiff Sensitivity Score >= 1) on Day 3
NCT03965039 (12) [back to overview]	Baseline Air Challenge
NCT03965039 (12) [back to overview]	Air Challenge
NCT03965039 (12) [back to overview]	Air Challenge
NCT03965039 (12) [back to overview]	Air Challenge
NCT03965039 (12) [back to overview]	Tactile Threshold
NCT03965039 (12) [back to overview]	Air Challenge
NCT03965039 (12) [back to overview]	Air Challenge
NCT03965039 (12) [back to overview]	Baseline Yeaple Probe
NCT03965039 (12) [back to overview]	Tactile Threshold
NCT03965039 (12) [back to overview]	Tactile Threshold
NCT03965039 (12) [back to overview]	Tactile Threshold
NCT03965039 (12) [back to overview]	Tactile Threshold
NCT04054635 (3) [back to overview]	Anterior Teeth Arrest Rates
NCT04054635 (3) [back to overview]	Posterior Arrest Rates
NCT04054635 (3) [back to overview]	Overall Arrest Rates
NCT04123665 (9) [back to overview]	Evaluation and Comparison of Gingival Health Measured by MGI Indices in Low MGI Subgroup (<=2.00) at 12 and 24 Weeks
NCT04123665 (9) [back to overview]	Evaluation and Comparison of Gingival Health Measured by Bleeding Index (BI) at 24 Weeks
NCT04123665 (9) [back to overview]	Evaluation and Comparison of Gingival Health Measured by BI at 12 Weeks
NCT04123665 (9) [back to overview]	Evaluation and Comparison of Gingival Health Measured by MGI Indices in High MGI Subgroup (>2.00) at 12 and 24 Weeks
NCT04123665 (9) [back to overview]	Evaluation and Comparison of Gingival Health Measured by BI Indices in Low MGI Subgroups (<=2.00) After 12 and 24 Weeks
NCT04123665 (9) [back to overview]	Evaluation and Comparison of Gingival Health Measured by BI Indices in High MGI Subgroup (>2.00) at 12 and 24 Weeks
NCT04123665 (9) [back to overview]	Number of Bleeding Sites After 12 and 24 Weeks
NCT04123665 (9) [back to overview]	Evaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 Weeks
NCT04123665 (9) [back to overview]	Evaluation and Comparison of Gingival Health Measured by Modified Gingival Index (MGI) at 12 and 24 Weeks
NCT04184271 (6) [back to overview]	Observed Silver Tmax
NCT04184271 (6) [back to overview]	Observed Fluoride Urinary Recovery
NCT04184271 (6) [back to overview]	Observed Silver 24 Hour Urinary Concentration
NCT04184271 (6) [back to overview]	Observed Silver Baseline-Corrected Cmax
NCT04184271 (6) [back to overview]	Observed Silver t1/2
NCT04184271 (6) [back to overview]	Observed Silver Cmax
NCT04186663 (7) [back to overview]	Average Serum Fluoride Concentrations
NCT04186663 (7) [back to overview]	Apparent Oral Clearance of Silver (CL/F)
NCT04186663 (7) [back to overview]	Predicted Time to Peak Serum Silver Concentration (Tmax)
NCT04186663 (7) [back to overview]	Serum Silver Exposure (AUC)
NCT04186663 (7) [back to overview]	Silver Half-life
NCT04186663 (7) [back to overview]	Apparent Volume of Distribution of Silver (V/F)
NCT04186663 (7) [back to overview]	Predicted Peak Serum Silver Concentration (Cmax)
NCT04239872 (29) [back to overview]	Area Under the Curve of Calcium Concentration in Saliva Overtime
NCT04239872 (29) [back to overview]	Area Under the Curve of Calcium Concentration in Dental Biofilm Solids Overtime
NCT04239872 (29) [back to overview]	Calcium Concentration in Dental Biofilm Solids at Baseline
NCT04239872 (29) [back to overview]	Calcium Concentration in Saliva at 121 Minutes
NCT04239872 (29) [back to overview]	Calcium Concentration in Saliva at 16 Minutes
NCT04239872 (29) [back to overview]	Fluoride Concentration in Dental Biofilm Solids at 60 Minutes
NCT04239872 (29) [back to overview]	Calcium Concentration in Saliva at 30 Minutes
NCT04239872 (29) [back to overview]	Calcium Concentration in Saliva at 61 Minutes
NCT04239872 (29) [back to overview]	Fluoride Concentration in Dental Biofilm Solids at Baseline
NCT04239872 (29) [back to overview]	Fluoride Concentration in Saliva at 16 Minutes
NCT04239872 (29) [back to overview]	Fluoride Concentration in Saliva at 30 Minutes
NCT04239872 (29) [back to overview]	Fluoride Concentration in Saliva at 61 Minutes
NCT04239872 (29) [back to overview]	Fluoride Concentration in Saliva at 90 Minutes
NCT04239872 (29) [back to overview]	Fluoride Concentration in Saliva at Baseline
NCT04239872 (29) [back to overview]	Fluoride Concentration in Saliva at 121 Minutes
NCT04239872 (29) [back to overview]	Calcium Concentration in Dental Biofilm Solids at 60 Minutes
NCT04239872 (29) [back to overview]	Calcium Concentration in Saliva at 90 Minutes
NCT04239872 (29) [back to overview]	Calcium Concentration in Saliva at Baseline
NCT04239872 (29) [back to overview]	Fluoride Concentration in Dental Biofilm Fluid at 120 Minutes
NCT04239872 (29) [back to overview]	Fluoride Concentration in Dental Biofilm Fluid at 15 Minutes
NCT04239872 (29) [back to overview]	Fluoride Concentration in Dental Biofilm Fluid at 60 Minutes
NCT04239872 (29) [back to overview]	Fluoride Concentration in Dental Biofilm Fluid at Baseline
NCT04239872 (29) [back to overview]	Fluoride Concentration in Dental Biofilm Solids at 120 Minutes
NCT04239872 (29) [back to overview]	Fluoride Concentration in Dental Biofilm Solids at 15 Minutes
NCT04239872 (29) [back to overview]	Calcium Concentration in Dental Biofilm Solids at 15 Minutes
NCT04239872 (29) [back to overview]	Calcium Concentration in Dental Biofilm Solids at 120 Minutes
NCT04239872 (29) [back to overview]	Area Under the Curve of Fluoride Concentration in Saliva Overtime
NCT04239872 (29) [back to overview]	Area Under the Curve of Fluoride Concentration in Dental Biofilm Fluid Overtime
NCT04239872 (29) [back to overview]	Area Under the Curve of Fluoride Concentration in Dental Biofilm Solids Overtime
NCT04249336 (3) [back to overview]	Percent Change in Mean Score of Pain Response From Baseline on Schiff Cold Air Sensitivity Scale Using Air Blast Stimulus
NCT04249336 (3) [back to overview]	Percent Change in Mean Scores of Pain Response From Baseline on Visual Analog Scale Using Mechanical Stimulus
NCT04249336 (3) [back to overview]	Percent Change in Mean Scores of Pain Response From Baseline on Visual Analog Scale Using Water Jet Stimulus
NCT04290624 (10) [back to overview]	Mean Oral Hygiene Index (OHI) at Week 6 and Week 12
NCT04290624 (10) [back to overview]	Mean Oral Debris Index (ODI) at Week 6 and Week 12
NCT04290624 (10) [back to overview]	Mean Number of Bleeding Sites (NBS) at Week 6 and Week 12
NCT04290624 (10) [back to overview]	Mean Modified Gingival Index (MGI) at Week 6 and Week 12
NCT04290624 (10) [back to overview]	Mean Interproximal TPI at Week 6 and Week 12
NCT04290624 (10) [back to overview]	Mean Calculus Index (CI) at Week 6 and Week 12
NCT04290624 (10) [back to overview]	Mean Bleeding Index (BI) at Week 12
NCT04290624 (10) [back to overview]	Mean BI at Week 6
NCT04290624 (10) [back to overview]	Mean Partial Denture Cleanliness Index (PDCI) at Week 6 and 12
NCT04290624 (10) [back to overview]	Mean Overall Turesky Plaque Index (TPI) at Week 6 and Week 12
NCT04710927 (2) [back to overview]	Clinical Outcome Based on Success After Intervention on MIH Affected Molar at 6 Months
NCT04710927 (2) [back to overview]	Clinical Outcome Based on Success After Intervention on MIH Affected Molar at 12 Months
NCT04950465 (5) [back to overview]	Change From Baseline in Tactile Threshold at Week 4 and 8 (Positive Control vs. Negative Control)
NCT04950465 (5) [back to overview]	Change From Baseline in Schiff Sensitivity Score at Week 8 (Test Dentifrice Versus [vs.] Negative Control)
NCT04950465 (5) [back to overview]	Change From Baseline in Tactile Threshold at Week 4 and 8 (Test Dentifrice vs. Negative Control)
NCT04950465 (5) [back to overview]	Change From Baseline in Schiff Sensitivity Score at Week 4 and 8 (Positive Control vs. Negative Control)
NCT04950465 (5) [back to overview]	Change From Baseline in Schiff Sensitivity Score at Week 4 (Test Dentifrice vs. Negative Control)
NCT05221749 (1) [back to overview]	Antibacterial Effect in Active Dental Caries Lesions
NCT05258721 (3) [back to overview]	Changes in Modified Gingival Index (MGI)
NCT05258721 (3) [back to overview]	Changes in Bleeding On Probing (BOP)
NCT05258721 (3) [back to overview]	Changes in Plaque Index (PI)

Number of Caries Incident Cases

A trained, calibrated dentist blinded to treatment arm performed visual-tactile dental exams at 1 and 2 years post-baseline. Group-specific number of incident cases were reported as the number of individual participants with caries at a follow-up visit. (NCT00066963)
Timeframe: two years

Intervention	participants (Number)
Counseling Only	42
FV 1x/Year + Counseling	23
FV 2x/Year + Counseling	14

Intervention	percentage of particpants (Number)
	Sensitivity	Accuracy
Cohort 2 - Combined 18F-NaF-CT/18F-FDG-PET Scan	96.2	89.8
Cohort 2 - WB-MRI Scan	81.4	74.7

Intervention	percentage of participants (Number)
	Sensitivity	Accuracy
Cohort 2 Combined 18F-NaF-CT/18F-FDG-PET Scan	95.7	87.6
Cohort 2 WB-MRI & 99mTc-MDP Bone Scintigraphy	91.6	83.0

Intervention	Participants (Count of Participants)
Cohort 3 - 99mTc-methyl Diphosphonate (MDP) Bone Scan	37
Cohort 3 - 18F-NaF / 18F-FDG PET/MRI	45

Intervention	Participants (Count of Participants)
	18F-NaF > 18F-FDG	18F-NaF = 18F-FDG	18F-NaF < 18F-FDG
Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET Scans	3	0	0

Intervention	Participants (Count of Participants)
	18F-NaF > 99mTc-MDP	18F-NaF = 99mTc-MDP	18F-NaF < 99mTc-MDP
Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET Scans	10	0	0

Intervention	percentage of particpants (Number)
	Sensitivity	Positive predictive value	Accuracy
Cohort 2 - Combined 18F-NaF-CT/18F-FDG-PET Scan	92.9	81.3	76.5
Cohort 2 - Whole Body-MRI Scan	92.9	86.7	82.4

Intervention	percentage of participants (Number)
	Sensitivity	Accuracy
Cohort 2 - 99mTc-MDP Bone Scintigraphy Scan	64.6	65.9
Cohort 2 Combined 18F-NaF-CT/18F-FDG-PET Scan	96.2	89.8

Intervention	μg*F/cm^2 (Least Squares Mean)
NaF Toothpaste(1450ppmF)	2499.47
NaF Toothpaste (1400ppmF)	2513.37
NaMFP/NaF Toothpaste (1450ppmF)	1923.76
NaF Toothpaste (675ppmF)	1861.80
Placebo Toothpaste (0ppmF)	686.18

Intervention	Percentage SMHR (Least Squares Mean)
NaF/Carbopol Toothpaste(1450ppmF)	28.31
NaF Toothpaste(1400ppmF)	26.32
NaMFP/NaF Toothpaste (1450ppmF)	26.13
NaF Toothpaste (675ppmF)	25.52
Placebo Toothpaste (0ppmF)	53.38

Intervention	micrograms (μg)*F/centimeters(cm)^2] (Least Squares Mean)
NaF Toothpaste (1450ppmF)	648.06
NaF Toothpaste (1400ppmF)	650.07
NaMFP/ NaF Toothpaste (1450ppmF)	541.16
NaF Toothpaste (675ppmF)	487.14
Placebo Toothpaste (0ppmF)	425.59

Intervention	Percentage SMHR (Least Squares Mean)
NaF Toothpaste(1450ppmF)	34.62
NaF Toothpaste(1400ppmF)	36.06
NaMFP/NaF Toothpaste (1450ppmF)	31.12
NaF Toothpaste (675ppmF)	27.15
Placebo Toothpaste (0ppmF)	11.10

Intervention	%SMHR (Least Squares Mean)
NaF/Carbopol Toothpaste (1400 Ppm F)	33.54
NaF Toothpaste (1350ppm F)	35.23
NaF Toothpaste (250 Ppm F)	24.98
NaMFP/NaF Toothpaste (1450 Ppm F)	29.57
Placebo Toothpaste (0 Ppm F)	22.05

Intervention	µg*F/cm^2 (Least Squares Mean)
NaF/ Carbopol Toothpaste (1400 Ppm F)	1283.13
NaF Toothpaste (1350ppm F)	1333.09
NaF Toothpaste (250 Ppm F)	680.20
NaMFP/NaF Toothpaste (1450 Ppm F)	1086.39
Placebo Toothpaste (0 Ppm F)	435.58

Intervention	%SMHR (Least Squares Mean)
NaF/Carbopol Toothpaste (1400 Ppm F)	33.54
NaF Toothpaste (1350 Ppm F)	35.23
NaMFP/NaF Toothpaste (1450 Ppm F)	29.57

Intervention	μg*F/g (Median)
NaF Toothpaste(1450ppmF)	0.20
NaF Toothpaste (1400ppmF)	0.22
NaMFP/NaF Toothpaste (1450ppmF)	0.12
Placebo Toothpaste (0ppmF)	0.01

Intervention	μg*F/g (Median)
NaF Toothpaste(1450ppmF)	2.00
NaF Toothpaste (1400ppmF)	1.56
NaMFP/NaF Toothpaste (1450ppmF)	0.76
Placebo Toothpaste (0ppmF)	0.03

Intervention	μg*F/g (Median)
NaF Toothpaste(1450ppmF)	0.09
NaF Toothpaste (1400ppmF)	0.09
NaMFP/NaF Toothpaste (1450ppmF)	0.07
Placebo Toothpaste (0ppmF)	0.00

Intervention	μg*F/g (Median)
NaF Toothpaste(1450ppmF)	0.71
NaF Toothpaste (1400ppmF)	0.72
NaMFP/NaF Toothpaste (1450ppmF)	0.28
Placebo Toothpaste (0ppmF)	0.02

Intervention	μg*F/g (Median)
NaF Toothpaste(1450ppmF)	0.04
NaF Toothpaste (1400ppmF)	0.04
NaMFP/NaF Toothpaste (1450ppmF)	0.02
Placebo Toothpaste (0ppmF)	-0.01

Intervention	ln(μgFminutes/cm^2) (Least Squares Mean)
NaF Toothpaste(1450 Ppm F)	0.54
NaF Toothpaste (1400 Ppm F)	0.54

fluorides

Cross-References

Synonyms (42)

Research Excerpts

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (2)

Pathways (46)

Protein Targets (5)

Inhibition Measurements

Biological Processes (13)

Molecular Functions (6)

Ceullar Components (19)

Bioassays (8)

Research

Studies (25,484)

Market Indicators

Research Demand Index: 92.12

Study Types

Clinical Trials (501)

Trial Overview

Trial Outcomes

Number of Caries Incident Cases

Cohort 2 - 18F-NaF/18F-FDG vs Whole-body MRI for Detection of Skeletal Lesions

Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI/99mTc-MDP Bone Scintigraphy

Cohort 3 - Skeletal Lesions Identified by 99mTc MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI

Cohort 3 - Total Skeletal Lesions Identified, Tc-99m MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI

Cohort 1 - 18F-NaF PET/CT vs 18F-FDG PET/CT

Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy

Cohort 2 - 18F-NaF/18F-FDG PET/CT vs Whole-body MRI for Detection of Extraskeletal Lesions

Cohort 2 - 18F-NaF/18F-FDG vs 99mTc-MDP Bone Scintigraphy for Detection of Skeletal Lesions

Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI

Enamel Fluoride Uptake (Demineralized Specimens)

Percentage SMHR of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (675ppmF) and Placebo Toothpaste (0ppmF)

Enamel Fluoride Uptake (Sound Enamel Specimens)

Percentage SMHR of Demineralized Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste(1450ppmF) and Placebo Toothpaste (0ppmF)

Percentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF)

Mean %SMHR of Enamel Specimens Exposed to NaF/Carbopol Toothpaste (1400 ppmF), NaF Toothpaste (1350ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (250ppmF) and Placebo Toothpaste (0ppmF)

Adjusted Mean Change From Baseline in Enamel Fluoride Uptake

Mean Percentage Surface Microhardness Recovery (%SMHR) of Enamel Specimens Exposed to NaF/Carbopol Toothpaste (1400 ppmF), NaF Toothpaste (1350ppmF) Compared to NaMFP/NaF Toothpaste (1450ppmF)

Change From Baseline in Fluoride Concentration at 1 Hour Post Brushing With Study Treatments

Change From Baseline in Fluoride Concentration at 15 Minutes After Brushing With Study Treatments

Change From Baseline in Fluoride Concentration at 2 Hours Post Brushing With Study Treatments

Change From Baseline in Fluoride Concentration at 30 Minutes Post Brushing With Study Treatments

Change From Baseline in Fluoride Concentration at 4 Hours Post Brushing With Study Treatments

Natural Log Transformed Area Under the Fluoride Concentration in Plaque Fluid by Time Curve (AUC) Between 0-4 Hours

Natural Log Transformed AUC for Fluoride Concentration in Plaque Fluid Between 0-4 Hours

Dental Plaque Index

Dental Plaque Index

Mean Gingival Plaque Units

Gingival Margin Plaque Index

Dental Plaque Index

Gingivitis Score

Dental Plaque

Bleeding Index (EIBI)

Antimicrobial Species in Plaque(Actinomyces)

Antimicrobial Species in Plaque(Sulfur Bacteria)

Antimicrobial Species in Tongue(Fusobacteria)

Antimicrobial Species in Tongue(Oral Streptococci)

Antimicrobial Species in Saliva(Veillonella)

Antimicrobial Species in Saliva(Total Anaerobic)

Antimicrobial Species in Saliva(Sulfur Bacteria)

Antimicrobial Species in Saliva(Oral Streptococci)

Antimicrobial Species in Saliva(Fusobacteria)

Antimicrobial Species in Saliva(Actinomyces)

Antimicrobial Species on the Cheek(Veillonella)

Antimicrobial Species in Plaque(Veillonella)

Antimicrobial Species in Plaque(Total Anaerobic)

Antimicrobial Species in Plaque(Oral Streptococci)

Antimicrobial Species in Plaque(Fusobacteria)

Antimicrobial Species on the Tongue(Actinomycetes)

Antimicrobial Species in Tongue(Sulfur Bacteria)

Antimicrobial Species on the Cheek(Total Anaerobic)

Antimicrobial Species on the Cheek(Sulfur Bacteria)

Antimicrobial Species on the Cheek(Oral Streptococci)

Intervention	Units on a scale (Mean)
Fluoride - A	3.12
Fluoride/Triclosan - B	2.90
Triclosan/Fluoride/Arginine	2.92
Triclosan/Fluoride/Cavistat	2.94

Intervention	Units on a scale (Mean)
Fluoride	2.79
Fluoride/Triclosan	2.82
Chlorhexidine Gluconate	1.99

Intervention	Units on a scale (Mean)
A- Placebo Comparator	0.942
B - Active Comparator	0.722
C - Experimental Toothpaste	0.705

Intervention	Units on a scale (Mean)
A- Placebo Comparator	2.273
B - Active Comparator	1.806
C - Experimental Toothpaste	2.041

Intervention	Units on a scale (Mean)
A- Placebo Comparator	0.325
B - Active Comparator	0.164
C - Experimental Toothpaste	0.141

Intervention	log CFU (Colony forming units) (Log Mean)
Placebo Toothpaste	0.023
Active Comparator	0.3881
Experimental	0.0538

Intervention	ph of dental plaque (Mean)
Active Comparator	4.88
Placebo - Silica Control	5.04
Experimental Toothpaste	4.98

Intervention	percentage of HbA1c levels in blood (Mean)
Triclosan/Copolymer/Fluoride Toothpaste	11.42
Fluoride Mouthrinse	10.81

Intervention	pH (Mean)
Control	4.78
Calcium Glycerophosphate	5.24
Fluoride	5.25
Calcium Glycerophosphate and Fluoride	5.44

Intervention	pH (Mean)
Control	5.40
Calcium Glycerophosphate	5.48
Fluoride	5.25
Calcium Glycerophosphate and Fluoride	5.70